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Abstract 
Bladder cancer is the 5th most common and the 9th most lethal cancer in the 
UK. Based on histopathological and genomic analysis, a model of two 
independent pathogenesis pathways has been suggested, resulting in either non-
invasive superficial or invasive urothelial tumours with potential to metastasise. 
Prominently, the fibroblast growth factor receptor 3 (FGFR3) is found mutated in 
up to 84% of non-invasive superficial tumours. Alterations in FGFR3 such as 
mutation or wild type receptor overexpression are also found in 54% of muscle-
invasive tumours. FGFR3 is a tyrosine kinase receptor for fibroblast growth 
factors (FGFs), which stimulates both the RAS/MAPK and the PI3K/AKT pathways 
and regulates a range of cellular processes such as cell growth and division 
during development. In this study we examined the role of FGFR3 in bladder 
cancer by using mice as a model organism.  
Firstly, we addressed whether combination of Fgfr3 and Pten mutation, UroIICre 
Fgfr3+/K644E Ptenflox/flox, is able to drive non-invasive superficial bladder cancer. 
We observed that the thickness of the double mutant urothelium was 
significantly increased compared to singly mutated Fgfr3 or Pten, UroIICre 
Fgfr3+/K644E and UroIICre Ptenflox/flox. Moreover, several cellular abnormalities 
were detected that were accompanied by differential expression of layer-
specific markers, which strongly suggested that they were caused cooperatively 
by Fgfr3 mutation and Pten deletion. The results supported the hypothesis that 
FGFR3 activation can play a causative role in urothelial pathogenesis of non-
invasive superficial bladder cancer together with upregulated PI3K-AKT 
signalling.  
Secondly, we aimed to identify mutations that cooperate with Fgfr3 and with 
other common bladder cancer mutations such as Pten and Ras, in promoting 
urothelial tumourigenesis by Sleeping Beauty (SB) insertional mutagenesis in 
mice. The SB system may constitute an inefficient tool in the bladder to induce 
urothelial tumourigenesis, since it failed to produce bladder tumours in Fgfr3 as 
well as in Hras mutant mice. In mice with Pten deletion, one tumour was 
generated and general hypertrophy with cellular abnormalities was observed in 
all samples. No direct association between Fgfr3 and Pten mutations was found; 
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however, SB mutagenesis supported that Fgfr3 and Pten cooperation may merge 
at the signalling downstream.  
Thirdly, we examined the role of the most common mutation in FGFR3, S249C, in 
the urothelium and in tumour progression and invasion by subjecting Fgfr3 
mutant mice to a bladder-specific carcinogen, N-butyl-N-(hydroxybutyl)-
nitrosamine (OH-BBN). We showed that FGFR3 S249C mutation by itself does not 
lead to urothelial abnormalities. However, in OH-BBN-induced tumours the 
presence of S249C increased the number of animals that formed bladder tumours 
by 4.4-fold. Our results present for the first time an effect of FGFR3 S249C 
mutation in invasive bladder cancer.  
Lastly, we sought to establish methods to generate and assess invasive bladder 
tumours using in vivo and in vitro techniques. First we examined the 
effectiveness of a Cre-expressing adenovirus (AdenoCre) to generate mouse 
models of bladder cancer with different combinations of genetic mutations. p53 
deletion or mutation together with Pten loss led to formation of aggressive 
bladder tumours; however the origin of these tumours was likely to be the 
bladder muscle. Hras activation in combination with Pten deletion did not 
produce tumours or any cellular abnormalities by 8 months. AdenoCre-mediated 
tumour induction was successful in the presence of β-catenin and Hras mutation. 
However, an issue of AdenoCre transduction was the frequent observation of 
tumours in various other tissues such as the pelvic soft tissue, liver, pancreas 
and lung. Using an optimised AdenoCre procedure, the technique would allow 
lineage tracing of cancer stem cells in a developing bladder tumour and 
potentially during metastatic spread. Secondly, we tested imaging techniques in 
the living animals and validated ultrasound as a functional method to detect 
bladder wall thickening, as well as to monitor tumour growth in vivo. Thirdly, 
with the aim to assess cell transformation, migration and response to drug 
treatment, we tested essential ex vivo techniques and assays such as 3D sphere 
culture, organotypic slice culture as well as a Collagen-I invasion assay. The 3D 
tumour sphere culture was successful with murine Wnt-activated tumours as well 
as with invasive human cell lines. The organotypic slice culture was assessed as a 
system to test the effect of therapeutic drugs on the tumour cells; however, an 
issue of tissue disintegration has yet to be overcome. The Collagen-I assay 
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successfully recapitulated invasion of a human bladder cancer cell line; 
however, the system needs to be adapted to murine bladder tumours.  
Taken together, this study presents for the first time evidence that support the 
functional role of FGFR3 signalling in the early stages of non-invasive urothelial 
carcinoma as well as in tumour progression of established neoplasms in mice. 
Given the wide availability of inhibitors specific to FGF signalling, our FGFR3 
mouse models in conjunction with optimised ex vivo assays and imaging systems 
may open the avenue for FGFR3-targeted translation in urothelial disease. 
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Abbreviations 
AdCre  AdenoCre 
APC  Adenomatous Polyposis Coli 
B-cat  β-Catenin 
BSA  Bovine serum albumin 
cDNA  Complementary DNA 
CGH  Comparative genomic hybridisation 
CIS  Carcinoma in situ 
CK  Cytokeratin  
CMV   Cytomegalovirus 
CRUK  Cancer Research UK 
CT  Computerised tomography 
DNA  Desoxyribonucleic acid 
E11  Embryonic day 11 
eGFP  Enhanced green fluorescent protein 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
ERK  Extracellular signal regulated kinase 
ES cells Embryonic stem cells 
FACS  Fluorescence-activated cell sorting 
FANFT  N-(4,5-nitro-2-furyl-2-thiazolyl)-formamide 
FGF  Fibroblast growth factor 
FGFR3  Fibroblast growth factor receptor 3 
GAB1  GRB2-associated-binding protein 1 
GRB2  Growth factor receptor-bound protein 2 
GCE  GFP-Cre-ERT2 
gDNA  Genomic DNA 
GDNF  Glial cell line-derived neurotrophic factor 
Abbreviations   17 
 
 
 
GFP  Green fluorescent protein 
GSTM1 glutathione S-transferase mu 1 
H&E  Hematoxylin and eosin 
HGF  Hepatocyte growth factor 
HLA  Human leukocyte antigen 
HRAS  Harvey rat sarcoma viral oncogene homolog 
IHC  Immunohistochemistry 
ISUP  International Society of Urologic Pathology 
ITR  Inverted terminal repeat 
IVIS  In vivo imaging system 
JAK  Janus protein tyrosine kinase 
KGF  Keratinocyte growth factor 
LiCl  Lithium chloride 
LOH  Loss of heterozygosity  
LSL  Lox stop lox 
MAPK  Mitogen-activated protein kinase 
MDM2  Mouse double minute 2  
MMTV  Mouse mammary tumour virus 
MNU  N-methyl-N-nitrosurea 
mRNA  Messenger RNA 
mTOR  Mammalian target of rapamycin 
NAT2  N-acetyltransferase 
Neo  Neomycin resistance gene 
OH-BBN N-butyl-N-(4-hydroxybutyl) nitrosamine 
PAH  Polycyclic aromatic hydrocarbon  
PCR  Polymerase chain reaction 
PFU  Plaque-forming unit 
PIP3  Phosphatidylinositol (3,4,5)-triphosphate 
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PI3K  Phosphatidylinositol 3-kinase 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha 
PTEN  Phosphatase and tensin homolog 
PUNLMP  Papillary urothelial neoplasms of low-malignant potential 
RA  Retinoic acid 
RB  Retinoblastoma protein 
RFP  Red fluorescent protein 
RNA  Ribonucleic acid 
RTK  Receptor tyrosine kinase 
SB  Sleeping Beauty 
SHH  Sonic hedgehog 
SMA  Smooth muscle actin 
SOS  Son of sevenless 
STAT3  Signal transducer and activator of transcription 3 
SV40  Simian virus 40 
Tg  Transgene, transgenic 
TGF  Transforming growth factor, Tumour growth factor 
TK  Tyrosine kinase 
TMA  Tissue microarray 
TNM  Tumour-Node-Metastasis 
TURBT Trans-urethral resection of bladder tumours 
UroIICre Uroplakin II Cre 
WHO  World Health Organisation 
WNT1  Wingless-int1 
X-gal  5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YFP  Yellow fluorescent protein 
Z/EG  lac Z/enhanced green fluorescent protein 
ZEB1  Zinc finger E-box-binding homeobox 1 
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1.1 The Bladder  
In order to study bladder cancer initiation, progression and invasion, it is 
essential to understand the normal function of the healthy bladder as part of the 
urinary system, as well as the composition and function of the urothelium, the 
tissue from which urothelial cell carcinoma emerges.  
The mammalian urinary system comprises kidneys, ureters, bladder and urethra. 
Anatomically, the bladder is composed of the dome, which is the roof of the 
bladder reaching laterally down to the two ureters, and the funnel-shaped 
trigone reaching from the ureters down to the bladder neck that connects to the 
urethra (Figure 1-1). 
The bladder, a hollow muscular organ, is composed of a so-called ‘detrusor 
muscle’ made of smooth muscles fibres covered in perivesical fat layers. Below 
the muscular coat, a layer of fibrous connective tissue interlaces with the 
urothelium, the inside layer of the bladder that faces the lumen. The connective 
tissue (also called stroma, submucosa or lamina propria) contains blood and 
lymphatic vessels, nerves and occasional glands.  
As a storage organ, the bladder can hold between 400 to 600ml of urine for 
about five hours. During this time the urothelium is continuously in contact with 
the urine and with any toxins or tumourigenic agents that may be dissolved 
therein.   
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Figure 1-1: Anatomy of the normal bladder 
Two ureters connect the kidneys to the bladder that is composed of dome and trigone. The neck is 
the area that connects the trigone to the urethra. The bladder wall (insert) is composed of 
urothelium, stroma, muscle and fat (inside to outside). 
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1.1.1 The Urothelium 
The urothelium is also called transitional cell epithelium, due the fact that it 
can stretch out into a single layer when storing the urine, and contract back 
upon releasing it. The urothelium is comprised of a sheet of extracellular matrix 
rich in  collagen-IV and laminin that separates the stroma from the urothelium 
(Brown et al., 2006).  
The human urothelium consists of four to seven cell layers, including a single 
basal cell layer, multiple intermediate cell layers, as well as a single umbrella 
cell layer facing the lumen. The murine urothelium has a similar composition, 
but comprises only three of these cell type layers in total (Figure 1-2). 
Basal cells are small round-shaped cells that line up along the basement 
membrane. They are characterised by the expression of Cytokeratin-5 (CK5), 
p63, and Sonic hedgehog (Shh) (Castillo-Martin et al., 2010, Gandhi et al., 2013, 
Shin et al., 2011, Karni-Schmidt et al., 2011). The same studies report that basal 
cells are negative for Cytokeratin-18 (CK18), Cytokeratin-20 (CK20) and 
Uroplakins. 
Intermediate cells are oriented perpendicular to umbrella and basal cells and 
can stretch into 1-4 layers. They express p63, Shh, and occasionally Uroplakins, 
but rarely CK5 (Castillo-Martin et al., 2010, Gandhi et al., 2013, Shin et al., 
2011). 
Umbrella cells are the terminally differentiated cell type in the urothelium that 
are facing the lumen. They are often binucleated and present morphologically 
with a stretched shape, covering the intermediate cell layer in an umbrella-like 
manner. Umbrella cells are marked by the expression of CK18 and CK20, which 
are absent in other layers (Castillo-Martin et al., 2010, Veranic et al., 2004). 
Umbrella cells also express Uroplakins (Kong, 2004, Gandhi et al., 2013), which 
are involved in the assembly of a protective barrier against urine, the apical 
plaques (Khandelwal et al., 2009). Expression of p63, Shh and CK5 is absent in 
umbrella cells (Castillo-Martin et al., 2010, Gandhi et al., 2013, Shin et al., 
2011, Karni-Schmidt et al., 2011).  
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Figure 1-2: Normal mouse urothelium 
Mouse urothelium consisting of three cell layers is characterised by the expression of different 
proteins. Umbrella cells express CK18, CK20 and UroII, intermediate cells express p63 and Shh, 
basal cells express p63, Shh and CK5.  
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1.1.2 Urothelial lineage and stem cells 
The question of urothelial lineage by which umbrella, intermediate and basal 
cells are generated has been debated for a long time and still remains 
controversial (Castillo-Martin et al., 2010, Khandelwal et al., 2009). 
The adult urothelium is a quiescent epithelium with a proliferation rate of 0.02-
0.05% in human and 0.1-1% in mice (Stewart et al., 1980). The turnover time is 
estimated to be 3-6 months (Khandelwal et al., 2009). However, upon chemical 
or mechanical injury the urothelium can rapidly regenerate (Khandelwal et al., 
2009, Shin et al., 2011), suggesting the presence of urothelial stem cells. 
Stem cells are unspecialised cells that have the ability to self-renew and to 
differentiate into several cell types (Weiner, 2008). In other epithelia such as 
the epidermis, there are populations of stem cells which are characterised as 
slowly cycling in vivo but showing a high proliferative potential in vitro (Morris 
and Potten, 1994). Elegant experiments have used these properties of slow 
turnover and long-term residence in tissue to characterise these cells. Labelling 
retaining studies first using BrdU, tritiated thymidine or EdU, and more latterly 
through the use of eGFP-tagged histone 2B (H2B-eGFP) allowed the visualisation 
and purification of these cells in vivo (Tumbar, 2004, Barker et al., 2007, 
Kurzrock et al., 2008).  
Unlike in many other organs, stem cells in the bladder have not been 
unambiguously identified. For a long time it had been assumed that urothelial 
stem cells reside exclusively in the basal cell compartment (Kurzrock et al., 
2008, Gaisa et al., 2011, Shin et al., 2011, Chan et al., 2009b).  
Much effort has been made in order to narrow down urothelial stem cells within 
the basal cell compartment using marker expression studies and lineage tracing. 
It has been suggested that 10% of the basal cells could represent candidate stem 
cells, which show long-term regenerative potential and retain BrdU label one 
year after its administration (Kurzrock et al., 2008).  
Furthermore, it was suggested that p63-expressing cells are the stem cells of the 
urothelium and that these are able to regenerate basal, intermediate and 
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umbrella (Pignon et al., 2013). However, it has been shown that p63 and its 
isoforms are also expressed in intermediate cells (Karni-Schmidt et al., 2011), 
which therefore does not limit urothelial progenitor cells to reside in the basal 
cell compartment. 
Another study reported the expression of secreted protein Shh in a 
subpopulation of CK5-positive basal cells, which are capable of regenerating all 
cell types within the urothelium (Shin et al., 2011). CK5-expressing basal cells 
are undetectable in the urothelium between E11 and E14 when progenitor 
potential is high, and they form after umbrella and intermediate cells (Gandhi 
et al., 2013).  
Recently, a new model of urothelial regeneration was suggested where at least 
two urothelial progenitor populations exist within the Shh-expressing population 
(Gandhi et al., 2013). The study describes fate-mapping in the urothelium upon 
chemical injury, where it was shown that CK5-positive cells do not generate 
umbrella cells. The study strongly suggested that lineage-tagged umbrella cells 
are descendants of intermediate cells, and it was therefore speculated that 
umbrella and intermediate cells arise from a separate lineage in the adult 
urothelium. The research group identified a second progenitor population, 
namely P-cells, which are a transient in the embryonic urothelium between day 
E11 and E13 and are marked by the expression of Foxa2, p63, Shh and Uroplakin. 
Fate-mapping suggested that P-cells are the progenitors of intermediate cells, 
which are present in the embryonic and adult urothelium. It remained unclear in 
the study where CK5-positive basal cells arise from and whether umbrella cells 
derive directly from P-cells or from P-cell-descendent intermediate cells.  
The study by Gandhi was supported by previous immunohistochemical 
characterisation of the mouse urothelium using layer-specific markers, which 
suggested that umbrella cells do not differentiate from basal to intermediate 
cells, but constitute a different cell lineage (Castillo-Martin et al., 2010, Karni-
Schmidt et al., 2011). The proposed model from the Castillo-Martin and Karni-
Schmidt protein expression studies was that a urothelial progenitor or stem cell 
population gives rise to two separate cell lineages with distinct expression 
profiles, namely basal/intermediate and umbrella cells.  
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Taken together, further studies are necessary in order to clearly identify 
urothelial stem cells and to better understand urothelial generation and 
development. Expansion of such studies into mechanisms of cancer cell 
transformation could help to shed light on bladder cancer initiation and 
progression. Furthermore, better understanding of urothelial stem cells and 
their exact location would be of great benefit to the generation of mouse 
models of bladder cancer, where the availability of a reliable stem cell targeting 
Cre is still a limitation. Thus we will be examining the recombination efficiency 
of an established promoter-driven UroplakinII-Cre as well as of a novel technique 
using adenoviral Cre delivery to the urothelium. 
1.2 Bladder cancer 
1.2.1 Epidemiology  
Bladder cancer is the 5th most common and the 9th most lethal cancer in the UK 
(Parkin et al., 2005), Cancer Research UK statistics, 2013). According to Cancer 
Research UK statistics 2013, about 10,300 people were diagnosed in 2010 in the 
UK, which is about 28 people per day. Worldwide, it is estimated that 383,000 
new cases are diagnosed per year. Generally, bladder cancer occurs in people 
aged 65 and over. Overall more men than women are affected, with bladder 
cancer being the 4th most common cancer in men in the UK and the 11th most 
common cancer in UK women (Cancer Research UK statistics, 2013). Between 
the mid-1970s and the 1990s male bladder cancer incidence rates increased, 
while female rates were lower but followed the same pattern. Bladder cancer is 
still prevalent in males, although both rates have decreased since the 1990s 
(Cancer Research UK statistics, 2013). 
1.2.2 Causes 
The principal risk factor of bladder cancer is smoking, which is estimated to 
account for 35% of the cases in the UK per year (Brennan et al., 2000, Wallerand 
et al., 2005)(Cancer Research UK statistics, 2013). Smoking is also associated 
with high stage and high grade urothelial tumours (Wallerand et al., 2005). 
Furthermore, occupational exposure to chemical carcinogens such as polycyclic 
aromatic hydrocarbons (PAHs), diesel exhausts, and aromatic amines is linked to 
a considerable number of bladder cancers as well (Kogevinas et al., 2003). 
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Although familial cases of bladder cancer are relatively rare, the risk is 2-fold 
higher in first degree relatives of bladder cancer patients (Burger et al., 2013). 
Inherited genetic factors such as N-acetyltransferase (NAT2), glutathione S-
transferase mu 1 (GSTM1) and a sequence variant on 4p16.3 are associated with 
genetic predisposition (Garcia-Closas et al., 2005). In Africa and the Middle East 
a large number of bladder cancers are caused by schistosomiasis, a parasitic 
disease (Cancer Research UK statistics, 2013). 
1.2.3 Types of bladder cancer 
Urothelial cell carcinoma is the most common type of bladder cancer (90%) in 
the Western world (Cancer Research UK statistics, 2013). Urothelial cell 
carcinoma develops from the innermost layer of the bladder wall, the 
urothelium (Chapter 1.1.1). Urothelial cell carcinoma can be of non-invasive or 
muscle invasive nature (Chapter 1.2.10). 
Squamous cell carcinoma accounts for 5% of the UK bladder cancers (Cancer 
Research UK statistics, 2013). This type of bladder cancer presents with a 
stratified skin-like tissue architecture. Squamous cell carcinoma is more common 
in developing countries in Africa and the Middle East, where it is linked to the 
infectious disease schistosomiasis (bilharzia). Squamous cell carcinoma of the 
bladder is also linked to chronic inflammation resulting from indwelling 
catheters, urinary calculi and urinary outflow obstruction (Cancer Research UK 
statistics, 2013). 
Other rare types of bladder cancer include adenocarcinoma, which accounts for 
1-2% of all bladder tumours and develops from mucus-producing glandular cells 
(Cancer Research UK statistics, 2013). Another rare type is soft tissue sarcoma, 
which originates in the detrusor muscle of the bladder (Cancer Research UK 
statistics, 2013). 
1.2.4 Symptoms  
The most common symptom of bladder cancer is blood in the urine (haematuria) 
seen in 80% of bladder cancer patients (Cancer Research UK statistics, 2013). 
Haematuria is usually not painful. Other symptoms can include frequency and 
urgency of passing urine.  
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1.2.5 Diagnosis 
Bladder cancer is mostly diagnosed by examination of the bladder lining using 
cystoscopy, where a tube with optic cables is inserted through the urethra under 
(local or) general anaesthesia. Tissue samples taken (biopsies) are taken from 
normal and abnormal looking areas. Moreover, a computerised tomography (CT) 
scan can be performed to examine the whole urinary tract. Blood and urine tests 
for early detection of bladder cancer are in development where hormone levels 
or ratios of specific proteins such as Bladder Tumour Antigen (BTA), Nuclear 
Matrix Protein 22 (NMP-22) or Mini Chromosome Maintenance 5 (MCM5) are 
analysed.  
1.2.6 Treatment  
Depending on the stage and behaviour of the bladder tumour, the treatment for 
each patient is managed differently.  
Superficial early bladder cancer can be removed by trans-urethral resection of 
the bladder tumour (TURBT) followed by regular cystoscopic surveillance. 
Adjuvant immunotherapy (intravesical instillation) is often given in form of 
Bacillus Calmette-Guerin (BCG) to stimulate the immune system and lower the 
chances of recurrence and progression (Babjuk et al., 2008). The exact 
mechanism by which BCG is effective is still unclear. 
Invasive bladder tumours can often only be treated by removing parts or the 
entire bladder by radical cystectomy. Alternatively, radiotherapy can save the 
bladder from being removed, but this treatment requires daily presence in the 
hospital for 6 weeks to receive the treatment, and it can cause bowel 
inflammation as a side effect. Neoadjuvant chemotherapy (intravenous) is often 
given before the surgery, and can be used in combination with radiotherapy to 
aid these treatments. Chemotherapy is often based on a Cisplatin-containing 
drug combination, such as Gemcitabine/Cisplatin (GC) or Methotrexate/ 
Vinblastine/ Doxorubicin (Adriamycin)/Cisplatin (MVAC) (Niegisch et al., 2013). 
The current standard care for metastatic disease, GC, shows a 49% response rate 
in the patients (von der Maase et al., 2005). Cisplatin acts by forming crosslinks 
to the DNA, leading to irreparable DNA damage that triggers cell death through 
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the apoptotic pathway (Bambury and Rosenberg, 2013). Gemcitabine is 
pyrimidine analogue that is integrated into the DNA during replication, leading 
to faulty nucleosides, and therefore triggering apoptosis (von der Maase et al., 
2000). 
Bladder cancer is one of the most expensive cancers of all to treat (Sangar et 
al., 2005). This is partly due to the intensive treatments that are necessary in 
case of an invasive tumour. Moreover, non-invasive tumours tend to recur 
frequently and therefore require repeated follow-up surveillance. 
1.2.7 Prognosis 
According to Cancer Research UK statistics 2013, about 80 to 90% of patients 
with non-invasive bladder cancer can live for more than 5 years. The prognosis 
for patients with muscle-invasive disease is less favourable, with only 50% 
survival at 5 years. Once the disease has become metastatic, the average 
survival drops to 12-18 months. 
 
1.2.8 Pathology of urothelial cell carcinoma 
1.2.8.1 Grading and staging  
Based on the growth pattern of urothelial tumours, four diagnostic categories 
are described (flat, exophytic papillary, endophytic, and invasive) (Montironi et 
al., 2008).  
Flat lesions show unaltered thickness of the urothelium, but are more 
characterised by atypic cellular features such as mitotic figures and loss of 
polarity. Flat lesions can present features such as reactive (inflammatory) 
atypia, dysplasia, or carcinoma in situ (CIS).  
Exophytic papillary neoplasms include papilloma, PUNLMP, and low- and high-
grade papillary carcinoma. These growths are characterised by a central 
fibrovascular core. Endophytic lesions, such as inverted papilloma, show features 
that are similar to exophytic papilloma; however, without the presence of a 
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central fibrovascular core. Invasive neoplasms exhibit lamina propria invasion 
and tumour cell infiltration into the detrusor muscle. 
When diagnosing a cancer and its anatomical progression, the tumour stage is 
generally determined using the Tumour-Node-Metastasis (TNM) classification 
system. 
The T stage is used to describe how far the cancer has grown (Figure 1-3). 
Carcinoma in situ (CIS) is an early high-grade but superficial lesion in the 
urothelium. Ta describes a superficial papillary tumour that is restricted to the 
urothelium. T1 cancers are tumours that have broken through the basement 
membrane and grown into the lamina propria (stroma). T2 cancers have invaded 
further into the detrusor muscle. T3 cancers show invasion into the adipose 
tissue surrounding the bladder wall. T4 stage describes invasion into 
neighbouring organs.  
The N stage describes four stages of lymph node infiltration by the growing 
tumour. N0 denotes no lymph node invasion; N1 indicates cells in one lymph 
node in the pelvic area; N2 in more than one lymph node in the pelvis; and N3 in 
one or more lymph nodes in the groin or other parts of the body. 
The M stage describes cancer spread into distant organs (M1 if positive, M0 if 
absent). Frequent sites of metastatic spread from a primary bladder tumour are 
the abdominal lymph nodes, the bones (pelvis and spine), lung and liver 
(Shinagare et al., 2011, Punyavoravut and Nelson, 1999).  
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Figure 1-3: Staging of bladder cancer 
Diagram showing the T stages of bladder cancer. T stages are classified as high-grade non-
invasive lesion called carcinoma in situ (CIS), non-invasive papillary carcinoma  (Ta), breakthrough 
of basement membrane with tumour cells in connective tissue (T1), invasion into muscle (T2), 
invasion into fat layer (T3) and  invasion of neighbouring tissues (T4). Source: Cancer Research 
UK, 2013, http://www.cancerresearchuk.org/cancer-help/type/bladder-cancer/treatment/bladder-
cancer-stage-and-grade 
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Grading of a cancer is determined upon microscopic examination of the biopsy 
sample. Low-grade cancers usually consist of cells that are normal looking and 
well differentiated and are associated with relatively slow growth, whereas 
high-grade cancers show high heterogeneity, poor differentiation and a tendency 
to grow quickly and progress. 
Non-invasive urothelial tumours were classified in 1973 by the World Health 
Organisation (WHO) and the International Society of Urologic Pathology (ISUP) as 
urothelial papilloma, tumours of grade 1 (G1; well differentiated), grade 2 (G2; 
moderately differentiated) or grade 3 (G3; poorly differentiated) (Table 1-1). 
In 2004 the WHO/ISUP made an attempt to re-classify early bladder tumours in 
order to improve their recognition and to provide better correlation of the 
neoplastic lesions with their cellular behaviour. Neoplasms were classified as 
urothelial papilloma, papillary urothelial neoplasms of low-malignant potential 
(PUNLMP), low-grade papillary urothelial carcinoma and high-grade urothelial 
carcinoma (Table 1-1). 
Although the 2004 system was meant to replace the urological cancer 
classification of 1973, the old system is still being used by many pathologists, 
since it has been validated in terms of prognosis and patient outcome (Chen et 
al., 2012). 
 
Table 1-1: WHO classification of urinary tumours in 1973 and 2004 
 
 
Introduction – Bladder Cancer  (Chapter 1)   33 
 
 
 
1.2.8.2 Multifocality of urothelial tumours 
Urothelial cell carcinoma typically presents with multifocal lesions (Habuchi, 
2005). These individual tumours within the same tissue can be of similar or 
completely different stage, grade and site. Two basic mechanisms of how these 
multifocal lesions arise have been debated (Hafner et al., 2002). The multiple 
tumours may either arise independently by separate genetic events or they can 
be of monoclonal origin.  
The majority of the reports have been suggesting a monoclonal origin of the 
multiple lesions, where one progenitor cell is transformed initially (Sidransky et 
al., 1992, Takahashi et al., 1998, Jones et al., 2005, Hartmann et al., 2000, 
Denzinger et al., 2006, Simon et al., 2001). Cells can subsequently undergo 
intraluminal spread using the urine to distribute and to implant at a different 
site within the bladder. Alternatively, they may reach other regions by 
intraepithelial migration, a process in which malignant cells spread throughout 
the urothelial lining.  
The second theory, which is also called “field effect” or “field cancerisation”, is 
supported by a number of studies, where the multiple tumours show indications 
of oligoclonal origin (Hafner et al., 2001, Spruck et al., 1994, Stoehr et al., 
2000). According to this concept individual cells acquire different mutations over 
time, and tumour lesions arise and develop independently. 
It needs to be kept in mind that the two clonality concepts are not mutually 
exclusive. The correct classification of multifocal urothelial tumours, however, 
is of clinical importance in terms of prognosis as well as on deciding on the most 
suitable treatment. 
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1.2.9 Genetics behind bladder cancer 
Genomic analysis such as by fluorescence in situ hybridisation (FISH), 
comparative genomic hybridisation (CGH) and sequencing techniques indicates a 
number of genes that are commonly deleted or mutated in bladder tumours 
(Knowles, 2008, Al Hussain and Akhtar, 2013) (Table 1-2). 
Genome-wide alterations, such as copy number changes or deletions of whole 
chromosomes, chromosome arms, and individual loci on chromosome arms, are 
frequent events in both non-invasive and invasive bladder cancer (Knowles, 
2008). Bladder tumours also frequently present with activation of major 
signalling pathways involving cell cycle regulating genes, genes involved in cell 
communication or transcriptional regulators. 
1.2.9.1 Genome-wide alterations 
Alterations in chromosome 9 (9p, 9q) are found in more than 50% of all bladder 
tumours of all grades and stages (Cairns et al., 1993), suggesting that this may 
be one of the earliest events in bladder cancer development (Kallioniemi et al., 
1995). Partial deletions of chromosome 9 are found in 35-65% of non-invasive 
bladder tumours (Blaveri et al., 2005, Simoneau et al., 2000), suggesting the 
presence of tumour suppressor genes in this genomic region. Chromosome 9 
contains an estimate of 800 to 900 genes (Humphray et al., 2004). A specific 
region on chromosome 9, 9p21-22, referred to as CDKN2A encoding for 
p16/INK4A and p14/ARF is frequently deleted in bladder cancer (Cairns et al., 
1994). However, the value of p16 as a prognostic biomarker in bladder cancer is 
still not entirely clear (Friedrich et al., 2001). Although it is not entirely clear 
which genes exactly are responsible for cancer relapse, chromosome 9 deletions 
are also associated with recurrence of non-invasive papillary bladder tumours 
(Simoneau et al., 2000). Loss of heterozygosity (LOH) of chromosome 10 is a 
frequent event in advanced tumours (Kagan et al., 1998, Cappellen et al., 1997). 
Chromosome 10 harbours the tumour suppressor gene PTEN, which is frequently 
deleted in bladder cancer and associated with a higher tumour grade (Aveyard et 
al., 1999). 
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1.2.9.2 Changes in genes related to the p53 pathway and cell cycle  
Alterations in genes that are involved in the regulation of p53 function, including 
TP53, p21, and RB1 are highly associated with advanced and muscle-invasive 
tumours (Sidransky et al., 1991, Stein et al., 1998, Cairns et al., 1991). MDM2, a 
negative p53 regulator is often found overexpressed in non-invasive tumours 
(Habuchi et al., 1994, Lianes et al., 1994). 
TP53 deletion is found in up to 70% of muscle-invasive bladder cancers (Sidransky 
et al., 1991, Lu et al., 2002). p53 is a nuclear phosphoprotein, which is encoded 
by the TP53 gene (Vogelstein et al., 2000). The transcription factor p53 acts as a 
major tumour suppressor and gate keeper at the G1/S checkpoint of cell cycle. 
Nuclear accumulation of p53 protein can be an indication of TP53 mutation, 
which is associated with greater risk of muscle-invasive disease and reduced 
survival (Esrig et al., 1994). Loss of wild type TP53 in tumour cells may help to 
escape growth control (Sidransky et al., 1991). 
TP53 mutations, such as point mutations and frameshift mutations, are also 
frequent events (~70%) in bladder cancer, resulting in functionally silent, 
missense, or dominant-negative forms of p53 protein (Habuchi et al., 1994). 
There are about six hotspot mutations in TP53 that lead to a dominant-negative 
form of p53 protein function (Greenblatt et al., 1994). An example is R175H, a 
gain-of-function missense mutation which strongly promotes tumour formation 
and metastatic spread in vivo (Liu et al., 2000). Mutant p53 may provide a 
growth advantage to tumour cells (Sidransky et al., 1991). 
LOH of the tumour suppressor ‘Retinoblastoma protein’ (RB) is found in 37% of 
muscle-invasive bladder tumours (Cairns et al., 1991). Encoded by the RB1 gene 
the RB protein functions as a regulator of the cell cycle at the G1/S phase and as 
a recruiter of chromatin remodelling enzymes and transcription factors (Classon 
and Harlow, 2002). RB also regulates p53 activity through mouse double minute 
2 homolog (MDM2) activation (Hsieh et al., 1999). During the G1 phase of the cell 
cycle, cyclin-dependent kinases (CDKs) phosphorylate and thereby inactivate RB. 
Not only loss of function but also phospho-RB (pRB) overexpression and 
hyperphosphorylation has been reported in bladder cancer (Chatterjee et al., 
2004). 
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Loss of p21 (CIP1/WAF1) expression in patients with muscle-invasive bladder 
cancer has been shown to be an indicator of tumour progression (Stein et al., 
1998). p21 is a cyclin-dependent kinase inhibitor protein that is encoded by the 
CDKN1A gene. p21 is a direct target of p53 and regulates cell cycle progression 
at the G1/S phase (el-Deiry et al., 1993). Loss of p21 was also strongly 
associated with higher recurrence and decreased overall survival (Stein et al., 
1998), supporting a generally protective function of p21 against disease 
progression. However, in carcinoma in situ patients, p21 expression on its own, 
as well as co-expressed with p53, was associated with recurrence, progression 
and mortality (Shariat et al., 2003), suggesting a context-dependent role of p21 
in bladder cancer. 
The mouse double minute 2 homolog (MDM2) has been found overexpressed in 
about 30% of non-invasive tumours (Habuchi et al., 1994, Lianes et al., 1994), 
and is mutually exclusive in the relationship with TP53 mutations (Network, 
2014). MDM2 encodes for an E3 ubiquitin-protein ligase that targets p53 protein 
for proteasomal degradation. 
1.2.9.3 Activation of tyrosine kinase receptors 
The fibroblast growth factor receptor 3 (FGFR3) is found mutated in 60-80% of 
non-invasive bladder cancers (Billerey et al., 2001, Cappellen et al., 1999, 
Tomlinson et al., 2007a, van Rhijn et al., 2012). FGFR3 is a tyrosine kinase 
receptor for FGFs, which stimulates both the RAS/MAPK and the PI3K/AKT 
pathways and triggers a range of cellular processes such as cell growth and 
division during development (Bottcher, 2005, Goetz and Mohammadi, 2013). In 
muscle-invasive disease, FGFR3 is found mutated in 0-30% of the cases (Billerey 
et al., 2001); however wild type receptor overexpression has been found in 54% 
of muscle-invasive tumours (Tomlinson et al., 2007a). A recent attempt to re-
classify urothelial cell carcinomas primarily based on molecular features has 
revealed that FGFR3 mutations and overexpression are associated with a 
subgroup of muscle-invasive bladder cancer with significantly poor prognosis 
(Sjodahl et al., 2012). In a recent study with focus on gene cooperation, FGFR3 
mutations were predominantly found alone (65%) (Juanpere et al., 2012). FGFR3 
and HRAS mutations have been shown to be mutually exclusive events in bladder 
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cancer, possibly due to redundant activation of downstream signalling (Kompier 
et al., 2010, Jebar et al., 2005, Juanpere et al., 2012). 
The epidermal growth factor receptor (EGFR; ERBB-1; HER1) is often found 
overexpressed in up to 50% of human invasive carcinomas (Colquhoun and 
Mellon, 2002). EGFR is a tyrosine kinase receptor for ligands including EGF and 
TGF-α, which stimulate both the RAS/MAPK and the PI3K/AKT pathways and 
leading to DNA synthesis, cell proliferation and angiogenesis (Oda et al., 2005). 
Interestingly, it has been shown that the EGFR pathway is upregulated upon 
FGFR3 inhibition, which constitutes a resistance mechanism to receptor 
inhibition (Herrera-Abreu et al., 2013). In the same study EGFR dominated the 
downstream signalling through repression of mutant FGFR3 expression. It was 
speculated that FGFR3 may initiate cancer development until at some point 
increased EGFR signalling dominates and represses FGFR signalling (Herrera-
Abreu et al., 2013). 
1.2.9.4 Changes in genes related to the MAPK/ERK pathway 
Activated MAPK/ERK signalling is implicated to be involved in bladder cancer 
(Kompier et al., 2010, Billerey et al., 2001). Hyperactive MAPK/ERK signalling is 
not only triggered by activated tyrosine kinase receptor signalling, but can also 
be caused by mutations in the rat sarcoma viral oncogene homolog (RAS). 
Harvey-RAS (HRAS) was the first oncogene isolated from a human bladder cancer 
cell line (Reddy et al., 1982). HRAS is a GTPase that is involved in regulating cell 
division in response to growth factor stimulation (Campbell et al., 1998). Point 
mutations in the HRAS gene can lead to constitutive activation of the GTPase 
protein and increased MAPK/ERK signalling, and thereby inducing uncontrolled 
cell division. HRAS is found mutated in non-invasive and invasive bladder cancer 
at a frequency that strongly varies between the different studies (15-40%) (Jebar 
et al., 2005, Knowles and Williamson, 1993, Fitzgerald et al., 1995, Ooi et al., 
1994, Czerniak et al., 1992).  
1.2.9.5 Changes in genes related to the PI3K/AKT pathway 
The Phosphatidylinositol 3-kinase (PI3K)/AKT pathway is implicated to be 
involved in bladder cancer with a large number of tumours showing mutations in 
PIK3CA or AKT1 or deletion of the tumour suppressor gene PTEN (Wu et al., 
Introduction – Bladder Cancer  (Chapter 1)   38 
 
 
 
2004, Knowles et al., 2009, Askham et al., 2010, Juanpere et al., 2012, Duenas 
et al., 2013). 
PI3K is an enzyme that leads to AKT pathway activation by catalysing the 
production of Phosphatidylinositol (3,4,5)-triphosphate (PIP3), the substrate of 
the Phosphatase and tensin homolog (PTEN) (Maehama and Dixon, 1998). A 
catalytic subunit of PI3K, PIK3CA, is mutated in 15-25% of non-invasive tumours, 
leading to a significant proliferative advantage through increased lipid kinase 
activity and constitutive AKT activation (Lopez-Knowles et al., 2006, Askham et 
al., 2010, Ross et al., 2013, Juanpere et al., 2012, Knowles et al., 2009, Kompier 
et al., 2010). In non-invasive tumours, PIK3CA mutation was associated with 
reduced recurrence (Duenas et al., 2013). In invasive bladder cancer cell lines, 
inhibition of PI3K has been shown to reduce the invasive capacity (Wu et al., 
2004). Co-occurrence of FGFR3 and PIK3CA mutations was found in urothelial 
cell carcinoma across all stages and grades (Lopez-Knowles et al., 2006, Kompier 
et al., 2010, Duenas et al., 2013). On the other hand, PIK3CA and AKT1 
mutations have been shown to be mutually exclusive, possibly due to redundant 
activation of downstream signalling (Juanpere et al., 2012). 
Loss of heterozygosity (LOH) of PTEN has been found in 30% of invasive tumours 
(Aveyard et al., 1999, Cappellen et al., 1997, Cairns et al., 1998). PTEN is a 
well-known negative regulator of the AKT/PI3K pathway. PTEN inhibits the PI3K-
AKT pathway by dephosphorylating PIP3, the product of PI3K (Maehama and 
Dixon, 1998). PTEN is located on chromosome 10, a chromosome that is also 
frequently affected by LOH in advanced tumours (Kagan et al., 1998, Cappellen 
et al., 1997, Dahia, 2000). Point mutations or homozygous deletion of PTEN have 
been found in 14-23% of invasive tumours (Wang et al., 2000, Cairns et al., 
1998).  
1.2.9.6 Changes in genes related to the WNT pathway 
The WNT pathway controls many events during development and regulates 
homeostasis in adult tissues (Reya and Clevers, 2005). Deregulation of WNT 
signalling can occur upon mutations in multiple components of the pathway, for 
example through LOH of the Adenomatous polyposis coli (APC) gene, which has 
been reported in 50% of bladder tumours (Bohm et al., 1997). Expression of ß-
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catenin has also been shown to be dysregulated in urothelial cell carcinoma (Zhu 
et al., 2000, Garcia del Muro et al., 2000, Nakopoulou et al., 2000). 
 
Table 1-2: Common genetic alterations in urothelial tumours 
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1.2.10 Model of two independent pathways of bladder cancer 
progression 
Based on histopathological and genomic analysis, a model of two independent 
pathogenesis pathways has been suggested, which could result in two different 
forms of urothelial cell carcinoma (Figure 1-1, adapted from (Knowles, 2008). 
According to the model, seventy percent of all urothelial cell carcinomas 
constitute non-invasive papillary tumours (Ta and T1), which are assumed to 
develop from a hyperplastic urothelium. Seventy percent of these papillary non-
invasive tumours have a low potential to progress (Ta), but high potential to 
reoccur after removal. Thirty percent of the non-invasive tumours present with a 
higher grade and show breakthrough of cancer cells beyond the basement 
membrane into the connective tissue (T1), which are potentially life 
threatening. Non-invasive papillary carcinomas can progress to a higher grade; 
however, whether high-grade non-invasive lesions can stage progress to an 
invasive lesion is still a subject of investigation (Sylvester et al., 2006, Zieger et 
al., 2000, Herr, 2000, Cheng et al., 1999, Leblanc et al., 1999). In contrast, 
thirty percent of all urothelial cell carcinomas constitute muscle-invasive 
tumours (T2), which are assumed to develop from a dysplastic urothelium or a 
carcinoma in situ (CIS). CIS is regarded as the precursor of invasive bladder 
carcinoma, which mostly present as flat lesions with a high potential to progress 
and to metastasise. 
Genomic analysis supports the model of two independent pathogenesis pathways 
since non-invasive and invasive tumours generally harbour different sets of 
mutations (Knowles, 2008). Alterations in chromosome 9 (9p, 9q) are found in 
more than 50% of all bladder tumours of all grades and stages (Cairns et al., 
1993) (Chapter 1.2.8). Mutations in RAS are frequent events of both pathways as 
well (Jebar et al., 2005). Prominently, FGFR3 is found mutated in 60-80% of non-
invasive bladder cancer (Billerey et al., 2001). On the other hand, invasive 
bladder carcinomas often carry TP53 and RB mutations. Analysis of gene 
cooperation and mutual exclusivity of certain genetic changes further support 
the two-pathway model. In a recent study with focus on gene cooperation, 
PIK3CA was mostly found co-mutated with FGFR3 or KRAS (35%) (Juanpere et al., 
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2012). On the other hand, mutual exclusivity has been found regarding FGFR3 
and TP53 mutations (Bakkar et al., 2003, van Rhijn et al., 2004). 
Most recently, invasive bladder tumours have been subcategorised into basal-, 
luminal-, and p53-like tumours based on their immunohistochemical expression 
pattern (Choi et al., 2014). The subtypes also showed distinct clinical outcome 
in regards to their growth behaviour and resistance to chemotherapy (Choi et 
al., 2014, Sjodahl et al., 2012)(see also Introduction to Chapter 5). 
 
 
Figure 1-4: Current model of bladder cancer progression in two independent pathways  
Non-invasive tumours (Ta, T1) arise from a hyperplastic urothelium and frequently present with 
alterations in FGFR3, chromosome 9, MDM2, RAS and PI3K. Invasive tumours (≥T2) arise from a 
dysplastic urothelium or carcinoma in situ (CIS) and frequently present with alterations in TP53, 
RB1 and PTEN. Adapted from (Knowles, 2008) 
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1.3 Fibroblast Growth Factor Receptors (FGFRs) 
Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors that 
mediate the effects of Fibroblast Growth Factors (FGFs) (Goetz and Mohammadi, 
2013). FGFRs are involved in a range of cellular processes such as cell division 
and differentiation, vascularisation and wound healing by stimulation of both the 
RAS/ Mitogen-Activated Protein Kinase (MAPK) and the Phosphatidylinositide-3 
Kinase (PI3K)/AKT pathway (Bottcher, 2005).  
The FGFR family consists of five receptors (FGFR1-FGFR5) that comprise several 
alternative splicing isoforms, which can bind 18 different FGF ligands (Wesche et 
al., 2011). FGFR1 is known to bind FGF1 (acidic-FGF, aFGF), FGF2 (basic-FGF, 
bFGF), FGF3, FGF4, FGF5, FGF6, FGF8 and FGF10; FGFR2 can additionally bind 
FGF7 and FGF9 (Powers et al., 2000). FGFR3 is known to be activated by FGF1, 
FGF2, FGF8, FGF9, and FGF18; and FGFR4 can bind to FGF 1, FGF 2, FGF 4, FGF 
6, FGF8 and FGF 9 (Powers et al., 2000, Davidson et al., 2005). A fifth member 
of the FGFR family, FGFR5, has been identified, which in contrast to FGFR1-4 
lacks a cytoplasmic tyrosine kinase domain (Sleeman et al., 2001, Kim et al., 
2001).  
FGF receptors are located at the cell surface, and are composed of an 
extracellular domain to receive FGF signals, a transmembrane domain, and an 
intracellular domain that mediates signal transmission into the nucleus (Figure 
1-5). The extracellular domain (ligand binding domain) of each monomer consists 
of three immunoglobulin (Ig)-like domains (Ig I, Ig II and Ig III) (Wesche et al., 
2011). The Ig II and III domains generally bind to the secreted FGF ligands. The 
transmembrane domain comprises a single helix structure, which anchors the 
receptor to the cell membrane. The intracellular domain (signal transmitting 
domain) is composed of two tyrosine kinase domains, TK1 and TK2. 
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Figure 1-5: Fibroblast Growth Factor Receptor (FGFR) 
The extracellular domain of FGFR3 is composed of three immunoglobulin (Ig)-like domains that 
bind to FGF ligands. The transmembrane domain comprises a single helix structure. The 
intracellular domain is composed of two tyrosine kinase (TK) domains to transmit the signal. 
Adapted from (Iyer and Milowsky, 2012) 
 
Based on immunohistochemistry, FGFRs are expressed in many tissues with a 
distinct spatial pattern (Hughes, 1997). High levels of FGFR1 are seen in the 
skin, heart, lung, kidney and ureter. FGFR2 is expressed in the prostate and 
stomach. FGFR3 is expression is seen in the appendix, colon, liver and cervix. 
FGFR4 expression is seen in the liver, kidney, ureter and some vasculature 
tissues (Hughes, 1997). 
In the normal bladder, expression of FGFR1 at the protein level is prominently 
seen in the urothelium but not in the detrusor muscle (Hughes, 1997). FGFR2 
mRNA and protein levels are exclusively detectable in the urothelial 
compartment but not in the submucosa or muscle, based on semi-quantitative 
RT-PCR and immunohistochemistry respectively (Diez de Medina et al., 1997). 
Expression of FGFR3 is generally low or undetectable by Western blotting and 
immunohistochemical analysis of tissue microarray (Gomez-Roman et al., 2005, 
Tomlinson et al., 2007a). FGFR4 expression is detected in the urothelium and in 
the muscle (Hughes, 1997). 
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FGFs such as FGF2 (bFGF) are expressed at higher levels in mesenchymal bladder 
tissue rather than in epithelial cells like the urothelium (Cheng et al., 2013). 
1.3.1 Downstream signalling 
FGF-mediated receptor kinase activity stimulates major signalling pathways such 
as the RAS/MAPK, PI3K/AKT and the JAK/STAT pathway, and thereby promotes a 
range of cellular processes including cell growth and division, vascularisation, 
wound healing, and embryonic development (Bottcher, 2005). 
Upon binding of an FGF molecule to the Ig-like region in the extracellular 
domain, the receptor dimerises and undergoes a conformational change that 
allows transphosphorylation of the tyrosine kinase domains of the intracellular 
part of the receptor (Brooks et al., 2012). The phosphorylated residues recruit 
adaptor proteins such as Phospholipase-C gamma (PLC-γ) or FGFR substrate 2 
(FRS2), which help form a complex composed of Son of sevenless (SOS), Growth 
factor receptor-bound protein 2 (GRB2) and GRB2-associated-binding protein 1 
(GAB1) (Wesche et al., 2011).  
The phosphorylated complex can activate the RAS/MAPK via phosphorylated 
GRB2/SOS (Figure 1-6) (Hart et al., 2001). PI3K/AKT activation is mediated by 
GRB2/GAB1 interaction with PI3K (Hart et al., 2001). FGFR can also activate the 
STAT pathway by direct interaction with Proline-rich tyrosine kinase 2 (PYK2) or 
indirectly through Janus-family kinase (JAK) activation (Hart et al., 2000). 
Furthermore, it has been shown that FGF receptor signalling can also activate 
Src kinases (Cunningham et al., 2010, Sandilands et al., 2007). 
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Figure 1-6: Fibroblast growth factor receptor signalling  
FGFR phosphorylates adapter proteins such as PLC-γ or FRS2/GAB1/SOS/GRB2 (blue), which 
stimulate RAS/MAPK (green), PI3K/AKT (red), and Src or JAK/STAT (orange) pathways. Negative 
regulators of FGFR signalling are Sprouty2 and Dusp6 (yellow). Adapted from (Iyer and Milowsky, 
2012, Bottcher, 2005, Ahmad et al., 2012a) 
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1.3.2 Negative regulation of FGFRs 
FGFR signalling can be regulated in the extracellular space, and at the 
transmembrane level, as well as within the cell.  
Well-known negative regulators of FGFR signalling are Sprouty (SPRY) family 
members, which disrupt downstream signalling by binding to GRB2 or RAF (Figure 
1-6) (Hacohen et al., 1998). Furthermore, MAPK phosphatase 3 (MKP3; DUSP6) 
and ‘Similar to FGF’ (SEF) proteins can compete for binding sites or directly 
inhibit downstream signalling by dephosphorylation (Kovalenko et al., 2003, Li et 
al., 2007). 
FGFR gene expression can be transcriptionally regulated by certain microRNAs. 
For example, mir-99, which is found downregulated in various human cancers, 
targets FGFR3 at the post-transcriptional level for its degradation (Oneyama et 
al., 2011, Catto et al., 2009, Kang et al., 2012).  
1.3.3 FGFRs in cancer 
Mutations in FGFR or receptor overexpression have been implicated to play a 
role in several cancer types, including multiple myeloma, cervical, prostate, 
breast, lung, gastric cancer and melanoma (Ahmad et al., 2012a, Wesche et al., 
2011, Turner and Grose, 2010). 
FGFR1 amplification is found in 17% of squamous cell carcinoma (Freier et al., 
2007), 21% of lung adenocarcinoma (Dutt et al., 2011), and in up to 10% of 
breast cancer (Jacquemier et al., 1994). FGFR1 overexpression has also been 
shown to play a role in tumourigenesis of the prostate (Sahadevan et al., 2007). 
Interestingly, overexpression of FGFR1 is also found in urothelial cell carcinoma 
across all stages and grades (Tomlinson et al., 2009).  
FGFR2 is found amplified in 10% of gastric cancers (Jang et al., 2001, Kunii et 
al., 2008) and 12% of endometrial cancers (Pollock et al., 2007). Overexpression 
of FGFR2 has also been shown to increase the susceptibility to breast cancer 
(Meier et al., 2008), indicating similar oncogenic properties to FGFR1 and 3. On 
the other hand, FGFR2 has also been suggested to act as a tumour suppressor, 
since expression of the receptor was found downregulated in a number of cancer 
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types, including bladder, liver, salivary glands, prostate and melanoma (Amann 
et al., 2010, Diez de Medina et al., 1997, Naimi et al., 2002, Gartside et al., 
2009). It is currently unclear whether FGFR2 is a tumourigenesis promoting or 
suppressing factor, or whether it may exhibit those opposite characteristics in a 
context-dependent manner (Ahmad et al., 2012a). 
FGFR3 mutations have been identified in several cancer types, including multiple 
myeloma, cervical and bladder cancer (Chesi, 2001, Cappellen et al., 1999, 
Billerey et al., 2001). The functional role of FGFR3 mutation in tumour 
formation was first demonstrated multiple myeloma (Chesi, 2001), skin 
hyperplasia in transgenic mice overexpressing mutant FGFR3 (Logie, 2005), 
induction of transformation of transfected cell lines (Bernard-Pierrot et al., 
2006) and in xenograft models (Qing et al., 2009, Bernard-Pierrot et al., 2006). 
The role of FGFR3 in bladder cancer is discussed in more detail in (Chapter 
1.3.4.1). 
FGFR4 is mutated in 7-8% of soft tissue sarcoma (Taylor et al., 2009) and has 
been described as a potential driver of tumour growth in human breast tissue 
(Roidl et al., 2010). Overexpression of FGFR4 has also been shown to play a role 
in tumourigenesis of the prostate (Murphy et al., 2010, Sahadevan et al., 2007). 
Moreover, high levels of FGF expression have been detected in several cancers, 
including FGF3, FGF8 and FGF10 in breast carcinoma (Theodorou et al., 2004, 
Naidu et al., 2001, Marsh et al., 1999). Elevated levels of FGF2 are found in 
bladder cancer (Marzioni et al., 2009, Cheng et al., 2013). Upregulation of FGF1, 
FGF2, FGF6, FGF7, FGF8 and FGF9 levels are detectable in prostate cancer 
(Kwabi-Addo et al., 2004). 
Taken together, the reports on genetic mutations and altered expression levels 
of FGFs and their receptors indicate a major role for FGF signalling in the 
development of a number of cancers. 
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1.3.4 Fibroblast growth factor receptor 3 (FGFR3) 
FGFR3 is well-known to play a vital role in bone development and growth 
(Bottcher, 2005). Activating FGFR3 mutations in the germ line can cause several 
forms of dwarfism, such as hypochondroplasia, achondroplasia and thanatophoric 
dysplasia and malformation of the cerebral cortex (Laederich and Horton, 2012, 
Iwata and Hevner, 2009, Iwata et al., 2000). In mice it has been shown that loss 
of FGFR3 leads to a neonatally lethal form of dwarfism (Colvin et al., 1996).  
Tissue-specific alternative splicing events give rise to two major FGFR3 isoforms, 
which differ in their Ig-like domains (Ig III) but share the same structure in their 
tyrosine kinase domains (Chellaiah et al., 1994). Isoforms IIIb and IIIc therefore 
vary in their ligand-receptor binding specificity (Chellaiah et al., 1994, Miki et 
al., 1992). FGFR3IIIb for example shows higher affinity for FGF1 (aFGF) and FGF7 
(KGF), but a lower affinity for FGF8 and FGF9, while FGFR3IIIc binds FGF1, FGF2, 
FGF4, FGF8 and FGF9 (Chellaiah et al., 1994, Ahmad et al., 2012a). The 
FGFR3IIIb splice variant appears to be expressed in epithelial lineages whereas 
FGFR3IIIc is predominantly expressed in fibroblastic cells (Scotet and Houssaint, 
1995). 
Based on quantitative RT-PCR, FGFR3 is 20 times higher expressed than any 
other FGFR in the urothelium (Tomlinson et al., 2005). FGFR3 mRNA levels were 
higher in epithelial cells, namely the urothelium, of the normal non-neoplastic 
bladder (Cheng et al., 2013).  
1.3.4.1 FGFR3 in bladder cancer 
Activating FGFR3 mutations and overexpression of the wild type receptor are 
two major mechanisms which are associated with urothelial tumourigenesis (Iyer 
and Milowsky, 2012). Enhanced receptor signalling poses a proliferation and 
survival advantage to urothelial cells (di Martino et al., 2009). Around 80% of 
non-invasive and more than 50% of invasive urothelial cell carcinomas present 
with alterations in FGFR3 signalling either by mutation, overexpression or both 
(Iyer and Milowsky, 2012).  
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1.3.4.2 FGFR3 mutation  
FGFR3 mutations are found in 60-80% of non-invasive urothelial cell carcinoma 
(Billerey et al., 2001, Cappellen et al., 1999, Tomlinson et al., 2007a, van Rhijn 
et al., 2012). Muscle-invasive tumours of high grade carry FGFR3 mutations in 
only 10-15% of the cases (Billerey et al., 2001). FGFR3 wild type tumours are 
generally associated with higher grade and higher stage compared to tumours 
with FGFR3 mutation (Bernard-Pierrot et al., 2006). 
Presence of an FGFR3 mutation in bladder cancer patients has been linked to 
favourable patient prognosis, as it is associated with low grade/stage pTa 
tumours (van Rhijn et al., 2012, Billerey et al., 2001, Hernandez et al., 2006).  
Previous studies have shown association between FGFR3 mutation in non-
invasive papillary tumours of low grade with a higher risk of recurrence 
(Hernandez et al., 2006, Hernandez et al., 2005). Non-invasive papillary tumours 
of high grade, on the other hand, were not associated with recurrence or 
progression in patients (Hernandez et al., 2006, Hernandez et al., 2005). 
However, in a more recent study, no association was found between FGFR3 
mutational status and recurrence, progression or muscle invasion (Ploussard et 
al., 2011).  
FGFR3 mutations in urothelial cell carcinoma can occur at different codons in 
the extracellular domain, the transmembrane domain, or the cytoplasmic 
tyrosine kinase domain, which can cause various changes in the receptor and 
aberrant signalling (Tomlinson et al., 2007a, di Martino et al., 2009).  
Common FGFR3 mutations are S249C (~66%) and R248C (~10%) leading to changes 
in the extracellular domain; Y373/375C (~15%) and G370/372C (~4%) occurring in 
the transmembrane domain; and K650/K652E (<2%) altering the cytoplasmic 
tyrosine kinase domain (Tomlinson et al., 2007a, Hernandez et al., 2006, 
Bernard-Pierrot et al., 2006) (Figure 1-7). 
The most frequent mutation in FGFR3, S249C, accounts for ~66% of human non-
invasive urothelial cell carcinoma with FGFR3 mutant status (Tomlinson et al., 
2007a, Duenas et al., 2013, Bernard-Pierrot et al., 2006). S249C is a point 
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mutation leading to a serine to cysteine exchange at position 249 in the linker 
region between the extracellular immunoglobulin-like domains Ig2 and Ig3 (d'Avis 
et al., 1998, Adar et al., 2002). S249C mutation triggers kinase activation 
through constitutive receptor dimerisation as a result of a higher level of 
disulfide bond formation in a completely ligand-independent manner (d'Avis et 
al., 1998, di Martino et al., 2009). 
A less frequent mutation (<2%) in FGFR3, K650E or K652E, leads to highly 
activated receptor signalling (Naski et al., 1996, Tomlinson et al., 2007a). K650E 
constitutes a point mutation in the tyrosine kinase (TK) domain, leading to a 
lysine to glutamic acid exchange at position 650 in the TK activation loop 
(Tavormina et al., 1995). K650E mutation causes a conformational change in the 
receptor which favours autophosphorylation (Naski et al., 1996). K650E mutant 
receptor signalling shows increased mitogenic activity, which is partially ligand-
independent, meaning it can be further enhanced by FGF binding (Naski et al., 
1996).  
 
 
 
Figure 1-7: Mutations in Fibroblast growth factor receptor 3 (FGFR3)  
Common FGFR3 mutations are found in the immunoglobulin (Ig)-like domain (S249C, R248C), in 
the transmembrane domain (Y375C, G372C), and in the tyrosine kinase domain (K652E, K652M). 
Adapted from (Iyer and Milowsky, 2012) 
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1.3.4.3 FGFR3 overexpression 
Overexpression of FGFR3 protein is also frequently found in urothelial cell 
carcinoma; however between the reports there is variation in terms of 
stage/grade association. For example, one study reported overexpression of 
FGFR3 protein in 49% of the bladder tumours, but no statistically significant 
stage or grade association was found (Matsumoto et al., 2004).  
In bladder carcinomas with unknown FGFR3 mutation status, elevated FGFR3 
expression was associated with non-invasive tumours of low-grade and early 
stage (Mhawech-Fauceglia et al., 2006, Tomlinson et al., 2007a). Another group 
reported 73% of non-invasive papillary carcinomas with unknown mutation status 
showed FGFR3 overexpression across all stages (Gomez-Roman et al., 2005).  
When FGFR3 expression levels were examined in relation to FGFR3 mutation 
status, correlation between receptor overexpression and presence of FGFR3 
mutation was indeed demonstrated, but the study lacked information on stage 
or grade of these tumours (Bernard-Pierrot et al., 2006). 
A later study confirmed that bladder carcinomas with known FGFR3 mutation are 
associated with FGFR3 overexpression, with 85% of the tumours showing strong 
FGFR3 expression (Tomlinson et al., 2007a). These tumours were predominantly 
non-invasive papillary carcinomas of low grade and early stage, demonstrating 
for the first time correlation between FGFR3 mutation, receptor overexpression, 
and low grade/early stage association. 
On the other hand, the same study also reported overexpression of FGFR3 in 42% 
of carcinomas with non-mutated wild type receptor, with the majority being 
high-grade muscle-invasive tumours (Tomlinson et al., 2007a). 
Given the high frequency activating FGFR3 mutations and overexpression of the 
wild type receptor in bladder cancer, it would be essential to further elucidate 
the functional importance of the receptor signalling in the urothelium and 
urothelial tumours. We will address this by using two different mouse models 
harbouring murine Fgfr3 K644E or human FGFR3 S249C mutation.  
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1.3.4.4 FGFR3 downregulation 
Interestingly, two studies have also reported tumour suppressive properties of 
FGFR3. In one, FGFR3 protein expression was downregulated in colorectal cancer 
(Sonvilla et al., 2010). In a second study, FGFR3 overexpression had tumour 
suppressive effects on pancreatic cancer (PDAC) cell lines (Lafitte et al., 2013). 
Interestingly, there is association between FGFR3 loss and tumour stage in high-
grade urothelial bladder cancers (Billerey et al., 2001, Tomlinson et al., 2007a, 
van Rhijn et al., 2012). Although yet unclear, it is possible that FGFR3 can either 
promote or suppress tumour development or progression in a context-dependent 
manner. 
1.3.5 FGFR as a target of therapy 
Inhibitors of FGF signalling have increasingly been developed to target many 
types of cancer (Brooks et al., 2012, Liang et al., 2013). Inhibition of FGFR has 
been suggested as a therapeutic option in urothelial cell carcinoma (Lamont et 
al., 2011, Tomlinson et al., 2007b). Several novel drugs against FGFRs including 
monoclonal antibodies, small-molecule inhibitors as well as ligand traps have 
been developed and show effectiveness in cell lines and xenograft models. An 
advantage of monoclonal antibodies is that they can be designed to specifically 
target one single type of FGFR; therefore, the dose-level can be maximised. 
Small-molecule inhibitors on the other hand cross-inhibit all FGFRs. A 
disadvantage of pan-FGFR3 inhibition is that this can cause more side-effects in 
the patient such as nausea or diarrhoea due to the involvement of FGFR 
pathways in phosphate and vitamin D homeostasis (Brooks et al., 2012).  
R3Mab is a monoclonal antibody against wild type and mutant forms of FGFR3IIIb 
and IIIc, which has been shown to exhibit anti-tumour activity against bladder 
carcinoma and multiple myeloma xenografts in mice (Qing et al., 2009). R3Mab 
prevents FGF-binding as well as receptor dimerisation by inducing a 
conformational change to the receptor (Qing et al., 2009). NVP-BGJ398 is a 
small-molecule inhibitor of pan-FGFR (FGFR 1, 2 and 3) which showed significant 
inhibition of angiogenesis, tumour cell proliferation, and induction of tumour 
cell death in bladder cancer xenografts that overexpress wild type FGFR3 
(Guagnano et al., 2011). NVP-BGJ398 prevents receptor phosphorylation and can 
have cytostatic or cytotoxic properties in a cell-dependent manner (Guagnano et 
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al., 2011). AZD4547, also a small-molecule inhibitor of pan-FGFR (FGFR 1, 2 and 
3), showed anti-tumour activity in FGFR-overexpressing tumour cell lines 
including acute myeloid leukemia, breast cancer and multiple myeloma (Gavine 
et al., 2012). Similarly to NVP-BGJ398, AZD4547 prevents receptor 
phosphorylation and can have cytostatic or cytotoxic properties in a cell-
dependent manner (Gavine et al., 2012). All of the named drugs are currently 
being used in clinical trials (Brooks et al., 2012, Liang et al., 2013). 
However, it needs to be kept in mind that the role of FGFR3 as a promoter or 
suppressor of tumourigenesis is not entirely elucidated and may be context-
dependent (Chapter 1.3.4.4.). FGFR3-targeted therapy therefore needs to be 
considered individually with caution.  
A major limitation to the clinical development of FGFR inhibitors is the 
resistance mechanisms of tumours against FGFR3-targeted therapy. Inhibition of 
the FGFR3 pathway using parallel siRNA screens has been shown to trigger EGFR 
pathway activation as an escape mechanism (Herrera-Abreu et al., 2013). EGFR 
dominated the downstream signalling through repression of mutant FGFR3 
expression. A reciprocal relationship was shown between FGFR and EGFR, 
demonstrated by upregulation of EGFR following FGFR inhibition and FGFR 
upregulation following EGFR inhibition. It was speculated that FGFR3 may 
initiate cancer development until at some point increased EGFR signalling 
dominates and represses FGFR signalling (Herrera-Abreu et al., 2013). Activation 
of the alternative receptor was capable of partially compensating for loss of the 
drug-targeted receptor tyrosine kinase signalling, which therefore constitutes a 
resistance mechanism that is of major clinical relevance in cancers where EGFR 
or FGFR are targeted. Another possible mechanism of acquired resistance to 
FGFR inhibition is the emergence of a second mutation site in FGFR3 as shown 
recently (Chell et al., 2013). In this study, human multiple myeloma cell lines 
with drug resistance to AZ4547 were generated. Sequencing then revealed the 
emergence of FGFR3 V555M as a gatekeeper mutation to evade FGFR3 inhibition 
(Chell et al., 2013). Similarly, FGFR3-dependent malignant melanoma cell lines 
have shown to gain resistance to NVP-BGJ398 (pan-FGFR) small-molecule 
inhibition by acquiring BRAFV600E or KRAS mutation (Guagnano et al., 2012).  
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For a translational benefit, further studies of the FGFR3 signalling pathway and 
its inhibitors are therefore essential and will aid the development of therapies 
for both non muscle-invasive and muscle-invasive bladder cancer with 
deregulation of FGF signalling.  
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1.4 Modelling bladder cancer in vivo and in vitro 
The progress of medical research relies on the generation and use of suitable 
animal models. Therefore, different strategies have been employed to induce 
bladder tumourigenesis using approaches such as xenografts, carcinogen-induced 
models as well as genetically engineered mouse (GEM) models (Chan et al., 
2009a). The incidence of spontaneous bladder tumours in mice is very low (<1 %) 
and is therefore not suitable as an investigational strategy (Oliveira et al., 
2006). Experimental models of urothelial cell carcinoma also include cell culture 
of human primary tumour cells or bladder cancer cell lines for investigation in 
vitro. Cell culture provides the opportunity to analyse cancer initiation and 
progression, as well as the effectiveness of therapeutic drugs in a controlled 
environment.  
1.4.1 Cell culture 
Non-invasive human bladder cancer cell lines with superficial papillary 
characteristics include RT112, 97-7 and Ku-7 (Table 1-3). RT112 is derived from 
a non-invasive papillary urothelial cell carcinoma of histological grade 2 (G2) in a 
female Caucasian (ATCC, American Type Culture Collection). RT112 
overexpresses FGFR3 with no detectable point mutations (Qing et al., 2009). 97-
7 is derived from a non-invasive urothelial cell carcinoma of histological grade 2-
3 (G2-3) in a female Caucasian, and carries an FGFR3 S249C mutation (Qing et 
al., 2009). Ku-7 is derived from a superficial papillary carcinoma of low grade 
with no detectable FGFR3 mutation (COSMIC, Catalogue of Somatic Mutations in 
Cancer database 2013). 
Invasive human bladder cancer cell lines with advanced stage and aggressive 
growth behaviour include T24, EJ138, RT4, KU-19-19 and UM-UC3 (Table 1-3). 
T24 is derived from an invasive urothelial cell carcinoma of grade 3 (G3) in a 
female Caucasian and carries a homozygous mutation in HRAS and TP53 (COSMIC, 
2013). EJ138 is in fact T24 (or sometimes referred to as MGH-U1), which has 
been shown by isoenzyme analysis and HLA profiles (O'Toole et al., 1983). RT4 is 
derived from a well-differentiated grade 1 (G1) but muscle-invasive urothelial 
cell carcinoma in a male Caucasian, and carries a homozygous mutation in 
CDKN2A and TSC1 (ATCC and COSMIC, 2013). RT4 overexpresses FGFR3 with no 
Introduction – Modelling bladder cancer in vivo and in vitro  (Chapter 1)  56 
 
 
 
detectable point mutations (Qing et al., 2009). Ku-19-19 is derived from a 
metastatic bladder carcinoma in a male Caucasian, and carries a KDM6A 
mutation (COSMIC, 2013). UM-UC3 is derived from a muscle-invasive bladder 
carcinoma in a male Caucasian, and carries a KRAS, TP53, CDKN2A and PTEN 
mutation (ATCC). 
Table 1-3: Human bladder cancer cell lines 
 
 
 
Furthermore, artificially transformed urothelial cell lines have been developed 
from stably transduced Normal human urothelial (NHU) cells or immortalised 
Normal human urothelial cells (TERT-NHUC) carrying mutation constructs, such 
as FGFR3IIIb (Bernard-Pierrot et al., 2006, di Martino et al., 2009). The 
advantage of these cell constructs is that the effect of a single specific mutation 
on normal urothelial cells can be analysed. Furthermore, potential inhibitors can 
be easily tested against stable expression levels of the specific construct. 
However, the artificial settings may not fully reflect the natural urothelial or 
tumour cell environment of a human bladder.  
There are two murine cell lines that are frequently used today, namely MB49 
and MBT2 (Loskog et al., 2005). MB49 originated from a 7,12-dimethylbenz[a] 
anthracene (DMBA)-induced tumour in a male C57BL/6 mouse that carries a Kras 
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mutation (Summerhayes and Franks, 1979). MBT2 is derived from a N-(4,5-nitro-
2-furyl-2-thiazolyl)-formamide (FANFT)-induced bladder tumour in C3H mice that 
carries p53 deficiency (Rikenbase, Japan, 2013) 
1.4.2 Orthotopic models 
Since cell culture cannot model the stroma and the complex microenvironment 
of a tissue or a tumour in vitro, techniques have been developed to inject 
cancer cells into living hosts by subcutaneous grafting or orthotopic injection 
directly into the organ. Therefore, in the case of bladder cancer, orthotopic 
models involve the implantation of primary tumour cells or cell lines directly 
into the urinary bladder of mice by catheterisation or laparotomy. 
Orthotopic models are divided in two categories, namely xenograft and 
syngeneic models. In orthotopic xenograft models, human bladder cancer cells 
are implanted into nude mice. Human cell lines include KU7, KU19, T24 and UM-
UC3, which resulted in tumour formation (Watanabe et al., 2000, Jurczok et al., 
2008). A disadvantage of a xenograft model is that the immune response of the 
host cannot be assessed, which plays an important role in regulating tumour 
growth. In orthotopic syngeneic models, murine bladder cancer cells are 
implanted into immunocompetent mice (Summerhayes and Franks, 1979, 
Gunther et al., 1999). The disadvantage of syngeneic models is that the 
introduced cancer cells are of murine origin that may not fully reflect human 
neoplasms, and that the resulting tumours tend to grow fast. 
Further limitations of orthotopic models are that they may differ from the 
original tumour in terms of morphology, growth behaviour and signalling 
characteristics, since cell lines in culture can acquire additional mutations over 
time and therefore undergo functional changes (Gabriel et al., 2007). 
Furthermore, the instillation procedure can be challenging as it involves either 
catheterisation of female mice or surgical laparotomy, both of which require 
general anaesthesia. Moreover, the tumour “take” rate in mice can vary from 
30-100%, depending on the cell line, genetic background of the mice, and pre-
treatment conditioning (Chan et al., 2009a). 
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1.4.3 Carcinogen-induced models 
Over the past 30 years, much effort has been made to model invasive urothelial 
cell carcinoma in mice using bladder-specific carcinogens (Becci et al., 1981, 
Ohtani et al., 1986, McCormick et al., 1981).  
Three chemicals have been shown to be most effective, namely FANFT (N-(4,5-
nitro-2-furyl-2-thiazolyl)-formamide), MNU (N-methyl-N-nitrosurea), and OH-BBN 
(N-butyl-N-(4-hydroxybutyl) nitrosamine) (Oliveira et al., 2006). FANFT is a 
nitrofuran, which induces invasive and metastatic bladder neoplasms that often 
exhibit squamous cell transformation (Soloway, 1977, Cohen et al., 1976). 
However, administration of FANFT via the diet requires 8-11 months for tumour 
induction and progression (Erturk et al., 1970). MNU is an alkylating agent that 
transfers methyl groups to nucleobases, which can generate derivatives such as 
6-O-methylguanine that can provoke transition mutations (PubChem Compound 
NCBI, 2014). MNU can trigger tumourigenesis of the urothelium upon a single 
dose via catheterisation (Kunze et al., 1989, Steinberg et al., 1991). For health 
and safety reasons, FANFT and MNU have been widely replaced by OH-BBN, 
which is derived from tobacco smoke, and which has now become one of the 
most well studied bladder carcinogens in mice (Becci et al., 1981, Ohtani et al., 
1986). 
Although OH-BBN is administered systemically by gavage or in drinking water, it 
induces tumourigenesis specifically in the urothelium (Becci et al., 1981, Ohtani 
et al., 1986, McCormick et al., 1981, He et al., 2012). The reason for bladder-
specificity is not entirely clear, but it is speculated that this may be due to 
prolonged exposure in the bladder, presence (or absence) of metabolic enzymes 
that activate (or detoxify) OH-BBN in the bladder as compared to other organs, 
or lower DNA repair capacity of urothelial cells compared to non-urothelial cells 
(He et al., 2012). 
OH-BBN causes different histological lesions in mouse and rat bladder models. In 
rats, OH-BBN administration promotes mainly superficial non-invasive tumours 
(Fukushima et al., 1976, Dunois-Larde et al., 2005). In mice, OH-BBN-induced 
tumours present with similar histology to advanced human urothelial cell 
carcinoma (Becci et al., 1981, McCormick et al., 1981, Ohtani et al., 1986). They 
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are generally of highly invasive nature and often show a mixed histology with 
features of both urothelial cell carcinoma and squamous cell differentiation 
(Becci et al., 1981, McCormick et al., 1981, Yamamoto et al., 1998). Similar to 
observations in human bladder cancer, OH-BBN causes clonally independent 
multifocal urothelial tumours in the same bladder (Yamamoto et al., 1998). 
Within these, an individual tumour generally originates from the same precursor 
cell and is therefore monoclonal (Yamamoto et al., 1998). 
OH-BBN tumours also show a similar molecular profile that is comparable to 
invasive human bladder tumours (Williams et al., 2008). Strikingly, TP53 
mutations are frequent events (~80%) in OH-BBN-induced invasive carcinomas 
(Ogawa et al., 1998, Yamamoto et al., 1997, Yamamoto et al., 1995). Mutations 
in the Hras gene were reported to be low (Ogawa et al., 1998, Yamamoto et al., 
1995). Consistent with the genetic profile of human invasive bladder carcinomas, 
activating FGFR3 mutations are a rare event in invasive tumours induced by OH-
BBN in mice (Billerey et al., 2001, Dunois-Larde et al., 2005).  
Analysis of gene expression in OH-BBN-induced tumours showed differential 
expression of cell cycle regulating genes such as p53, and signalling pathways 
involving RAS, EGFR, TGF-β (el-Marjou et al., 2000, Yao et al., 2004). In human 
invasive carcinomas EGFR is found overexpressed in up to 50%  of the tumours 
(Colquhoun and Mellon, 2002). Similarly, in invasive OH-BBN-induced mouse 
tumours, EGFR is frequently found overexpressed (el-Marjou et al., 2000, Yao et 
al., 2004).  
Overall, mouse models of chemically induced bladder cancer are excellent 
models to investigate the mechanisms of urinary bladder carcinogenesis, since 
they promote tumourigenesis in a bladder-specific fashion and recapitulate 
tumour development in well-defined stages from carcinoma in situ (CIS) to 
invasive carcinoma. However, tumour induction and progression in carcinogen-
induced models can take as long as 8-14 months. Furthermore, the experiments 
require adequate health and safety regulations for the involved staff. 
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1.4.4 Genetically engineered models  
Genetically engineered mice (GEM) have significantly advanced the 
understanding of urothelial cell carcinoma at the molecular level over the past 
20 years (Frese and Tuveson, 2007). GEM include transgenic mice, knock-in and 
knock-out mice, as well as a variety of genetic modification tools to achieve 
tissue-specificity and/or temporal induction of the genetic modification (Frese 
and Tuveson, 2007). 
1.4.4.1 Generation of GEM 
Transgenic mice are generated by pronuclear injection, by which foreign 
homologous DNA is injected into the pronucleus of a zygote that is subsequently 
transplanted into a foster female (Gordon and Ruddle, 1981). Transgene 
integration, however, takes place in a random manner. Thus, the integration 
site, copy number and integration pattern are usually not predictable.  
Endogenous GEM such as knockin and knockout mice are generated by targeted 
recombination via embryonic stem (ES) cell injection. In this procedure, 
embryonic stem cells are isolated from a blastocyst and cultured in vitro. A 
plasmid with the gene of interest is introduced into the ES cells by 
electroporation where the sequence integrates into the host genome by 
homologous recombination. Recombined cell clones are then selected against a 
toxin to which they are resistant through a resistance gene introduced by the 
plasmid. Successfully recombined and selected ES cells are injected into a 
blastocyst and subsequently implanted into a pseudopregnant foster female 
(Capecchi, 1994). Replacement by the artificial construct can lead to complete 
disruption of the endogenous gene in the case of a targeted tumour suppressor, 
or to mutant protein expression at physiological levels in the case of an 
introduced oncogenic mutation. 
Constitutive knockouts present the introduced genetic modification in all cells of 
the body. A variety of conditional modification tools have been engineered in 
order to achieve tissue-specificity or time-specific gene alteration, for example 
the Cre/loxP recombination technology or the inducible CreER-T system (Nagy, 
2000).  
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The Cre/loxP system utilises the Cre recombinase enzyme, which targets two 
specific sequences loxP sequences placed before and after the gene of interest 
in order to excise it from its original location (Nagy, 2000). The CreER-T system 
is used to generate inducible knockins and knockouts in order to control 
temporal activity. The system is based on a fusion protein of CMV/Cre with a 
mutant ligand-binding domain of the estrogen receptor (ER). Therefore, Cre 
expression can specifically be activated by treatment with tamoxifen, an ER 
antagonist, providing a time-specific switch between a wild type and a mutant 
state.  
1.4.4.2 Cre promoters 
The expression of the gene of interest can be modulated by the nature of the 
promoter that controls Cre expression. For example, constitutive GEM can be 
generated using a ubiquitous promoter for Cre expression, whereas conditional 
GEM carry a tissue-specific promoter to express Cre in only one specific cell 
type. 
In order to express Cre recombinase in the bladder, a number of tissue-specific 
promoters have been employed. The Uroplakin II (UroII) promoter is one of the 
most frequently used promoters of transgene expression in the urinary bladder. 
UroplakinII is expressed in mice in umbrella and intermediate cells (Choi et al., 
2009, Lin et al., 1995, Kong, 2004) from embryonic day 16 (E16) 
(Oottamasathien et al., 2007). The UroII promoter has been used to promote the 
expression of Cre enzyme for loxP-specific gene targeting in knockin and 
knockout models (Ahmad et al., 2012b). Furthermore, the UroII promoter has 
been used to directly promote the expression of oncogenes such as SV40T, Hras 
and Egfr without the use of Cre recombinase expression (Zhang et al., 1999, 
Zhang et al., 2001, Cheng et al., 2002). 
Recently, it was found that the original promoter contained a region of UroII 
that was oppositely inserted, which may result in a differential expression 
pattern of Uroplakin. Therefore, a modified Uroplakin II promoter has been 
cloned to express Cre (UPKIICre) with the correct insertion (Ayala de la Pena et 
al., 2011). This new UPKIICre promoter has shown differences in the effects of 
Cre-mediated recombination in the bladder compared to the original UroIICre 
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promoter. For example, mice expressing SV40T under the UPKII promoter 
developed CIS only (Ayala de la Pena et al., 2011), while SV40T under the 
UroIICre promoter resulted in muscle-invasive bladder cancer (Grippo and 
Sandgren, 2000, Zhang et al., 1999). 
Other Cre drivers in the urothelium include the fatty acid-binding protein (Fabp) 
promoter, which drives Cre expression in all cell layers of the urothelium as well 
as in the renal calyces and pelvis, ureters, and small intestinal and colonic 
epithelium (Saam and Gordon, 1999, Tsuruta, 2006). Shh-Cre is primarily active 
in a subgroup of urothelial basal cells; but it is also expressed in the prostate 
(Shin et al., 2011). CK5-and ΔNp63-Cre have been used to drive the expression of 
the recombinase in the urothelium (Pignon et al., 2013, Gandhi et al., 2013). 
However, CK5 and p63 are also commonly expressed in the skin (Di Como et al., 
2002, Moll et al., 2008). A relatively novel technique has been developed to 
deliver Cre recombinase to the urothelium using a Cre-expressing adenovirus 
(AdenoCre; AdCre) (Puzio-Kuter et al., 2009). In contrast to promoter-based Cre 
expression, AdenoCre allows transduction and recombination of a specific 
number of cells (see also Introduction to Chapter 6). 
1.4.4.3 Advantages and disadvantages of GEM 
The advantages of GEM are that candidate tumour suppressor genes or 
oncogenes can be deleted or mutated singly or in combination, constitutively or 
conditionally, and thereby model the conditions of known cancer signalling 
pathways. On the other hand, tumours of GEM models often show less 
heterogeneity than is generally found in human tumours (Ahmad et al., 2012b). 
Secondly, the cancer cell of origin may not be the same as in the humans since 
the location of tumourigenesis strongly depends on the promoter that is used. 
Furthermore, due to the fact that only a small number of candidate mutations 
are introduced, GEM models may not represent the full spectrum of mutations 
and genome-wide alterations that are seen in human tumours. Finally, GEM 
models often have long latency and incomplete penetrance. Furthermore, 
depending on the nature of the promoter that is used, the introduced constructs 
may be expressed at non-physiological levels (Ahmad et al., 2012b).  
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1.4.4.4 Human bladder cancer genetics in mice 
Fgfr3 models 
Given the preponderance of FGFR3 mutations in urothelial cell carcinoma, a 
number of attempts have been made to model this event in the mice. 
Surprisingly, as yet these attempts have failed to produce a mouse model of 
tumourigenesis that recapitulates human tumourigenesis. Much of this study will 
be investigating why this is the case and how we could generate models that 
develop tumours driven by FGFR3. 
It has been shown in mice that Fgfr3 K644E mutation alone under the control of 
Uroplakin II promoter to drive Cre expression in the urothelium (UroIICre  
Fgfr3+/K644E) did not result in urothelial tumourigenesis by 18 months (Ahmad et 
al., 2011c), indicating that mutant FGFR3 alone it is insufficient to drive 
urothelial tumourigenesis. 
Fgfr3 mutation in combination with Kras activation under the control of UroIICre 
(UroIICre  Fgfr3+/K644E Kras+/G12D) also failed to produce tumours by 12 months 
(Ahmad et al., 2011c), indicating that FGFR3 and KRAS do not cooperate in 
driving urothelial tumourigenesis. This result supports the finding that FGFR3 
and HRAS are unlikely to occur together in human bladder tumours (Jebar et al., 
2005). However, UroIICre  Fgfr3+/K644E Kras+/G12D mice developed skin papilloma 
due to unexpected UroII promoter activity in the skin (Ahmad et al., 2011c), 
indicating a functional role of activated FGFR3 signalling in contributing to 
tumourigenesis. 
Similarly, Fgfr3 mutation in combination with ß-catenin activation (UroIICre  
Fgfr3+/K644E ß-catenin+/exon3) did not result in urothelial tumourigenesis (Ahmad et 
al., 2011c). However, these mice developed lung carcinoma due to UroII 
promoter activity in the lung. These results support that FGFR3 plays a 
functional role in tumourigenesis in the presence of cooperating mutations in a 
tissue-specific fashion.  
One potential reason why these studies did not observe urothelial cancer could 
be that they were using an Fgfr3 K644E mutation that is relatively uncommon in 
bladder cancer. Thus in this study we will assess whether the most common 
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FGFR3 mutation in bladder cancer, S249C, might be more tumour promoting in 
this system. 
Egfr models 
The effect of other receptor tyrosine kinases such as EGFR that stimulate the 
RAS/MAPK pathway in a similar manner as FGFR3 has extensively been 
investigated in the mouse bladder. 
Overexpression of EGFR using the UroII promoter (UroII EGFR+) has been shown 
to produce urothelial hyperplasia in mice around 10 months of age, without 
progression to carcinoma (Cheng et al., 2002).  
EGFR activation in combination with HRAS activation (UroII EGFR+ Hras Q61L) did 
not promote neoplastic progression of the hyperplastic urothelium by 10 months 
(Cheng et al., 2002). However, EGFR activation in combination with SV40T 
overexpression (UroII EGFR+ SV40T+) promoted the development of high-grade 
bladder carcinomas by 10 months (Cheng et al., 2002), indicating that activated 
EGF receptor tyrosine kinase signalling functionally contributes to 
tumourigenesis in the presence of cooperating mutations. 
Hras models 
Aberrant signalling through RAS/MAPK as a major signalling pathway downstream 
of FGFR3 has been implicated to play a role in urothelial cancer. In mice, HRAS 
activation with low copy number (1-2 copies) under the control of the UroII 
promoter (UroII Hras Q61L) led to urothelial hyperproliferation by 10 months and 
low-grade non-invasive urothelial carcinoma formation between 12-26 months 
(Zhang et al., 2001). Similar observations were made in mice with high copy 
number (30-48 copies) where mice presented low-grade non-invasive urothelial 
carcinoma already by 5 months of age (Zhang et al., 2001). This finding was 
supported by another study using the same mouse model (UroII Hras Q61L), where 
homozygous Hras hyperactivation led to urothelial hyperplasia with progression 
to low-grade superficial papillary bladder tumours by 6 months in 100% of the 
cases (Mo et al., 2007). However, the very same model (UroII HrasQ61L) used by 
our group showed urothelial hyperplasia, but no tumour formation was observed 
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by 12 months (Ahmad et al., 2011b).This could be due to different mouse 
genetic background or different animal units. 
HRAS activation in combination with ß-catenin activation under the control of 
UroIICre (UroIICre HrasQ61L ß-cateninexon3/exon3) resulted in low-grade, non-
invasive urothelial carcinoma (Ahmad et al., 2011b). HRAS activation in 
combination with p53 deletion (UroIICre Hras+ p53flox/flox) resulted in superficial 
low-grade papillary tumours or high-grade tumours in 30% of the mice by 3-6 
months (Gao et al., 2004). HRAS activation in combination with EGFR activation 
(UroII Hras Q61L EGFR+) resulted in urothelial hyperplasia without indication of 
tumour formation by 10 months (Cheng et al., 2002). 
Given that Hras in combination with cooperating mutations is a potent driver of 
urothelial tumourigenesis, we will investigate the effect of RAS/MAPK activation 
through Hras G12V mutation and relevant cooperating mutations in an AdenoCre-
induced mouse model and in a Sleeping Beauty insertional mutagenesis mouse 
model. 
p53 models 
A dominant-negative p53 truncation mutation expressed under the UroII 
promoter in mice (UroII p53dom.neg.), leading to disruption of endogenous p53 
protein function in the urothelium, has been shown to produce hyperplasia and 
dysplasia without progression to carcinoma by 20 months (Gao et al., 2004). 
Similar results were obtained when p53 was homozygously deleted under the 
control of a modified UroplakinII-Cre promoter (UPKIICre p53flox/flox), where the 
mice failed to form urothelial tumours (Ayala de la Pena et al., 2011). Likewise, 
using an AdenoCre-driven mouse model of p53 deletion (AdCre p53flox/flox), no 
urothelial abnormalities were observed (Puzio-Kuter et al., 2009).  
However, p53 inactivation in combination with homozygous Pten deletion using 
AdenoCre (AdCre p53flox/flox Ptenflox/flox) led to formation of CIS or invasive 
bladder tumours with 100% penetrance by 6 months including metastasis in 60% 
of the cases by 4-6 months (Puzio-Kuter et al., 2009). p53 deletion in 
combination with HRAS activation (UroIICre p53flox/flox Hras+) resulted in 
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superficial low-grade papillary tumours or high-grade tumours in 30% of the mice 
by 3-6 months (Gao et al., 2004).  
Rb models 
Deletion of Rb1 using the UroIICre promoter in mice (UroIICre Rb1flox/flox) has 
been shown to promote apoptosis, but failed to produce urothelial cell 
carcinoma (He et al., 2009). 
Rb1 deletion in combination with p53 inactivation under the control of UroIICre 
(UroIICre Rb1flox/flox) resulted in urothelial hyperplasia with nuclear 
abnormalities in 10-20% of the cases without progression to carcinoma by 28 
months (He et al., 2009). Similarly, using the AdenoCre promoter, Rb1 deletion 
in combination with Pten deletion (AdCre Rb1flox/flox Ptenflox/flox) or p53 
inactivation (AdCre Rb1flox/flox p53flox/flox) did not promote carcinoma formation 
(Puzio-Kuter et al., 2009). 
SV40 T models 
The Simian vacuolating virus 40 (SV40) is a polyomavirus (DNA virus) that can 
integrate into infected host cells and potentially induce tumours (Ali and 
DeCaprio, 2001). Through expression of large T antigen, SV40 can suppress p53 
and pRB protein function (Ali and DeCaprio, 2001), which makes it a useful 
experimental tool to assess the effect of inactivation of the two key tumour 
suppressors in mice. 
SV40 T antigen overexpression under the control of UroIICre (UroII SV40T+) using 
a low copy number results in severe urothelial dysplasia followed by CIS 
formation (Zhang et al., 1999). Using a high copy number of the transgene, UroII 
SV40T+ mice presented with invasive, metastatic bladder cancer (Cheng et al., 
2002). Interestingly, a follow-up study using the same model reported that the 
majority of CIS eventually evolved into high-grade, superficial papillary tumours 
before a small fraction of them advanced to invasive and metastatic cancer 
(Cheng et al., 2003). SV40 expression under the Cytokeratin 19 (CK19) promoter 
(CK19 SV40T+) resulted in CIS followed by highly invasive bladder tumours by 12 
weeks of age, as well as 20% of the mice developing metastasis to the lungs at 
12 weeks (Grippo and Sandgren, 2000). Papillary lesions were not observed in 
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this model. Expression of SV40 under the control of a modified Uroplakin II 
promoter (UPKII SV40T+) resulted in CIS at one week after birth (Ayala de la Pena 
et al., 2011). However, muscle invasion and metastasis was an infrequent event 
in this model. 
SV40 T antigen overexpression in combination with EGFR overexpression (UroII 
EGFR+ SV40T+) promoted the development of high-grade bladder carcinomas in 
mice by 10 months (Cheng et al., 2002). Given that SV40T targets many 
pathways, this could suggest that in mice multiple hits are required to transform 
the quiescent bladder epithelium into bona fide urothelial tumours. Thus in this 
study we combine a number of events with FGFR3 mutation to assess whether 
this can provoke urothelial carcinogenesis. 
Pten models 
Homozygous Pten deletion under the control of UroIICre in mice (UroIICre 
Ptenflox/flox) did not lead to any abnormal urothelial phenotype (Ahmad et al., 
2011a). Similarly, using the AdenoCre promoter, homozygous Pten deletion 
(AdCre Ptenflox/flox) did not lead to any urothelial abnormalities (Puzio-Kuter et 
al., 2009).  
However, using the Fabp promoter to drive Cre expression in all layers of the 
urothelium, along with intestinal epithelium (FabpCre Ptenflox/flox), homozygous 
Pten deletion resulted in urothelial hyperplasia by 6 weeks and high-grade 
muscle-invasive carcinoma formation in 22% of cases by 13 months of age (Yoo et 
al., 2006). Another study using the same mouse model (FabpCre Ptenflox/flox) 
reported hyperplasia by 2 months and the development of non-invasive bladder 
tumours in 10% of cases by 10 months (Tsuruta, 2006). This inconsistency 
between studies is still unclear but could represent different cell populations 
targeted by the different Cre promoters, mouse genetic background or even 
different animal units. 
Pten deletion in combination with ß-catenin activation under the control of 
UroIICre (UroIICre ß-catenin+/exon3 Ptenflox/flox) resulted in low-grade non-invasive 
urothelial carcinoma (Ahmad et al., 2011a). Homozygous Pten inactivation in 
combination with p53 deletion using AdenoCre (AdCre p53flox/flox Ptenflox/flox) led 
Introduction – Modelling bladder cancer in vivo and in vitro  (Chapter 1)  68 
 
 
 
to formation of CIS or invasive bladder tumours with 100% penetrance by 6 
months including metastasis in 60% of the cases by 4-6 months (Puzio-Kuter et 
al., 2009). 
Given that loss of PTEN appears to be able to contribute to urothelial 
tumourigenesis, we will use a model with Pten deletion as an experimental tool 
to assess the effects of PI3K-AKT activation in the presence of Fgfr3 mutation in 
the urothelium.  
 
Wnt models 
ß-catenin activation under the control of the UroIICre promoter (UroIICre ß-
cateninexon3/exon3) has been shown to produce localised hyperproliferative lesions 
in the bladder epithelium by 3 months without progression to carcinoma (Ahmad 
et al., 2011a). 
ß-catenin activation in combination with Pten deletion (UroIICre ß-catenin+/exon3 
Ptenflox/flox) resulted in low-grade, non-invasive urothelial carcinoma (Ahmad et 
al., 2011a). Similarly, ß-catenin activation in combination with HRAS activation 
(UroIICre ß-cateninexon3/exon3 HrasQ61L) resulted in low-grade, non-invasive 
urothelial carcinoma (Ahmad et al., 2011b).  
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1.5 Aims of the study 
Bladder cancer poses a major health issue worldwide that causes considerable 
morbidity and mortality due to ineffective or lacking therapeutic strategies. It is 
therefore essential to better understand the disease process and the molecular 
changes and mechanisms behind bladder cancer formation and progression in 
order to develop novel therapy approaches. Alterations in FGFR3 signalling are 
frequently found in bladder cancer, either by mutation, overexpression or both. 
However, there are open questions that urgently need to be addressed, such as 
the functional role of FGFR3 in cancer initiation, invasion and progression of 
tumours, as well as the exact mechanism of FGFR3-dependent tumourigenesis as 
a valuable step towards the discovery of novel therapeutic targets.  
The overall aim of this study is to examine the role of FGFR3 mutation in 
bladder cancer initiation and progression by using mouse models.  
The following 4 objectives were addressed: 
I. To investigate the role of FGFR3 in non-invasive bladder cancer. This 
first experiment was based on our previous findings that Fgfr3 mutation 
alone is insufficient to drive tumourigenesis in the urothelium (Ahmad et 
al., 2011c), suggesting that a cooperating mutation may be obligatory for 
FGFR3-dependent tumorigenesis. We found an indication that increased 
PI3K/AKT signalling may be required for tumour formation in the bladder. 
Hypothesising that the putative cooperating mutation is a regulator of 
PI3K/AKT signalling, we targeted a candidate gene, Pten, to test the 
synergistic effects of FGFR3 and PI3K-AKT signalling activation in the 
bladder (Chapter 3). 
II. To identify mutations that cooperate with FGFR3, PTEN, or RAS in 
promoting urothelial tumourigenesis. It has been shown in mouse models 
that Fgfr3, Pten and Ras are unable to drive urothelial tumourigenesis 
when mutated individually. It would therefore be important to test their 
potential to cooperate with a second, randomly introduced mutation that 
can be identified and validated. This unbiased screening approach could 
also help to identify novel mutations that play an important role in 
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bladder cancer. Hypothesising that Fgfr3, Pten, and Hras are 
fundamentally able to promote cancer formation in the presence of 
cooperating mutations, we generated mice with these mutations in 
conjunction with transposable “Sleeping Beauty” elements. (Chapter 4). 
III. To investigate the role of FGFR3 mutation in tumour progression and 
invasion. Alterations in FGFR3 signalling either by mutation or 
overexpression are found in 50% of invasive bladder tumours. However, it 
is unclear whether FGFR3 activation can actively promote tumour 
progression, or whether it is acquired during the evolution of the cancer 
without functional contribution to its progression. To address whether an 
FGFR3 mutation can predispose urothelial cells to tumourigenesis, and to 
evaluate its role in tumour progression in established tumours, we 
subjected Fgfr3-mutant and Wild type mice to a bladder-specific 
carcinogen, N-butyl-N-(hydroxybutyl)-nitrosamine (OH-BBN). We 
compared the effect of two different point mutations in Fgfr3, as well as 
the effect of Pten deletion and Fgfr3-Pten double mutation in the invasive 
tumours (Chapter 5). 
IV. To establish techniques in order to generate and assess invasive 
bladder tumours. The progress of anti-cancer drug development relies on 
the generation and use of suitable animal models, as well as on the 
essential techniques to analyse and assess the effect of the therapy. We 
therefore first aimed to generate an invasive bladder cancer model with 
metastatic potential, in which recombination is promoted in a spatially 
and temporally controlled fashion using a Cre-expressing adenovirus. In 
order to then detect and monitor tumour development and progression in 
the living animals, we tested fluorescent imaging and ultrasound imaging 
in the mouse bladder. Furthermore, with the aim to assess cell 
transformation, migration and response to drug treatment, we tested 
essential ex vivo techniques and assays (Chapter 6). 
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Chapter 2 
Materials and Methods 
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2.1 Mice 
All mice were maintained under non-barrier conditions and given a standard diet 
(CRM (E) expanded diet from Special Diets Services; Cat no 801730) and water ad 
libitum.  
The Biological Services department at the Beatson Institute provided animal 
husbandry including setting up matings, weaning pups, and tail tipping for 
genotyping.  
Mice were sacrificed using an approved schedule 1 procedure. All experiments 
were carried out with the Personal Licence 60/12893 in accordance with the 
Project Licence 60/4271 under the UK Home Office guidelines.  
2.1.1 Mouse lines and genotyping alleles 
Mouse lines used throughout the project are indicated in (Table 2-1). 
DNA extraction from tail tips and genotyping by PCR was performed by 
Transnetyx, USA, (http://www.transnetyx.com/). The company uses a method 
based on real time PCR and DNA hybridisation to detect the presence or absence 
of alleles in the DNA. 
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Table 2-1: Mouse lines and genotyping alleles 
 
 
 
2.1.2 Genetic background of mice 
UroIICre transgenic mice were originally on FVB/N background (Mo et al., 2005). 
Tg(UroII-hFGFR3IIIbS249C) transgenic mice were on C57/CBA mixed background 
(Chapter 2.3). The background of all other mice was C57Bl/6.  
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2.2 Sleeping Beauty mutagenesis 
Bladders were gently emptied of urine. Tissues were generally snap-frozen in 
liquid nitrogen immediately after collection and stored at -80C until further 
preparation. 
2.2.1 T2/Onc3 excision PCR assay 
Excision of the T2/Onc3 transposon in the UroIICreFgfr3+/K644E RosaSBaseLSL 
T2/Onc3 bladder was assessed by PCR (Collier et al., 2005). Bladders and tail 
tips were thawed on ice, and genomic DNA was extracted using the QIAamp DNA 
Mini kit (Qiagen). PCR products were visualised in a 1.5% agarose gel containing 
ethidium bromide. 
T2/Onc3 excision PCR primers and PCR conditions were as follows (Table 2-2 and 
Table 2-3): 
 
Table 2-2: T2/Onc3 excision PCR primers 
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Table 2-3: T2/Onc3 excision PCR conditions  
 
 
 
2.2.2 Splinkerette PCR and Sequencing  
Splinkerette PCR was performed to amplify transposon junctions from genomic 
DNA of mice carrying transposon insertions.  
Genomic DNA was extracted from snap frozen mouse bladders and tails using 
DNeasy kit (Qiagen). Splinkerette PCR, sequencing and bioinformatics analysis 
was performed by Dr Louise Van Der Weyden and Dr David J. Adams at the 
Sanger Institute (Cambridge, UK) as previously described (Uren et al., 2009). See 
also Introduction to Chapter 4. 
 
2.3 Generation of Tg(UroII-hFGFR3IIIbS249C) 
The vector design was performed by Dr Tomoko Iwata (University of Glasgow), Dr 
Darren Tomlinson (LIMM, Leeds, UK) and Prof Margaret Knowles (LIMM, Leeds, 
UK). 
A pGEM-T vector (Promega) was used containing a multiple cloning site (MCS) for 
EcoRI, SpeI, SalI, and NotI (Figure 1-1). The MCS was cloned into pGEM digested 
with NcoI and SacI. The UroplakinII (UroII) fragment of 2.5kb was released from 
a vector supplied by Robert Weeks (Dunedin, New Zealand) using EcoRI and SpeI, 
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and ligated into the same sites in the pGEM MCS. Human FGFR3IIIb cDNA was 
mutated at position 249 and at the stop codon. The clones contained restriction 
sites for SalI at the 5’ end and NotI at the 3’ end of the gene for ease of cloning 
into pGEM-UroII. A poly-A sequence was added 156 bp after the 3’ end of the 
FGFR3 gene. The resulting pGEM-UroII-hFGFR3IIIb-S249C construct contained 
10,294 bp and was fully sequenced. 
 
 
 
Figure 2-1: Tg(UroII-hFGFR3IIIbS249C) vector map  
Schematic representation of pGEM-T vector containing murine UroplakinII promoter and human 
FGFR3IIIb cDNA with S249C mutation.  
Materials and Methods  (Chapter 2)   77 
 
 
 
In order to test the expression level of the construct, three human bladder 
cancer cell lines (VMCUB-1, VMCUB-3 and UMUC-3) were transfected with pGEM-
UroII-hFGFR3IIb-S249C or the empty vector. RNA was extracted and an RT-PCR 
was performed to determine FGFR3 expression levels. A 1.8-fold increase in 
FGFR3 expression was detected in cells with the full construct compared to 
control cells containing the empty vector (Dr Darren Tomlinson, data not 
shown).  
Transgenic animals were generated by pronuclear injection of the pGEM-UroII-
hFGFR3IIb-S249C vector construct. Mouse studs and donors were on C57/CBA F1 
background. Tg(UroII-hFGFR3IIIbS249C) transgenic mice were therefore on 
C57/CBA F2 mixed background and further crossed with C57Bl/6. The presence 
of the transgene in the offspring was confirmed in two mice by sequencing (Dr 
Tomoko Iwata, data not shown). 
Presence of the FGFR3 S249C mutation in Tg(UroII-hFGFR3IIIbS249C) bladders 
was assessed by PCR. PCR primers and conditions are indicated in (Table 2-4 and 
Table 2-5). Tail tips were thawed on ice, and genomic DNA was extracted using 
the QIAamp DNA Mini kit (Qiagen). PCR products were visualised in a 1.5% 
agarose gel containing ethidium bromide. 
Amplified PCR product of Tg(UroII-hFGFR3IIIbS249C) was extracted from 1.5% 
agarose gels using the QIAquick PCR purification kit (Qiagen #28104). Sequencing 
was done by the Beatson Sequencing Service (AB Applied Biosystems, 3130XL).  
 
Table 2-4: Tg(UroII-hFGFR3IIIbS249C) PCR primers 
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Table 2-5: FGFR3 S249C PCR conditions 
 
 
 
2.4 OH-BBN treatment 
Mice were administered 0.05% w/v N-butyl-N-(4-hydroxybutyl) nitrosamine (OH-
BBN, TCI UK #B0938) in drinking water, which was prepared freshly three times a 
week. Two different lengths of treatment were performed. In one, animals were 
treated for 10 weeks with OH-BBN followed by 10 weeks of regular water 
(further called “10+10 weeks”). In the other, animals were subjected to 20 
weeks continuously of OH-BBN (further called “20 weeks”). Animals were 
sacrificed at different time points during the procedure or when 20 weeks were 
completed.  
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2.5 Virus injections 
Cre-expressing Adenovirus and Lentivirus (Feline Immunodeficiency Virus) was 
injected into the bladder upon laparotomy as previously described (Table 2-6) 
(Puzio-Kuter et al., 2009, Seager et al., 2010).  
2.5.1 Virus preparation 
Virus was mixed with 10% Hexadimethrine bromide (Polybrene, Sigma #107689-
10G) and kept on ice until injection.  
Table 2-6: Cre viruses  
 
 
 
2.5.2 Anaesthesia 
Mice were anaesthetised using  2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-
ethane (Isoflurane-Vet 100% w/w Inhalation Vapour, Liquid, Merial Animal Health 
Ltd., UK) through a Key Fill Vapouriser 5% connected to medical air and an 
active scavenging unit (Vet Tech Solutions). Isofluorane was supplied at level 4 
to put the mouse asleep. During the procedure, mice were maintained at level 
2. 
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2.5.3 Surgical procedure 
The lower abdomen was shaved, and a small incision was made to expose the 
bladder (Figure 2-2). The bladder was emptied of urine using a 0.5ml syringe (BD 
Micro Fine 0.5ml 29G x 12.7mm). The virus was orthotopically instilled via a 
second syringe. The bladder was let sink back into the abdomen, and the incision 
was closed with suture (Coated Vicryl Suture, 4/0 Violet 45cm, 17mm 3/8Circle 
Taper Point Needle, MidMeds UK#W9074) and wound clips (Clay Adams Clips, Vet 
Tech solutions #IN015A). Animals were monitored for recovery. 
 
 
Figure 2-2: Virus injection into mouse bladder 
Schematic representation of the urinary tract that is exposed upon laparotomy. Adenovirus is 
injected into the emptied bladder using a syringe. Adapted from (Seager et al., 2010) 
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2.6 Live imaging 
Prior to live imaging, mice were either anaesthetised (Chapter 2.5.2) or 
sacrificed before the procedure. 
2.6.1 Fluorescent imaging 
The abdominal area of mice was shaved using an electric hair trimmer. Mice 
were scanned by IVIS Spectrum (Perkin Elmer). Filter-pair imaging with epi-
illumination was used. mCherry (red channel) was used with excitation 
wavelength at 587 nm and emission at 610 nm. GFP (green channel) was used 
with excitation at 465 nm and emission at 520 nm. The field of view was set at 
13.3 cm. The focus of subject height was set at 1.5 cm. Auto settings were used 
for exposure and photo acquisition. Pictures were analysed using Photoshop 
software (Adobe Photoshop CS2).  
2.6.2 Ultrasound scanning 
Hair in the abdominal region was removed using depilatory cream (Nair). 
Ultrasound gel (Henleys Medical, salt-free) was applied to the abdomen, and the 
animal was tape-secured to a heated (40 C) ultrasound platform. Bladders were 
then imaged by ultrasound (Vevo 770, Visualsonics Inc., 25MHz transducer) and 
photos were converted to JPEG format using OsiriX software (OsiriX 5.7 32-bit, 
Geneva, Switzerland) and analysed using ImageJ software (NIH, Bethesda, USA). 
2.7 Tissue harvest and fixation 
Bladders were gently emptied of urine and placed in 10% formalin for overnight 
fixation. Fixed bladders were embedded in paraffin by the Beatson Histology 
Service with the bladder dome facing up and the trigone down. Alternatively for 
X-Gal staining, formalin-fixed bladders were transferred into 10%, 20%, and 30% 
sucrose in PBS, OCT-embedded with the bladder dome facing up and the trigone 
down, and frozen in liquid nitrogen. Paraffin or OCT-frozen sections were cut 
starting from the trigone side of the bladder.  
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2.8 Histology 
Haematoxylin and eosin (H&E) and PAS staining (Leica Microsystems staining 
solutions #3803812 and #03800E) was performed on 4 m paraffin-embedded 
sections by the Beatson histology Service (Table 2-7). 
X-Gal staining (K1465-01, Invitrogen Life Technologies, UK) was performed on 10 
m formalin-fixed OCT-embedded frozen sections by the Beatson histology 
Service (Table 2-7). 
Table 2-7: Processing methods for histological staining 
 
 
 
2.9 Immunohistochemistry 
Routine immunohistochemistry was performed by the Beatson histology service 
(Caspase-3, E-Cadherin, GFP, Ki67, Pten, pAKT, pERK, p21, p63, SMA, β-
catenin). Immunofluorescent staining experiments were greatly supported by 
Despoina Natsiou (University of Glasgow).  
The specificity of each antibody has been carefully examined at the outset of 
the experiments at the Histology Services of the Beatson Institute for Cancer 
Research and by myself. Ki67, Caspase-3, E-cadherin, pERK, pAKT, p-mTOR, 
PTEN and p21, are routinely used in the Institute and validated in multiple 
tissue/cancer types. For pERK we have performed an experiment with p-Erk1/2 
antibody (Cell Signaling, #4370; 1:100) together with the Blocking Peptide 
specific to this antibody (Cell Signaling, #1150; 1:50, as directed by the 
manufacturer's instructions). CK5, CK18, Uroplakin II and p63 have been 
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optimised for bladder tissue: positive and negative control slides were added to 
each experiment as appropriate. As an internal control, we evaluated negative 
staining in the areas that are not supposed to be stained within the same 
sections together with the presence of staining in the intended tissue/cellular 
components. 
Slides were dewaxed in xylene for 2x5min, and rehydrated in 100%, 95% and 70% 
ethanol with a final step in PBS. 
To reduce endogenous peroxidase activity, samples were incubated in 0.3% H2O2 
in distilled water for 20 min.  
Antigen retrieval was routinely performed in 0.01M citric acid (pH 6) in a boiling 
waterbath for 20-30 minutes. For β-catenin immunostaining, retrieval was 
performed for 50 min. For CK5, CK18 and UroII immunostaining, retrieval was 
performed in a pressure cooker inside a microwave with open lid for 15 min and 
with closed lid for 4 minutes at full power. Slides were then allowed to cool 
down for 20 min at room temperature. 1M citric acid was made up by 105.07g in 
500 ml (no pH adjustment); 5ml of 1M solution were used to make 500ml of 
0.01M citric acid to be pH adjusted by NaOH. 
To prevent endogenous staining, non-specific sites were blocked with 5% normal 
goat serum in PBS for 1 hour. Incubation with primary antibody was performed 
overnight at 4ºC (Table 2-8). 
Signals were subsequently visualised by chromogenic or fluorescent procedure. 
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Table 2-8: Primary antibodies 
 
 
Materials and Methods  (Chapter 2)   85 
 
 
 
2.9.1 Chromogenic signals 
Biotinylated secondary antibody (Table 2-9) was applied for 2 hours at room 
temperature, followed by the ABC Elite Standard kit (Vector Labs, PK-6100) for 
signal enhancement for 1 hour at room temperature. Sections were incubated 
with 3,3'-Diaminobenzidine (DAB; K3468, Dako) until colour development. 
Sections were subsequently counterstained with haematoxylin, dehydrated in 
100%, 95% and 70% ethanol with a final incubation in xylene for 5 minutes, and 
mounted with DPX (Distyrene, Plasticizer, Xylene) mounting media. 
Table 2-9: Biotinylated secondary antibodies 
 
 
 
2.9.2 Fluorescent signals 
Following fluorescent antibody incubation (Table 2-10), sections were incubated 
with 4',6-diamidino-2-phenylindole (DAPI; 1:1000) and mounted with Vectashield 
(Vector Labs, H-1000).  
Table 2-10: Fluorescent secondary antibodies 
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2.9.3 Scanning of slides  
Slides were scanned by Nanozoomer slide scanner (Hamamastu) and analysed by 
SlidePath Digital Image Hub (Leica Biosystems).  
 
2.10 Microscopy 
Pictures of chromogenic staining were taken by Axio Imager light microscope 
(Zeiss A1). Pictures of fluorescent staining were taken by Zeiss upright confocal 
microscope (Zeiss 710). IHC staining was examined in the minimum of n=3 per 
genotype. 
 
2.11 Measurements of urothelial thickness 
Three representative photos were taken for each H&E stained section at 40x 
magnification. Urothelial thickness was measured in 25-30 µm intervals at 
random fashion using ImageJ software (NIH, Bethesda, USA). Each picture 
contained 20-50 measurements. The mean value of the thickness was initially 
calculated per sample, and was then subsequently used to determine the mean 
value per genotype as presented in the results.  
 
2.12 Measurements of urothelial cell size 
To determine the cell size, IHC with E-cadherin was performed by the Beatson 
Histology Service. Measurement of urothelial cell size was performed by Louise 
King (University of Glasgow). 
Three representative photos were taken for each tissue section at 40x 
magnification. Each cell was marked around the cell membrane and the areas 
were quantified using ImageJ. The sizes of fifteen cells each layer were 
measured per layer per sample.   
Materials and Methods  (Chapter 2)   87 
 
 
 
2.13 Human tissue microarray (TMA) 
TMA staining of clinical specimen was performed by Dr Tomoko Iwata (University 
of Glasgow) and the Beatson Histology Service. TMA scoring was performed by Dr 
Theo van der Kwast (UHN, Toronto, Canada) and Dr Bas van Rhijn (NCI, 
Amsterdam, Netherlands). 
The medical-ethical committee of the University Health Network, Toronto (02-
0515-C and 08-0263-T) and the Research Ethics Board (REB), Canada, approved 
the work with human tissue and to extract clinical data.  
66 samples of T1 urothelial tumours of low- and high-grade according to WHO 
2004 classification system, and G2 and G3 according to WHO 1973 classification 
system were subjected to immunohistochemistry for pmTOR and FGFR3 (B9). 
TMA sections were scored according to the 4 point scale (0=negative, 1=faint, 
2=intermediate, 3=strong/intense) and the 2 point scale (0= normal, 
1=overexpression).  
 
2.14 Statistics 
Statistics were performed using SPSS software (SPSS Statistics Version 19, IBM). 
For thickness, cell size, proliferation, and apoptosis experiments we used the 
Kruskal-Wallis test for non-parametric distribution of data in order to define 
overall significance across multiple categories (genotypes). The Mann-Whitney 
test was subsequently used to analyse individual significance between the 
genotypes. For human tissue micro array (TMA) analysis and frequency analysis 
of histological features in OH-BBN-induced tumours we used Pearson Chi-Square 
test. 
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2.15 Cell and tissue culture 
2.15.1 Preparation of cell stocks  
Cells were harvested at 70-80% confluency, frozen in the specific growth media 
(Table 2-11) containing 10% DMSO, and stored at -80C. For reconstitution, cells 
in cryovials (Starlab, Milton Keynes, UK) were thawed in a 37°C water bath, 
washed with PBS or growth media, resuspended in Matrigel and subsequently 
seeded. 
2.15.2 Cell counting 
Cells were counted using either a haemocytometer (Marienfeld, Neubauer-
improved) for absolute numbers or by a cell counter (Roche, Casy Innovatis) for 
relative cell numbers. For cell counts in the haemocytometer, single cells were 
mixed 1:1 with Trypan blue. A 10l aliquot was then applied to the 
haemocytometer chamber. Cells in the 4 x 16 squares were counted using a light 
microscope with phase contrast. The number of cells was then calculated by 
multiplying the total cell number of all 4 squares by the Trypan blue dilution 
factor (2), which results in the number of cells x 104/ml. For the automated cell 
counter, cell pellets were resuspended in 5-10ml PBS. 400l of the suspension 
was mixed with 19.6ml of Casiton solution (Roche). The automated cell counter 
displays the number of cells/ml. 
2.15.3 Culture of human cell line EJ138 
A liquid nitrogen stock of EJ138 at passage 34 was obtained from the Radiation 
Oncology group, University of Glasgow. EJ138 was maintained in DMEM with 2mM 
of L-Glutamine, 10% FBS and 1% of Penicillin-Streptomycin without addition of 
growth factors. Cell culture dishes were incubated at 37°C under 5% CO2, and 
the media was changed three times a week. Cells were counted and seeded on 
Collagen-I matrices (Chapter 2.15.6). 
2.15.4 Primary cell culture from mouse bladder 
Bladders were harvested and placed in cold PBS until preparation of the culture. 
To generate single cells, bladders were inverted and the urothelium or tumorous 
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tissue was scraped off using a scalpel. Cell clumps were manually broken down 
using a pipette.  
After washing with PBS, the cell pellet was incubated for 20-30 min in 1ml 
TrypLE (Gibco, Invitrogen) containing 10l (0.8 g/ml) recombinant DNase I 
(Roche) and 100l DNase I reaction buffer (Roche). Cells were washed in PBS and 
filtered through a 70m cell strainer (BD Falcon, 70m yellow). Cells were then 
used for Matrigel culture or Collagen-I invasion assay. 
 
2.15.5 Matrigel culture and colony formation assay 
Single cells were counted and seeded in approximately 25l Matrigel droplets 
(BD Biosciences, #356231) in 24-well plates and covered with either ADF media 
(Table 2-11) supplemented with growth factors (Table 2-12). 
Cells were resuspended in Matrigel at a known concentration and droplets of the 
mixture were seeded in 24-well plates. After allowing the Matrigel droplets to 
solidify for a few minutes at 37°C, 0.5ml of ADF growth media (Table 2-11) 
supplemented with growth factors (Table 2-12) was added per well. Plates were 
incubated at 37°C under 5% CO2, and the media was changed three times a 
week.  
Colonies were counted using a light microscope with phase contrast at 10x 
magnification.  
To passage the cells, colonies in the Matrigel were resuspended into single cells 
using a 1000ul pipette tip; cells were washed 2-3 times with PBS, counted and 
re-seeded. 
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2.15.6 Collagen-I invasion assay  
Invasion into an organotypic matrix containing human fibroblasts from skin 
explants and Collagen-I from rat tails has been described previously (Timpson et 
al., 2011). 
Single cells at a known concentration in 1ml DMEM media were seeded onto 
Collagen-I matrices containing either normal human fibroblasts (NHF) (Timpson 
et al., 2011) or telomerase-immortalised fibroblasts (red TIFF) (Munro et al., 
2001). Cells were allowed to attach to the matrix for 3-4 days.  
Matrices were then transferred onto grids with an air-media interface. Cells 
were allowed to invade for 14 days with DMEM media being changed every other 
day. Matrices were cut in halves and fixed in 4% PFA overnight. H&E staining as 
well as immunohistochemistry was performed on 4 m-thick paraffin-embedded 
sections. 
2.15.7 Organotypic slice culture 
Organotypic slice culture of the bladder was performed as previously described 
(Batourina et al., 2012).  
Bladders or bladder tumours were cut into 2-3mm slices using dissecting scissors 
(Straight 7mm blades, Coherent Vannas #500086) under a dissection microscope. 
Duplicate slices were placed with the urothelium facing down on membrane 
culture inserts (Millipore #PICM0RG50) in glass bottom dishes (In Vitro Scientific 
#D35-20-1-N) containing basal conditional media (Table 2-11) supplemented with 
recombinant rat glial cell line-derived neurotrophic factor (rGDNF), human 
hepatocyte growth factor (hHGF), and human keratinocyte growth factor (hKGF, 
also known as FGF7) (Table 2-12). Explants were covered with a drop of sterile 
mineral oil (Sigma-Aldrich # M5904). 
Cultures were maintained at 37°C with 5% CO2 concentration. Basal conditional 
medium was changed three times a week.   
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2.15.8 Tamoxifen induction of organotypic slice culture 
Organotypic slice cultures were induced by addition of 1uM 4-Hydroxytamoxifen 
solution or for controls using 1.2 μl 100% ethanol. 5mg of 4-OH-Tamoxifen 
powder (Sigma, H7904-25mg) was resuspended in 2.5ml 100% ethanol to produce 
a 5mM stock solution. 1ul of the 4-OH-Tamoxifen stock solution was added per 
10ml media. The organotypic slices were then incubated at 37˚C in 5% CO2 
atmosphere for 20hrs before the culturing media was changed and new growth 
factors were added.  
 
2.15.9 R3Mab treatment of organotypic slice culture 
Organotypic slice explants were subjected to 10nM R3Mab (Genentech, 
MFGR1877s) or 10nM control antibody (Genentech, gD 5237) every other day for 
4 days in basal conditional media. Slices were placed in 4% PFA overnight, 
paraffin-embedded and processed for histological staining. 
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Table 2-11: Media components 
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Table 2-12: Growth factors 
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Chapter 3 
The role of FGFR3                                                  
in non-invasive bladder cancer 
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3.1 Introduction  
In order to study the functional role of FGFR3 activation in bladder 
tumourigenesis, we have previously generated a mouse model in which Fgfr3 
K644E, a constitutively active form of FGFR3 (Iwata et al., 2000), is conditionally 
expressed  in the urothelium by placing Cre recombinase expression under the 
Uroplakin II (UroII) promoter (UroIICre Fgfr3+/K644E) (Ahmad et al., 2011c). These 
mice did not develop bladder cancer at 18 months, suggesting that cooperating 
mutations are required for FGFR3 to drive tumourigenesis in the bladder. In the 
same study in combination with K-Ras or β-Catenin, Fgfr3 activation caused 
tumours in the skin and in the lungs, respectively, suggesting that FGFR3 is able 
to induce tumourigenesis in the presence of cooperating mutations (UroIICre 
Fgfr3+/K644EKras+/G12D and UroIICre Fgfr3+/K644E ß-catenin+/exon3). It was observed 
that the PI3K/AKT pathway was highly upregulated in these lung tumours, while 
it remained unchanged in the bladder of mice with the same genotype (Ahmad 
et al., 2011c). This could indicate that increased PI3K/AKT signalling may be 
required for tumour formation in the bladder.  
In human bladder tumours, mutations in FGFR3 and PI3K/AKT pathway genes and 
their activation are strongly co-associated (Lopez-Knowles et al., 2006, Kompier 
et al., 2010, Duenas et al., 2013). A catalytic subunit of PI3K, PIK3CA, is 
frequently mutated in non-invasive urothelial cell carcinoma, leading to a 
significant proliferative advantage through increased lipid kinase activity and 
constitutive AKT activation (Lopez-Knowles et al., 2006, Askham et al., 2010, 
Ross et al., 2013). FGFR3 signalling can activate the PI3K/AKT pathway by 
phosphorylated GRB2/GAB1 interaction with PI3K (Hart et al., 2001). 
 
The PI3K/AKT pathway is involved in a range of cellular processes such as 
proliferation, apoptosis, survival and migration by controlling the expression of a 
range of proteins including Bcl-2-associated X (Bax), nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB), mouse double minute 2 homolog 
(MDM2) and mammalian target of rapamycin (mTOR) (Fresno Vara et al., 2004). 
mTOR has been shown to be a candidate for effective therapeutic targeting 
(Ahmad et al., 2011a, Puzio-Kuter et al., 2009). Furthermore, PI3K/AKT 
signalling increases the expression of cell-cycle regulating genes such as p21 by 
suppressing GSK3β and activating mTOR (Yohn et al., 2011). p21 was previously 
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shown to be up-regulated in the mouse urothelium in which Pten is deleted (Yoo 
et al., 2006). 
In this chapter we aimed to test the synergistic effects of FGFR3 and PI3K-AKT 
signalling activation. At the time of planning and initiating the experiments, a 
mouse model with activating Pi3k mutation was unavailable. Therefore we used 
a mouse line with Pten deletion as an experimental tool to assess the effects of 
PI3K-AKT activation in the presence of Fgfr3 mutation in the urothelium.  
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3.2 Establishment of the UroIICre Fgfr3+/K644E Ptenflox/flox 
mouse model  
3.2.1 Generation of the cohorts 
We generated cohorts of UroIICre Fgfr3+/K644E (n=25), UroIICre Ptenflox/flox (n=20) 
and UroIICre Fgfr3+/K644E Ptenflox/flox (n=24) and examined bladders at 5-18 
months (Table 3-1). Some animals were euthanised due to causes unrelated to 
changes in the bladder, including infection or lymphoma. Mice were also 
sacrificed due to skin rash on the back owing to UroIICre recombination in the 
epidermis (Ahmad et al., 2011c). 
The term “Control” used throughout Chapter 3, as opposed to “Wild type” in 
other chapters refers to mice of C57Bl/6 (n=7) and mice with presence of 
T2/Onc3 (n=4), which does not lead to any abnormal bladder phenotype by 
itself.  
 
Table 3-1: Summary of mouse cohorts with Fgfr3 and Pten mutation  
 
 
  
Results – The role of FGFR3 in non-invasive bladder cancer  (Chapter 3)  98 
 
 
 
3.2.2 FGFR3 and PTEN protein expression 
Protein levels of the targeted genes were assessed by immunohistochemistry in 
n=3 samples per genotype (Figure 3-1). We detected similar levels and patterns 
of FGFR3 protein expression in the urothelium of Control (A) and UroIICre 
Fgfr3+/K644E (C) as we have reported previously (Ahmad et al., 2011c). FGFR3 
levels were also similar in UroIICre Ptenflox/flox (E) and UroIICre Fgfr3+/K644E 
Ptenflox/flox (G), indicating that FGFR3 expression was neither influenced by Fgfr3 
mutation nor deletion of Pten.  
Levels of PTEN protein were similarly low in Control (B) and UroIICre Fgfr3+/K644E 
(D), indicating that PTEN expression is unaltered in the presence of Fgfr3 K644E 
mutation. Knockdown of Pten expression in the urothelium of UroIICre 
Ptenflox/flox was considered as successful (F).  
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Figure 3-1: FGFR3 and PTEN expression in the UroIICre Fgfr3
+/K644E 
Pten
flox/flox 
urothelium 
Immunohistochemistry for FGFR3 in bladders of Control (A), UroIICre Fgfr3
+/K644E
 (C), UroIICre 
Pten
flox/flox
 (E) and UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 (G). Immunohistochemistry for PTEN in bladders 
of Control (B), UroIICre Fgfr3
+/K644E
 (D), and UroIICre Pten
flox/flox
 (F). Scale bar represents 100 µm 
(A-G).  
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3.2.3 Recombination under the UroIICre promoter 
Cre-dependent recombination in the urothelium under the UroII promoter was 
assessed by X-gal staining and GFP expression using Z/EG reporter mice (Figure 
3-2). 
In the presence of the UroIICre allele, cells with a GFP-positive nucleus were 
observed in the majority of umbrella and intermediate cells, whereas basal cells 
showed fewer cells with GFP-positivity (A). Successful recombination was 
confirmed with only little X-gal staining remaining in some of the umbrella cells 
of the urothelium in UroIICre Z/EG (B), which is most likely an artefact since 
similar staining is seen in Z/EG (C). 
 
 
Figure 3-2: Recombination in the urothelium under UroIICre 
Paraffin sections of UroIICre Z/EG Pten
flox/flox
 stained by GFP (A). Frozen sections of UroIICre Z/EG 
(B) and Z/EG only (C) with X-gal staining. Scale bar represents 100 µm (A-C).  
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3.3 Increased thickness of the UroIICre Fgfr3+/K644E 
Ptenflox/flox urothelium 
To see the effect of Pten deletion together with Fgfr3 mutation in the 
urothelium, we analysed H&E-stained sections of Wild type (Control), UroIICre 
Fgfr3+/K644E, UroIICre Ptenflox/flox, and UroIICre Fgfr3+/K644E Ptenflox/flox (Figure 
3-3). 
The UroIICre Fgfr3+/K644E urothelium (n=25) (b, f) appeared similar to that of 
Control (n=11) (a, e) in regards to the morphology of the three layers, namely 
umbrella, intermediate and basal cells (e, insert). A mild increase in urothelial 
thickness was observed in UroIICre Ptenflox/flox (n=12 out of 20, 60%) (c, g). 
Furthermore, we observed a severe increase in thickness in the urothelium of 
UroIICre Fgfr3+/K644E Ptenflox/flox bladders (n=20 out of 24, 83%) (d, h) compared to 
Control. 
 
 
Figure 3-3: Increased thickness of the UroIICre Fgfr3
+/K644E
 Pten
flox/flox 
urothelium by H&E 
Representative H&E sections of Control (a, e), UroIICre Fgfr3
+/K644E
 (b, f), UroIICre Pten
flox/flox 
(c, g), 
and UroIICre Fgfr3
+/K644E
 Pten
flox/flox 
(d, h) at low (a-d) and high magnification (e-h). Scale bar 
represents 200 µm in panel a-d and 100 µm in panel e-h.  
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We have quantified the changes in urothelial thickness in mice aged to 11-18 
months. Consistent with our previous observations (Ahmad et al., 2011c, Ahmad 
et al., 2011a), we found no significant difference in urothelial thickness between 
UroIICre Fgfr3+/K644E and Control, or between UroIICre Ptenflox/flox and Control 
(Figure 3-4). There was no significant difference when UroIICre Fgfr3+/K644E and 
UroIICre Ptenflox/flox were compared. However, urothelial thickness was 
significantly increased when both mutations were present in UroIICre Fgfr3+/K644E 
Ptenflox/flox (n=13) compared to either UroIICre Fgfr3+/K644E (n=9) (p=0.00005, 
Mann-Whitney test) and UroIICre Ptenflox/flox (n=7) (p=0.00049), suggesting that 
this increase is owing to the cooperation of Fgfr3 and Pten mutation. 
 
 
Figure 3-4: Quantification of thickness in UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 urothelium  
Thickness of the urothelium in Control, UroIICre Fgfr3
+/K644E 
(Fgfr3), UroIICre Pten
flox/flox
 (Pten) and 
UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 (Fgfr3 Pten).  
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We have also analysed the effect of homozygous mutation in Fgfr3 (UroIICre 
Fgfr3K644E/K644E) (Figure 3-5). The urothelium of UroIICre Fgfr3K644E/K644E mice 
indeed showed thickening (n=11 out of 12) (A, B). Furthermore, mice with 
double homozygous mutations in Fgfr3 and Pten (UroIICre Fgfr3K644E/K644E 
Ptenflox/flox) revealed a similar phenotype to that of UroIICre Fgfr3+/K644E 
Ptenflox/flox (n=2 out of 3) (C, D). 
 
 
Figure 3-5: Thickening of the urothelium in UroIICre Fgfr3
K644E/K644E 
and UroIICre 
Fgfr3
K644E/K644E 
Pten
flox/flox
 
Representative H&E sections of bladders of UroIICre Fgfr3
K644E/K644E 
(A, B) and UroIICre 
Fgfr3
K644E/K644E 
Pten
flox/flox 
(C, D). Scale bar represents 100 µm (A-D).  
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3.4 Abnormal morphology of UroIICre Fgfr3+/K644E 
Ptenflox/flox urothelium 
Next we examined the appearance of the urothelia more closely (Figure 3-6). 
In addition to increased urothelial thickness, several abnormal features in 
cellular morphology were observed in UroIICre Fgfr3+/K644E Ptenflox/flox, including 
vacuolisation (arrow in c), condensed cellular appearance (circled in e), 
enlargement of cells and nuclei (arrow heads in e, f), and loss of orientation 
(mis-localisation of umbrella, intermediate and basal cells).  
High glycogen levels were detected in vacuoles observed in UroIICre Fgfr3+/K644E 
Ptenflox/flox by Periodic acid-Schiff (PAS) staining (n=3) (g).  
At least one of these cellular features were observed in the majority of UroIICre 
Fgfr3+/K644E Ptenflox/flox bladders (n=20, 83%), while none of these abnormal 
features were present in Control (n=11) (a, d), UroIICre Fgfr3+/K644E (n=25) or 
UroIICre Ptenflox/flox urothelium (n=20).  
 
 
Figure 3-6: Abnormal morphology of the UroIICre Fgfr3
+/K644E 
Pten
flox/flox 
urothelium 
Representative H&E sections of Control (a, d) and UroIICre Fgfr3
+/K644E
 Pten
flox/flox 
(b, c, e, f). Scale 
bar represents 200 µm in panel a-c and 100 µm in d-g. 
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3.5 Differential expression of layer-specific markers 
In order to see whether the abnormal phenotype is caused by a change in 
urothelial cell identities, the bladders were stained with urothelial markers well-
established in mice (Figure 3-7). 
UroplakinII (UroII) is a marker for umbrella and some intermediate cells (Kong, 
2004), while Cytokeratin 5 (CK5) is expressed in basal cells of the normal 
urothelium (Shin et al., 2011, Castillo-Martin et al., 2010) (a, b).  
However, in the UroIICre Fgfr3+/K644E Ptenflox/flox urothelium, UroII-positive cells 
were present in deeper layers close to the submucosa, while CK5 expression was 
absent in some parts of the innermost layers of the urothelium, showing an 
inverse expression pattern (e, f, i, j).  
Furthermore, p63, which is normally present in the nuclei of basal and 
intermediate cells (Castillo-Martin et al., 2010) (c), showed a disorganised 
expression pattern (g, k).  
Double staining of CK18, an alternative marker of umbrella cells in mice 
(Castillo-Martin et al., 2010), together with CK5 clearly showed the abnormal 
localisation of CK18-positive cells deep in the urothelium of UroIICre Fgfr3+/K644E 
Ptenflox/flox (h, l), indicating abnormal differentiation of urothelial cells in 
UroIICre Fgfr3+/K644E Ptenflox/flox. 
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Figure 3-7: Abnormal cellular identity in the UroIICre Fgfr3
+/K644E
 Pten
flox/flox 
urothelium 
Immunohistochemistry for UroplakinII (a, e, i), CK5 (b, f, j and d, h, l), p63 (c, g, k), CK18 (d, h, l), 
and double staining with CK18 (green) and CK5 (red) (d, h, l) in Control (a-d) and UroIICre 
Fgfr3
+/K644E
 Pten
flox/flox 
bladders (e-l). Scale bar represents 200 µm in a-d and 100 µm in e-l. 
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3.6 Increase in the size of intermediate cells in UroIICre 
Fgfr3+/K644E Ptenflox/flox urothelium 
The increase in the urothelial thickness can be caused by deregulation of cell 
size and/or cell number.  
We first addressed whether these were due to changes in cell size, and if so, 
whether the cell size change was seen in specific urothelial cell populations 
(Figure 3-8). An example of E-cadherin staining is shown in UroIICre Fgfr3+/K644E 
Ptenflox/flox bladder (a), in which cells are lined in red for the measurement of 
surface area.  
No significant difference in cell size was observed in the innermost basal and 
outermost umbrella layers among the cohorts (b, d). In contrast, in the 
intermediate layer (between the inner and outermost layers), while Fgfr3 
mutation alone did not influence the cell size (UroIICre Fgfr3+/K644E, n=5), Pten 
mutation alone (UroIICre Ptenflox/flox, n=6) increased the cell size compared to 
Control (n=5, p=0.017, Mann-Whitney test) (c). Furthermore, the presence of 
both Fgfr3 and Pten mutations (UroIICre Fgfr3+/K644E Ptenflox/flox urothelia, n=10) 
further increased the cell size comparing to Fgfr3 mutation alone (p=0.001), as 
well as to Pten alone (p=0.016), suggesting that the Fgfr3 mutation cooperates 
with the Pten loss to further increase the cell size.  
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Figure 3-8: Differential effects of Fgfr3 and Pten mutations in regulation of cell size in the 
urothelium  
Example of cell surface measurement on E-cadherin-stained section (a). The sizes of umbrella (b), 
intermediate (c) and basal cells (d) among the different genotypes.  
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3.7 Increased proliferation in UroIICre Fgfr3+/K644E 
Ptenflox/flox urothelium 
Next we examined the proliferation in the urothelium by Ki67 
immunohistochemistry (Figure 3-9). Albeit in a relatively small number of cells, 
Ki67 positivity was identified in all layers of the urothelium, including umbrella 
cells (a) (Castillo-Martin et al., 2010).  
Taken all layers together, a significant increase in Ki67-positive cells was seen in 
the presence of both Fgfr3 and Pten mutation (UroIICre Fgfr3+/K644E Ptenflox/flox, 
n=9, p=0.004), as well as in the presence of Pten mutation only (UroIICre 
Ptenflox/flox, n=6, p=0.009, Mann-Whitney test), compared to Fgfr3 mutation only 
(UroIICre Fgfr3+/K644E, n=5) (c). This indicates that cell proliferation was 
increased due to Pten loss.  
Similar effects were observed in the outermost umbrella and intermediate layer 
(d, e), while no significant changes were seen in the innermost basal layer (f). 
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Figure 3-9: Differential effects of Fgfr3 and Pten mutations in regulation of proliferation in 
the urothelium 
Ki67 -stained sections of Wild type (a) and UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 (b). Proliferation in all 
layers (c), umbrella (d), intermediate (e) and basal cells (f) among the different genotypes. Scale 
bar represents 100 µm in panel a-b.  
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3.8 Increased apoptosis in the UroIICre Fgfr3+/K644E 
urothelium 
We have also examined apoptotic events (Figure 3-10). Very few apoptotic 
events were observed in the urothelium of all cohorts including Control (a) and 
UroIICre Fgfr3+/K644E Ptenflox/flox urothelium (b).  
Overall, apoptosis was significantly increased when both Fgfr3 and Pten 
mutations were present (UroIICre Fgfr3+/K644E Ptenflox/flox, n=10) or Fgfr3 
mutation alone (UroIICre Fgfr3+/K644E, n=5) compared to UroIICre Ptenflox/flox 
(p=0.004 and 0.032, respectively, Mann-Whitney test) (c). As there was no 
additional increase with both mutations together comparing to Fgfr3 mutation 
alone, the increase in the apoptosis is likely to be owing to the Fgfr3 mutation. 
Similar effects were observed in the outermost umbrella and intermediate cell 
layers (d, e).  
In contrast, in the innermost basal cell layer, apoptotic events were increased 
when Pten mutation was present (UroIICre Ptenflox/flox, n=5) (f). However, the 
overall small number of apoptotic cells in the basal layer made the 
interpretation of results difficult.  
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Figure 3-10: Increased apoptosis in the UroIICre Fgfr3
+/K644E
 Pten
flox/flox 
urothelium  
Caspase-3-stained sections of Wild type (a) and UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 (b). Apoptosis in all 
layers (c), umbrella (d), intermediate (e) and basal cells (f) among the different genotypes. Scale 
bar represents 100 µm in panel a-b.  
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3.9 Changes in MAPK/AKT signalling and cell cycle 
regulation 
To examine underlying mechanisms leading to the observed phenotype, we 
addressed how Fgfr3 and Pten mutations altered their downstream signalling 
cascades. The activation of MAPK and PI3K-AKT pathways were characterised in 
the bladder using antibodies that recognise the phosphorylated forms of ERK1/2 
(pERK1/2) and AKT (Ser473) (pAKT), respectively (Figure 3-11). 
 
In Controls, phosphorylated ERK1/2 (pERK1/2) was observed in a cell-specific 
fashion in the urothelium, however not limited to a particular layer (n=9) (a). 
Staining was similar in UroIICre Fgfr3+/K644E (n=9) and UroIICre Ptenflox/flox (n=9) 
(d, g). In contrast, in UroIICre Fgfr3+/K644E Ptenflox/flox samples (n=9/12, 75%) 
pERK1/2 was seen in all layers in a cell-specific fashion (j), which resembles the 
overall pattern of UroII and CK5 staining (Figure 3-7). 
 
Phosphorylated AKT (Ser473) (pAKT) was absent in Control (n=3), UroIICre 
Fgfr3+/K644E (n=6) and UroIICre Ptenflox/flox (n=7) (Figure 3-11 b, e, h), but up-
regulated in 55% of UroIICre Fgfr3+/K644E Ptenflox/flox samples (n=6/11, k).  
 
p21 was present most abundantly in the outermost umbrella layer in Control 
(n=3) (c), and this remained similar in UroIICre Fgfr3+/K644E (n=3) and UroIICre 
Ptenflox/flox (n=3) (f, i). However, in UroIICre Fgfr3+/K644E Ptenflox/flox urothelium 
(n=4), p21 was expressed throughout all urothelial layers (l). This p21 
upregulation appeared to have coincided with the overall up-regulation of PI3K-
AKT signalling (k).  
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Figure 3-11: Deregulation of downstream signalling and cell cycle arrest in the UroIICre 
Fgfr3
+/K644E
 Pten
flox/flox 
urothelium 
Immunohistochemistry for phosphorylated ERK (pERK) (a, d, g, j), phosphorylated AKT (pAKT) (b, 
e, h, k) and p21 (c, f, i, l) on Control (a-c), UroIICre Fgfr3
+/K644E
 (d-f), UroIICre Pten
flox/flox
 (g-i), and 
UroIICre Fgfr3
+/K644E
 Pten
flox/flox
 bladders (j-l). Scale bar represents 50 µm in a, b, d, e, g, h, j, k, and 
100 µm in c, f, i, l.   
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3.10 Analysis of pathway association between FGFR3 
and AKT signalling by tissue microarray (TMA) 
In order to address whether PI3K-AKT signalling is functionally associated with 
FGFR3 activation in human non-muscle invasive bladder cancer, we evaluated 
the levels of FGFR3 protein expression and the phosphorylated form of mTOR, p-
mTOR (S2448) in 66 T1 urothelial tumours on tissue microarray platform. TMA 
was performed by Dr Theodorus van der Kwast and Dr Bas van Rhijn at the 
Princess Margaret Hospital in Toronto, Canada. 
Immunohistochemistry staining intensity of FGFR3 and p-mTOR on the TMA was 
categorised using the 4-point scale: strong (blue), intermediate (green), faint 
(yellow) and negative (white) (Figure 3-12). FGFR3 and p-mTOR levels were then 
analysed for correlation. An increase in intermediate FGFR3 expression (green) 
was associated with increased level of p-mTOR (p=0.014, Pearson Chi-Square 
test). This may indicate presence of synergy of FGFR3 and PI3K-AKT pathways. 
The decrease in strong expression of FGFR3 (blue) was statistically not 
significant (p=0.101).  
 
Figure 3-12: Tissue microarray analysis of FGFR3 and p-mTOR expression levels in T1 
urothelial tumours 
Immunohistochemistry staining on human non-invasive T1 tumours was categorised as strong 
(blue), intermediate (green), faint (yellow) and negative (white). Right panel shows correlation 
between increased FGFR3 expression (green) and increased level of p-mTOR.  
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Similar trends were observed when the levels were characterised in each tumour 
grade (Figure 3-13). The increasing trend of intermediate expression of FGFR3 
(green) along the increased p-mTOR level was not statistically significant in non-
invasive low-grade (a) and high-grade (b) papillary urothelial carcinoma 
according to WHO 2004 classification system, and G2 (c) and G3 (d) according to 
WHO 1973 classification system (p=0.579, 0.056, 0.124, and 0.058, in a-d, 
respectively). This may be due to the low number of available samples 
indicated.  
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Figure 3-13: Tissue microarray analysis of FGFR3 and p-mTOR expression levels according 
to tumour grade 
Non-invasive low-grade (a) and high-grade (b) papillary urothelial carcinoma according to WHO 
2004 classification system, and G2 (c) and G3 (d) according to WHO 1973 classification system 
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3.11 Discussion  
The present study provides functional evidence that supports that upregulation 
of FGFR3 signalling together with that of PI3K-AKT signalling plays a role in the 
initiation of urothelial tumourigenesis. Furthermore, this chapter demonstrates 
that Fgfr3 and Pten mutations cooperatively promote morphological changes of 
the urothelium, while not when mutated individually.  
3.11.1 The UroIICre Fgfr3+/K644E Ptenflox/flox model 
The current model carries a K644E mutation in Fgfr3. In vitro, this mutation 
promotes strongly enhanced signalling through a conformational change in the 
receptor that favours autophosphorylation (Naski et al., 1996). Additionally, its 
kinase activity can be further enhanced by FGF binding (Naski et al., 1996). 
However, K644E mutation is only found in less than 2% of human non-invasive 
bladder cancers. Although the kinase domain mutations such as K644E are less 
common compared to S249C in humans (Tomlinson et al., 2007a, Duenas et al., 
2013, Bernard-Pierrot et al., 2006), this mouse line offers several advantages as 
an experimental model, namely because the Cre-Lox construct enables the 
expression of mutant Fgfr3 in a urothelium-specific fashion and the mutation is 
highly activating, thus maximising the chance of a detectable phenotype. 
However, our model did not show increased FGFR3 signalling in the bladder in 
vivo. 
3.11.2 UroIICre recombination 
Recombination analysis in the urothelium Z/EG reporter mice indicated that 
UroplakinII-Cre (UroIICre) predominantly recombines in umbrella and 
intermediate cells but less extensively in basal cells (Figure 3-2). The original 
reference reported recombination in all three layers; however, it seemed to 
predominantly occur in umbrella and intermediate cells as indicated by their 
lacZ staining (Mo et al., 2005). This is in accordance with our results where lacZ 
staining was predominantly observed in umbrella and intermediate cells. 
Moreover, the thickening of the intermediate cell layer in UroIICre Fgfr3+/K644E 
Ptenflox/flox accompanied by cellular abnormalities further supports that UroIICre 
recombination predominantly occurs in the intermediate cell layer. If the cancer 
cell of origin of urothelial cell carcinoma naturally resides in the basal cell 
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compartment, it is possible that it is not recombined under UroIICre and the 
mutations of interest are not introduced in the correct cells to initiate 
tumourigenesis. This may be supported by the fact that our animal model failed 
to develop bladder tumours by 18 months. To further determine the exact 
location of recombination it would be useful to cross the UroIICre to a Rosa26 
tdRFP reporter mouse line (Luche et al., 2007), where recombination events can 
be visualised by RFP immunohistochemistry. 
3.11.3 Urothelial thickening 
Mild urothelial thickening was observed in 60% of mice with Pten deletion, 
although this increase was statistically not significant upon quantification 
(Figure 3-4). Previously it was reported that loss of Pten under the control of the 
FabpCre promoter leads to urothelial hyperplasia (Tsuruta, 2006, Yoo et al., 
2006). Moreover, using the UroIICre promoter, Pten loss in combination with 
hyperactivated ß-Catenin even leads to the development of urothelial papillary 
carcinomas (Ahmad et al., 2011a). Pten loss with p53 deletion using adenoviral 
Cre delivery led to high-grade muscle-invasive bladder cancer (Puzio-Kuter et 
al., 2009). In our current study, hyperplasia was not observed following Pten 
loss. This is consistent with the observations in previous studies by our group 
(Ahmad et al., 2011a) and others (Puzio-Kuter et al., 2009).  
In contrast to the mild urothelial thickening observed in mice with homozygous 
Pten deletion, mice with homozygous mutation in Fgfr3 showed strong increase 
in urothelial thickness, emphasising the potent effect of activated FGFR3 
signalling (Figure 3-4). 
Mice heterozygous for Fgfr3 mutation and homozygous for Pten deletion showed 
a statistically significant increase in urothelial thickness, but not when Fgfr3 or 
Pten were singly mutated, suggesting that this increase is owing to the 
cooperation of Fgfr3 and Pten mutation (Figure 3-3 and Figure 3-4). The 
urothelium of these mice showed global hypertrophy with several cellular 
characteristics indicative of abnormal differentiation, which was overall similar 
to the histopathology seen in urothelial papilloma in humans.  
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Although mice with Fgfr3 mutation and Pten deletion showed a thickened 
urothelium with increased proliferation, it did not produce tumours in the 
animal model up to 18 months. This indicates that pathogenesis caused by FGFR3 
and PI3K-AKT signalling pathway mutations are unlikely to progress unless 
further mutations occur that overcome the intact cell cycle inhibitor machinery. 
In humans, FGFR3 mutations are highly associated with non-muscle-invasive 
bladder cancer with better clinical outcome (Billerey et al., 2001, van Rhijn et 
al., 2002).  
3.11.4 Abnormal urothelial differentiation 
Significantly, while the papillary structures with fibro-vascular cores seen in 
human non-muscle-invasive bladder cancer were not observed, the urothelium of 
UroIICre Fgfr3+/K644E Ptenflox/flox did demonstrate several morphological 
abnormalities that may reflect pathogenesis in humans. These included 
increased urothelial thickness, caused by an increase in cell size and cell 
proliferation, and loss of polarity (Figure 3-6 and Figure 3-7). These 
histopathological features are comparable to hyperplasia and dysplasia, 
regarded as early stages in the putative model of bladder cancer pathogenesis in 
humans.  
This functional cooperation was also reflected by the atypical expression of 
layer-specific markers indicating abnormal differentiation and/or maturation of 
cells in the UroIICre Fgfr3+/K644E Ptenflox/flox urothelium (Figure 3-7). UroplakinII-
positive cells were present in deeper layers close to the submucosa, while CK5 
was absent in some parts of the deeper layers of the urothelium, showing an 
inverse expression pattern. Double staining with CK18 together with CK5 clearly 
showed the abnormal localisation of umbrella cells deep in the urothelium of 
UroIICre Fgfr3+/K644E Ptenflox/flox, indicating abnormal differentiation and/or 
maturation of cells as an effect of Fgfr3 and Pten mutation in combination. A 
recent study in vitro showed similar large, vacuolated and flattened cell 
morphology and increased proliferation of Normal Human Urothelial (NHU) cells 
stably expressing hotspot PI3KCA mutations (Ross et al., 2013). Despite the 
difference that these effects solely resulted from PIK3CA activation in vitro, the 
findings are supportive of our observations in mice. This may reflect the 
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complexity of signalling events leading to tumourigenesis in vivo, in which 
multiple gene mutations and epigenetic events are likely to be required.  
3.11.5 Cell size and cell number 
The increase in intermediate cell size was observed owing to both Fgfr3 and 
Pten mutations in combination, whereas that of cell proliferation was mainly an 
effect of Pten deletion (Figure 3-8 and Figure 3-9). These results indicate that 
Fgfr3 and Pten mutation cooperatively caused urothelial hypertrophy, while 
Pten contributed to hyperplasia in the UroIICre Fgfr3+/K644E Ptenflox/flox 
urothelium. The effects of Fgfr3 and Pten mutations were cell-type specific, 
particularly in intermediate and umbrella cell layers. The basal cell layer was 
not significantly affected in this model.  
3.11.6 Changes in downstream signalling 
Cooperation of Fgfr3 and Pten mutations seem to have resulted in deregulation 
of the MAPK pathway in the double mutant, which may correlate with abnormal 
differentiation and/or maturation of urothelial cells, indicating the local 
involvement of the MAPK pathway in pathogenesis through regulation of cell 
differentiation (Figure 3-11).  
The observed p21 upregulation appeared to have coincided with the overall up-
regulation of PI3K-AKT signalling, which is in accordance with the evidence in 
vitro that activation of PI3K-AKT pathway up-regulates p21 (Yohn et al., 2011). 
The elucidation of precise causal mechanisms, however, requires further 
studies.  
Furthermore, up-regulation of pAKT was observed when both Fgfr3 and Pten 
mutations together, and not in single mutants (Figure 3-11). In humans, a higher 
pAKT level was found in 50% bladder tumours, independent of stage/grade and is 
associated with the presence of mutations, including PIK3CA, FGFR3, and both 
together (Juanpere et al., 2012).  
Potential cooperation of the FGFR3 and the AKT pathways was further supported 
by a TMA of human T1 samples where an increase in expression of FGFR3 protein 
was correlated with increased level of p-mTOR (Figure 3-12). Activation of PI3K-
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AKT downstream protein, mTOR, is confirmed to be strongly associated with 
pAKT (Korkolopoulou et al., 2012). Relationship between FGFR3 overexpression 
and p-mTOR is relatively unstudied and one report showed no statistical 
association (Korkolopoulou et al., 2012). However, in the current study, although 
the number of analysed T1 bladder samples was small, we were able to show 
association of the intermediate level of FGFR3 overexpression with increased p-
mTOR (Figure 3-12 and Figure 3-13). In humans, PIK3CA mutations were also 
found in normal urothelium, indicating that it is an early event (Duenas et al., 
2013).  
Further work would include a larger clinical cohort to establish whether 
concurrent FGFR3 mutation and p-mTOR activation confers a better prognosis in 
non-muscle-invasive bladder cancer patients.  
3.11.7 Limitations of the model 
There are several differences between the nature of our mouse model in 
relationship to human bladder cancer that may limit the direct interpretation. 
Firstly, although we used Pten loss as an experimental tool in this study, in 
humans, occurrence of FGFR3 mutations are associated with non-invasive 
bladder cancer  while PTEN loss with muscle-invasive tumours, and therefore 
little overlap is expected (Askham et al., 2010, Knowles, 2008). FGFR3 mutations 
and loss of heterozygosity in PTEN are found together only in a small number of 
cases of TaG1, T1G2, and T2G3 (Askham et al., 2010). Statistically, PTEN loss 
was not associated with upregulation of pAKT in clinical bladder cancer 
specimen (Askham et al., 2010). However, in the absence of available mouse 
lines with Pi3kca mutations, we turned to a model that enables conditional Pten 
deletion (Tsuruta, 2006, Yoo et al., 2006). PTEN is a well-known inhibitor of 
PI3K-AKT signalling and it was shown that its deletion resulted in pAKT 
upregulation in bladder tumours in mice (Ahmad et al., 2011a). Secondly, a 
study of clinical specimens reported that 85% of tumours with FGFR3 mutations 
also overexpressed FGFR3 protein (Tomlinson et al., 2007a). In contrast, changes 
in FGFR3 protein level were not apparent in our model (Figure 3-1). This could 
be due to the expected low level of endogenous protein expressed in the mouse 
urothelium. The mechanism of Fgfr3 mutations leading to an increased protein 
level is unclear; however in vitro studies showed that impaired lysosomal 
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degradation of FGFR3 protein was caused by mutations, increasing the stability 
of FGFR3 mutant protein in the plasma membrane (Cho et al., 2004). 
3.11.8 Future plans 
Considering that Fgfr3 in combination with other mutations can induce 
substantial architectural and cellular changes in the urothelium, it would be 
interesting to identify potential other cooperating mutations that drive 
urothelial tumourigenesis together with activated FGFR3. Particularly, it would 
be interesting to analyse the effect of Pi3k mutation in combination with Fgfr3, 
and whether the result is comparable to our current model where Pten deletion 
is utilised to activate AKT signalling. 
3.11.9 Conclusion 
Altogether, our study demonstrated that Fgfr3 and Pten mutations cooperatively 
promote morphological changes of the urothelium, but not when mutated 
individually. Furthermore, this study provides functional evidence that supports 
that upregulation of FGFR3 signalling plays a causative role in urothelial 
pathogenesis of non-invasive bladder cancer together with upregulated PI3K-AKT 
signalling. 
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Search for cooperating genes 
by Sleeping Beauty mutagenesis  
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4.1 Introduction  
The Sleeping Beauty (SB) system is a method to screen functional genes by 
insertional mutagenesis (Dupuy et al., 2005, Dupuy et al., 2009). The SB system 
is based on transposon excision by a transposase and subsequent reintegration 
into a random location in the genome (“cut and paste”), which can either lead 
to a gain-of-function event or to interruption of the reading frame and therefore 
silencing of a gene (Copeland and Jenkins, 2010). Transposon-derived sequences 
are common components (40%) of the human and mouse genome, which 
demonstrates the importance of transposition in the context of evolution 
(Lander et al., 2001, Waterston et al., 2002).  
Sleeping Beauty transposons belong to the group of Tc1/mariner transposable 
elements that were initially isolated from salmonid fish species (Ivics et al., 
1997). Thereafter, great effort has been made to genetically improve these 
transposable elements in order to generate a powerful tool for forward genetic 
screens, and for generating novel phenotypes in mice in a less time-consuming 
and less technically challenging manner in contrast to vector-based gene-trap 
approaches with ES cells. 
The SB transposase is encoded by the Cre-inducible RosaSBaseLSL allele, which 
allows tissue-restricted expression of the enzyme (Dupuy et al., 2009). The 
T2/Onc3 transposon concatemer on the other hand contains ~200 copies of the 
SB transposon (Dupuy, 2005). The SB transposase recognises two imperfect 
terminal sequences called “inverted repeats” up- and downstream of each 
individual transposon (T2/Onc3), excises it from its concatemer and reintegrates 
about 40-50% of the mobilised T2/Onc3s into another place in the genome in a 
random fashion (Copeland and Jenkins, 2010). T2/Onc3 is equipped with a bi-
directional polyA (pA) sequence that allows integration in either orientation. 
Furthermore, due to the presence of splice donor and splice acceptor sequences 
in T2/Onc3, the  transposon integration can promote expression of an oncogene 
or terminate transcription of a tumour suppressor gene along with neutral 
mutations resulting from integration into non-functional sites within the genome 
(Dupuy et al., 2005, Collier et al., 2005). 90% of all insertions lead to a gain-of-
function effect (Copeland and Jenkins, 2010). 
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The frequency of SB transposition in somatic cells varies greatly in a tissue-
dependent manner (5-30 events per cell type) (Collier et al., 2005, Dupuy et al., 
2005). In the mouse germline 1-2 transpositions occur per animal born (Dupuy et 
al., 2001). T2/Onc3 can continuously be re-mobilised into subsequent locations. 
It generally leaves a footprint of about five nucleotides at its previous insertion 
site, and can therefore potentially still interrupt the reading frame of a gene 
after its departure, even though this event remains undetected by splinkerette 
PCR (Copeland and Jenkins, 2010).  
Splinkerette PCR is an assay in which transposon junctions are amplified from 
genomic DNA of mice carrying transposon insertions. Following restriction 
enzyme digestion, DNA fragments are ligated to a linker sequence 
(“splinkerette”). After a clean-up digestion reaction to remove DNA segments 
with splinkerette adapters on both ends of the fragment, a primary PCR with 
splinkerette-specific primers is performed. Thereafter, a secondary nested PCR 
is performed using the primary PCR product. Secondary PCR products are 
visualised by agarose electrophoresis, purified from the gel, and cloned into a 
vector (“TOPO-shotgun cloning”). TOPO-shotgun cloning is a de-multiplexing 
step for the pool of different splinkerette-PCR products that have resulted from 
the multiple SB transposition events in the tissue of interest. Ligation products 
are transformed into bacterial cells and amplified in 96-well plates for 
subsequent capillary read sequencing.  
Although generally the entire genome is accessible to SB transposition (Collier et 
al., 2005), it has been reported that 50-80% of the SB germline transpositions 
show preference in the site of relocation, which is particularly near the original 
location (“local hopping” (Carlson et al., 2003). A lower frequency of local 
hopping has been reported in ES cells (Liang et al., 2009) and various somatic 
cell types (Collier et al., 2005, Starr et al., 2009, Dupuy et al., 2005).  
The SB system has been established in tissues such as the liver (Keng et al., 
2009), gastrointestinal tract (March et al., 2011, Starr et al., 2009), pancreas 
(Mann et al., 2012), hematopoietic system (Dupuy et al., 2005),  soft tissue 
(Collier et al., 2005), mouse embryonic stem cells (Luo et al., 1998) and in the 
germline (Dupuy et al., 2001). SB has also been shown to carry on its insertional 
mutagenesis activity in metastatic lesions (Dupuy et al., 2009, Keng et al., 2009, 
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Mann et al., 2012). However, Sleeping Beauty has not been tested in the bladder 
yet. 
In this chapter we aimed to identify genes that cooperate with Fgfr3 or Pten to 
promote tumourigenesis using an unbiased screening approach. More 
specifically, we sought to elucidate whether Fgfr3 K644E mutation is 
fundamentally able to drive urothelial cell carcinoma in the presence of SB-
induced mutations. Furthermore, since our previous results indicated functional 
cooperation between Fgfr3 and Pten mutation (Chapter 3), we sought to 
investigate whether insertional mutagenesis may support these data. We 
hypothesised that Fgfr3 mutation may be identified among the common 
insertional sites in sequenced Pten-mutant Sleeping Beauty tumours; and that 
Pten inactivation may be found in Fgfr3-mutant SB tumours.  
In addition, we sought to identify genes that can cooperate with a strongly 
activating Hras mutation to promote bladder cancer. HRAS is found mutated at 
variable frequencies in different reports on human bladder cancer, ranging from 
6-70% (Czerniak et al., 1992, Jebar et al., 2005, Fitzgerald et al., 1995). 
However, it may not be the sole initiator (Knowles and Williamson, 1993, Ahmad 
et al., 2011b), indicating that a second mutation may be required. In mice, Hras 
mutation is known to cause low-grade non-invasive bladder cancer either by 
itself (Zhang et al., 2001, Mo et al., 2007) or together with activated WNT 
signalling (Ahmad et al., 2011b), as well as high-grade invasive urothelial cell 
carcinoma in combination with p53 inactivation (Gao et al., 2004).  
Experimentally, we approached the question of gene cooperation by generating 
Sleeping Beauty mouse cohorts that carried an additional Fgfr3, Pten or Hras 
mutation. We intended to sequence any resulting SB-induced tumours for the 
common insertional sites in order to reveal the genetic alterations that 
cooperatively promoted tumourigenesis. 
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4.2 Sleeping Beauty mutagenesis in the urothelium of 
UroIICre Fgfr3+/K644E  
We generated a cohort of n=29 mice in which heterozygous K644E mutation in 
Fgfr3 is combined with the transposase allele RosaSBaseLSL and the transposon 
donor T2/Onc3 (Dupuy et al., 2009) in the urothelium, UroIICre Fgfr3+/K644E 
RosaSBaseLSL T2/Onc3 (Table 4-1). We also generated a cohort of mice with 
Sleeping Beauty elements only, UroIICre RosaSBaseLSL T2/Onc3 (n=10), as well as 
a cohort with homozygous Fgfr3 mutation, UroIICre Fgfr3K644E/K644E RosaSBaseLSL 
T2/Onc3 (n=18). None of the mice showed clinical signs of bladder tumours by 8-
21 months. 
 
Table 4-1: Sleeping Beauty mouse cohorts with Fgfr3 mutation 
*UroIICre Fgfr3
K644E/K644E 
RosaSBase
LSL 
T2/Onc3 mice were sacrificed at the time where kyphosis 
became prevalent. This phenotype is due to a low-level of FGFR3 expression in the presence of 
homozygous Fgfr3
K644Eneo 
allele (Li et al., 1999, Iwata et al., 2000, Deng et al., 1996). **The 
increase in urothelial thickness observed in UroIICre Fgfr3
K644E/K644E 
RosaSBase
LSL
T2/Onc3 was 
milder comparing to those in UroIICre Fgfr3
+/K644E 
Pten
flox/flox
. 
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We evaluated whether Sleeping Beauty transposon excision had occurred in the 
bladder by T2/Onc3 PCR assay (Figure 4-1). 
Successful mobilisation of the transposon (225 bp) from its concatemer form (2.2 
kb) was confirmed in all of ten tested samples of UroIICre Fgfr3+/K644E 
RosaSBaseLSL T2/Onc3. DNA extract from the tail, where transposon jumping is 
not expected to occur, was used as negative control (lane: Tail), while colon 
crypt cells, in which successful transposition had been confirmed previously 
(unpublished), was used as a positive control (lane: Crypt). 
 
 
Figure 4-1: T2/Onc3 excision PCR 
1.5% agarose gel showing mobilisation of transposon (225 bp) in UroIICre Fgfr3
+/K644E
 
RosaSBase
LSL
 T2/Onc3 T2/Onc3 samples (lanes: 1-10) and controls (lanes: tail, crypt, water). 
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We analysed the urothelial appearance in UroIICre Fgfr3+/K644E RosaSBaseLSL 
T2/Onc3 (Fgfr3+/K644E SB+, n=29) and UroIICre Fgfr3K644E/K644E RosaSBaseLSL T2/Onc3 
(Fgfr3K644E/K644E SB+, n=18) at 18 months (Figure 4-2). 
Fgfr3+/K644E SB+ mice retained a histologically normal urothelial appearance (B), 
similar to control mice with SB transposase and transposon (UroIICre 
RosaSBaseLSL T2/Onc3 (SB+, n=10) (A). 
Fgfr3K644E/K644E SB+ mice were sacrificed at an average of 12 months for kyphosis. 
The kyphosis phenotype is similar to that of Fgfr3 knockout mice caused by the 
homozygous effects of the knock-in allele (Fgfr3+/K644Eneo) in reducing 
transcription of FGFR3 in the full body (Li et al., 1999, Iwata et al., 2000).  
More than half of the Fgfr3K644E/K644E SB+ cohort (61%, n=11 out of 18) retained 
histologically normal urothelial appearance. However, 39% (n=7 out of 18) of the 
mice showed mild hyperplasia (D), similar to that in UroIICre Fgfr3K644E/K644E 
(Fgfr3K644E/K644E, n=10) (C, and Figure 3-5 A, B), but milder than UroIICre 
Fgfr3+/K644E Ptenflox/flox (Figure 3-3 h). 
 
Figure 4-2: Sleeping Beauty insertional mutagenesis in the presence of Fgfr3 mutation  
Representative H&E sections of UroIICre
 
RosaSBase
LSL
 T2/Onc3
 
(SB
+
) (A), UroIICre Fgfr3
+/K644E
 
RosaSBase
LSL
 T2/Onc3
 
(Fgfr3
+/K644E
 SB
+
) (B), UroIICre Fgfr3
K644E/K644E
 (Fgfr3
K644E/K644E
) (C) and 
UroIICre Fgfr3
K644E/K644E
 RosaSBase
LSL
 T2/Onc3
 
(Fgfr3
K644E/K644E
 SB
+
) (D). Scale bar represents 
100 µm in A-D.   
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4.3 Sleeping Beauty mutagenesis in the urothelium of 
UroIICre Ptenflox/flox  
We generated a cohort of n=20 mice in which homozygous Pten deletion 
combined with the transposase allele RosaSBaseLSL and the transposon donor 
T2/Onc3 (Table 4-2). One UroIICre Ptenflox/flox RosaSBaseLSL T2/Onc3 animal out 
of n=20 (5%) developed a tumour.  
 
Table 4-2: Sleeping Beauty mouse cohorts with Pten mutation 
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Histologically, the bladder tumour in UroIICre Ptenflox/flox RosaSBaseLSL T2/Onc3 
(Ptenflox/flox SB+) was superficial and of low grade (n=1) (Figure 4-3 A). 
Furthermore, in 45% (n=9 out of 20) of Ptenflox/flox SB+, a global hypertrophic 
phenotype was observed (B), similar to UroIICre Fgfr3+/K644E Ptenflox/flox (Figure 
3-3 h).  
 
 
Figure 4-3: Sleeping Beauty insertional mutagenesis in the presence of Pten mutation  
Representative H&E sections of a UroIICre Pten
fllox/flox
 RosaSBase
LSL
 T2/Onc3 tumour (Pten
flox/flox
 
SB
+ 
tumour, n=1) (A) and UroIICre Pten
fllox/flox
 RosaSBase
LSL
 T2/Onc3 urothelium (Pten
flox/flox
 SB
+
, 
n=9) (B). Scale bar represents 100 µm in A-B. 
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The similarity of urothelial phenotype in Ptenflox/flox SB+ and UroIICre Fgfr3+/K644E 
Ptenflox/flox led us to the hypothesis that the SB mutagenesis may have targeted 
the Fgfr3 gene or caused gene alterations leading to similar downstream effects. 
We therefore assessed FGFR3 expression by immunohistochemistry (Figure 4-4). 
The relative level of FGFR3 protein in Ptenflox/flox SB+ bladders (B) was unchanged 
compared to the SB+ control (A) (n=5 each), indicating that other genes may have 
been targeted in the mutagenesis.  
 
 
Figure 4-4: FGFR3 expression in UroIICre Pten
fllox/flox 
SB
+
 urothelium  
Immunohistochemistry for FGFR3 in bladders of UroIICre RosaSBase
LSL
 T2/Onc3 (SB
+
) (A) and 
UroIICre Pten
flox/flox 
RosaSBase
LSL
 T2/Onc3 (Pten
flox/flox 
SB
+
) (B). Scale bar represents 100 µm in A-
B. 
  
Results – Search for cooperating genes by Sleeping Beauty mutagenesis  (Chapter 4) 134 
 
 
 
Since Fgfr3 was not likely a direct target, we tested by immunohistochemistry in 
n=3 samples each whether the MAPK or the AKT pathway had generally been 
affected by the SB mutagenesis (Figure 4-5 and Figure 4-6). 
Similar to UroIICre Fgfr3+/K644E Ptenflox/flox (Figure 3-11 j), phosphorylated ERK 
was observed in a cell-specific fashion in the urothelium of Ptenflox/flox SB+ 
(Figure 4-5 H), while its level remained low in UroIICre RosaSBaseLSL T2/Onc3 
(SB+), UroIICre Fgfr3+/K644E RosaSBaseLSL T2/Onc3 (Fgfr3+/K644E SB+), and in the 
tumour of Ptenflox/flox SB+ (B, E, K).  
Expression of p21 was restricted to umbrella cells in SB+ (C) and Fgfr3+/K644E SB+ 
(F). In contrast, p21-positive cells were scattered in all layers of the Ptenflox/flox 
SB+ urothelium (I), however, less extensive than in UroIICre Fgfr3+/K644E 
Ptenflox/flox (Figure 3-11 l). Increased numbers of p21-positive cells were 
observed in the tumour developed in Ptenflox/flox SB+ (Figure 4-5 L).   
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Figure 4-5: Sleeping Beauty insertional mutagenesis in the presence of Fgfr3 and Pten 
mutation 
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Phospho-AKT was up-regulated in the Ptenflox/flox SB+ tumour (Figure 4-6 D). 
However, unlike UroIICre Fgfr3+/K644E Ptenflox/flox (Figure 3-11 k), its level 
remained low in the Ptenflox/flox SB+ urothelium (n=3) (Figure 4-6 C). Phospho-AKT 
levels were similarly low in the urothelium of SB+ (n=3) (A) and Fgfr3+/K644E SB+ 
(B). 
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Next, we performed splinkerette PCR and subsequent sequencing to analyse 
common insertion sites in hyperplastic bladders (n=8) as well as in the tumour 
(n=1) of Ptenflox/flox SB+ mice (Table 4-3). Splinkerette PCR, sequencing and 
bioinformatics analysis were performed by Dr Louise van der Weyden and Dr 
David J. Adams at the Sanger Institute in Cambridge, UK. 
We were unable to obtain information on individual samples, such as the genetic 
changes in the tumour itself. However, the tumour sample was included in the 
analysis of the most common insertional sites in Ptenflox/flox SB+ bladders. 
Although the number of analysed samples was small, we observed transposon 
insertions in a number of known cancer driver genes, which include 
transcriptional regulators Ep400 (Samuelson et al., 2005) and Asxl2 (Katoh, 2013) 
and the known drivers of epithelial- mesenchymal transition (EMT), Cadherin1 
(Cdh1) and Notch1. While interactions between FGF signalling with Ep400 and 
Asxl2 have not been reported so far, regulation of EMT by FGF signalling is 
documented (Katoh and Nakagama, 2013), supporting that Fgfr3 and Pten 
cooperation may merge at the signalling downstream, leading to the apparent 
Ptenflox/flox SB+ urothelial phenotype.  
 
Table 4-3: Common insertional sites in UroIICre Pten
flox/flox 
SB
+
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4.4 Sleeping Beauty mutagenesis in the urothelium of 
UroIICre Hras+/G12V  
We generated a cohort of n=16 Sleeping Beauty mice carrying a strongly 
activating Hras G12V mutation combined with the transposase allele 
RosaSBaseLSL and the transposon donor T2/Onc3 (Table 4-4).  
In order to test whether enhanced MAPK signalling can promote tumourigenesis 
in the mouse urothelium by adding an activating Fgfr3 mutation to the HRAS-
hyperactivated bladder, we also generated a cohort of n=5 UroIICre Fgfr3+/K644E 
Hras+/G12V animals combined with the Sleeping Beauty elements (Table 4-4). 
None of the Hras mutant mice or Fgfr3-Hras mutant mice with the Sleeping 
Beauty elements showed clinical signs of bladder tumours by 18 months. 
 
Table 4-4: Sleeping Beauty mouse cohorts with Hras mutation 
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We then analysed the histological appearance of the Sleeping Beauty urothelia 
with Hras and Fgfr3-Hras mutation and the ones of Hras and Fgfr3-Hras controls 
without Sleeping Beauty elements (Figure 4-7). 
UroIICre Hras+/G12V controls alone did not show gross urothelial abnormalities 
apart from mild hyperplasia at 12 months of age (Hras+/G12V, n=16, A). Similar 
observations were made in mice with Hras mutation and the additional SB 
elements, UroIICre Hras+/G12V RosaSBaseLSL T2/Onc3 (Hras+/G12V SB+, n=16, B). 
A normal urothelial phenotype and occasionally mild hyperplasia was present in 
UroIICre Fgfr3+/K644E Hras+/G12V animals at 12 months (Fgfr3 Hras, n=15, C). 
Additional SB elements did not produce any abnormal urothelial phenotype in 
UroIICre Fgfr3+/K644E Hras+/G12V RosaSBaseLSL T2/Onc3 either (Fgfr3 Hras SB+, n=3 
at 18 months, n=2 at 7 months, D). 
 
 
Figure 4-7: Sleeping Beauty insertional mutagenesis in the presence of Hras mutation 
and/or in combination with Fgfr3 mutation  
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4.5 Discussion 
The aim of this chapter was to identify mutations that cooperate with FGFR3, 
PTEN, or RAS mutation in promoting urothelial tumourigenesis an unbiased 
fashion. We have therefore performed Sleeping Beauty (SB) insertional 
mutagenesis. This unbiased screening approach was also intended to identify 
novel mutations that play an important role in urothelial tumourigenesis.  
4.5.1 SB in UroIICre Fgfr3+/K644E 
We generated a cohort of n=29 mice in which a heterozygous Fgfr3 K644E 
mutation is introduced together with transposable Sleeping Beauty (SB) 
elements. SB controls presented a histologically normal urothelium that were 
indistinguishable from Wild type bladders. None of the UroIICre Fgfr3+/K644E SB+ 
mice showed clinical signs of bladder tumours, but a histologically normal 
urothelial appearance, suggesting that a second mutation by SB mutagenesis 
alongside Fgfr3 was insufficient to cause bladder tumours.  
Nor did a homozygous mutation in Fgfr3, Fgfr3K644E/K644E SB+, promote 
tumourigenesis (Figure 4-2). It could be hypothesised that an additional 
mutation in combination with Fgfr3 K644E is generally insufficient for 
tumourigenesis to occur, indicating that Fgfr3 may require more than one 
additional mutation in order to successfully transform urothelial cells. 
In anticipation of potential gene cooperation with Pten, the lack of hypertrophic 
phenotype in Fgfr3+/K644E SB+, as observed in UroIICre Fgfr3+/K644E Ptenflox/flox 
(Chapter 3) is likely to be due to the low probability of homozygous targeting 
that would be required for Pten loss to take effect.  
4.5.2 SB in UroIICre Ptenflox/flox 
We also performed the SB mutagenesis in the presence of Pten mutation (n=20), 
where one UroIICre Ptenfllox/flox SB+ animal (5%) developed a bladder tumour. In 
45% (n=9) we observed global hypertrophy (Figure 4-3), phenocopying the 
changes that we previously observed in UroIICre Fgfr3+/K644E Ptenflox/flox urothelia 
(Chapter 3). Immunohistochemistry indicated that FGFR3 is unlikely a direct co-
operator with Pten deletion in the SB model. However, it could be involved at 
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the level of its downstream signalling, particularly that of the MAPK-pathway 
(Figure 4-5), which was indicated in the hypertrophic urothelium that has led to 
similar downstream effects.  
Hypertrophic UroIICre Ptenfllox/flox SB+ bladders were sequenced in collaboration 
with the Sanger Institute. We identified four frequently disrupted genes in these 
hypertrophic bladders, which include transcriptional regulators (Ep400, Asxl2), 
and drivers of EMT (Cdh1 and Notch1). FGF signalling to Notch1 and Wnt 
cascades are able to regulate EMT (Katoh and Nakagama, 2013), which further 
supports that FGFR3 and PTEN signalling may merge downstream. It is possible 
that the transposon excision has left footprints that are not detected by 
splinkerette PCR, but that do lead to a loss-of function mutation.  
4.5.3 Identification of cooperating mutations in SB-induced 
UroIICre Ptenfllox/flox tumours 
Although FGFR3 was unlikely to be the direct co-operator with Pten deletion in 
the SB model, involvement at the level of its downstream signalling, particularly 
in the MAPK pathway was indicated in the hypertrophic regions. We identified 
four frequently disrupted genes in these hypertrophic bladders by splinkerette 
PCR and sequencing, which include transcriptional regulators (Ep400, Asxl2), and 
drivers of EMT (Cdh1 and Notch1) (Table 4-3).  
Ep400 is a chromatin-remodelling factor that is associated with cellular 
transformation by Adenoprotein E1A (Chan et al., 2005). Ep400 complex 
interaction has been found with adenoviral E1A, Simian vacuolating virus 40 
(SV40), myc, p53 and p21 (Chan et al., 2005). By regulating 
p53/p21transcription, Ep400 controls cellular senescence and apoptosis (Chan et 
al., 2005, Samuelson et al., 2005). With regards to cancer, decreased Ep400 
expression was shown to be associated with advanced tumour stage and higher 
grade of malignancy in renal cell carcinoma (Macher-Goeppinger et al., 2013). 
The role of Ep400 in the bladder has not been reported so far. 
ASXL family members are epigenetic scaffolding protein involved in 
transcriptional regulation through PRC2, BAP1 and/or NHR complexes (Katoh, 
2013). ASXL2 promotes adipocytic differentiation by upregulating transcription 
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of the fatty acid binding protein 4 (Fabp4) (Katoh, 2013). Truncation of ASXL2 
occurs in prostate, pancreatic and breast cancer (Katoh, 2013). A potential role 
of ASXL2 in the bladder has not been reported to date.  
Cadherins are involved in cell–cell adhesion, determination of cell polarity and 
differentiation (Berx and van Roy, 2009). Cadherin 1 (Cdh1, or E-Cadherin) binds 
to p120-catenin and β-catenin (Berx and van Roy, 2009). Loss of Cdh1 is 
associated with cancer cell motility and constitutes a marker of EMT (Berx and 
van Roy, 2009). E-cadherin is repressed by other EMT indicator proteins such as 
Snail, ZEB2 and Slug (Berx and van Roy, 2009). 
Notch1 is a transmembrane receptor that regulates an evolutionarily conserved 
intercellular signalling pathway that controls differentiation, survival, 
proliferation, and cell-to-cell interactions (Allenspach et al., 2002). Upregulated 
Notch signalling through overexpression of Notch-ligand Jagged2 in bladder 
carcinoma cell lines was associated with invasion and metastasis (Li et al., 
2013). 
4.5.4 SB in UroIICre Hras+/G12V 
We also performed the SB mutagenesis in the presence of Hras mutation (n=16). 
UroIICre Hras+/G12V SB+ showed a normal urothelial phenotype apart from mild 
hyperplasia at 12 months of age. An additional Fgfr3 mutation to further 
enhance MAPK signalling in combination with Hras mutation in the presence of 
the SB elements did not result in any abnormal urothelial phenotype either. 
4.5.5 SB as an insertional mutagenesis tool in the bladder 
The PCR assay confirmed successful excision of the T2/Onc3 transposon from the 
concatemer in all tested samples (Figure 4-1). However, it should be noted that 
this assay does not address transposon re-integration. Furthermore, the assay 
does not reveal potentially altered expression patterns of the transposase in 
terms of time and location.  
The fact that mice carrying a strongly activating Hras mutation did not develop 
tumours at any stage (Figure 4-7) indicates that Sleeping Beauty is a rather 
inefficient tool for the analysis of the urothelium in contrast to other organs 
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(Keng et al., 2009, Starr et al., 2009, March et al., 2011). Neither did the 
combination of Fgfr3 and Hras mutation with SB mutagenesis lead to urothelial 
pathogenesis (Figure 4-7). 
An explanation for the inefficiency of SB in the urothelium could be the low 
proliferation rate of the mouse bladder (0.1-1%) (Stewart et al., 1980), which 
likely results in only few transposition and insertional mutagenesis events. In our 
experimental settings it is possible that tumour initiation may not have occurred 
in the relatively small number of cohort samples that underwent the SB 
experiment (n=29), considering that n=60-100 mice were used for SB 
mutagenesis in other organs with tumourigenesis occurring in 70-100% of the 
animals (Starr et al., 2009, Keng et al., 2009, Dupuy et al., 2009). Another 
possible explanation for the inefficient outcome of the SB screening could be 
that bladder cells in comparison to other somatic cell types may express certain 
host factors (e.g. DNA-bending proteins; (Zayed et al., 2003) at insufficient 
levels, which are required for transposition. Moreover, Sleeping Beauty can 
potentially miss small genetic loci such as miRNAs, which may influence bladder 
tumourigenesis. The role of miRNAs in bladder tumourigenesis has recently 
become a subject of investigation (Guancial et al., 2014a). 
4.5.6 Future work 
For future analysis of cooperating mutations in bladder cancer it may be of 
interest to test other insertional mutagenesis systems. An alternative to Sleeping 
Beauty that has been shown to mobilise transposable elements even with better 
efficiency in somatic cells (up to 300 times) is the Piggy Bac insertional 
mutagenesis system (Liang et al., 2009, Cadinanos and Bradley, 2007). Piggy Bac 
(PB) is also based on transposon integration, but displays higher transposition 
efficiency as well as no indication of local hopping (Ding et al., 2005, Liang et 
al., 2009). PB carries an inducible ERT2 domain, which allows the transposition 
to be turned off in the absence of tamoxifen after the tumours are initiated 
(Cadinanos and Bradley, 2007). However, similar to SB, the low proliferation 
rate of the bladder may as well lower the chances of obtaining sufficient results 
when screening for gene cooperation. Furthermore, the type of mutation that is 
induced by PB may be similar to the SB system, where 90% of all insertions 
represent gain-of-function mutations (Copeland and Jenkins, 2010). 
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4.5.7 Conclusion 
Altogether, no direct association between Fgfr3 and Pten mutations was found in 
urothelial tumours despite confirmation of successful transposon excision. 
However, the SB system itself may constitute a tool of questionable efficiency in 
the bladder since even a strongly activating Hras mutation in conjunction with 
SB was unable to induce urothelial tumourigenesis and Pten deletion together 
with Sleeping Beauty only produced one single bladder tumour. We therefore 
decided to move to another system to increase mutations within the bladder to 
cooperate with FGFR3 with a relevant mutational spectrum. 
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Chapter 5 
The role of FGFR3                                                    
in tumour progression and invasion 
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5.1 Introduction  
Carcinogen-induced bladder tumour models have been studied in order to 
investigate the effect of specific genetic alterations on malignant progression 
such as loss of p53, activation of Signal transducer and activator of transcription 
3 (Stat3), as well as deficiency of Secreted protein acidic and rich in cysteine 
(Sparc) or p21 (Ho et al., 2012, Tsuruta, 2006, Said et al., 2013, Ozaki et al., 
1998). Heterozygous p53 knockout mice showed increased susceptibility to 
urothelial tumour formation upon OH-BBN exposure compared to carcinogen-
treated Wild type controls, emphasising the role of p53 as a tumour suppressor 
(Ozaki et al., 1998). Loss of SPARC, a protein whose role in bladder physiology 
and tumourigenesis had been unclear and conflicting, was shown to accelerate 
bladder carcinogenesis and progression compared to Wild type litter mates (Said 
et al., 2013). Stat3 activation in the urothelium promoted the development of 
invasive bladder cancer though the carcinoma in situ (CIS) pathway as opposed 
to Wild type mice that frequently developed urothelial hyperplasia and non-
invasive cancer (Ho et al., 2012). 
Presence of an FGFR3 mutation in bladder cancer patients has been linked to 
favourable patient prognosis, as it is associated with low grade/stage pTa 
tumours (van Rhijn et al., 2012, Billerey et al., 2001, Hernandez et al., 2006). 
On the other hand, FGFRs have also been implicated in the regulation of 
epithelial-to-mesenchymal transition (EMT), invasion, and formation of distant 
metastasis in bladder cancer cell lines (Tomlinson et al., 2012, Cheng et al., 
2013, Billottet et al., 2008, Savagner et al., 1994, Chaffer et al., 2006). FGFR3 
wild type receptor overexpression has been found in 42% of muscle-invasive 
tumours (Tomlinson et al., 2007a). Mutations in FGFR3 are found in 10-15% of 
high grade invasive neoplasms (Billerey et al., 2001). Therefore, in total more 
than 50% of invasive urothelial cell carcinomas present with alterations in FGFR3 
signalling either by mutation, overexpression or both (Iyer and Milowsky, 2012). 
However, the mechanistic role of FGFR3 in muscle-invasive bladder cancer is 
still not entirely clear. A recent attempt to re-classify urothelial cell carcinomas 
primarily based on molecular features has revealed a subgroup of muscle-
invasive bladder cancer that present with FGFR3 mutations and overexpression, 
which was associated with significantly poor prognosis (Sjodahl et al., 2012). 
p63-positivity has been identified as an indicator of progression and lethality in 
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muscle-invasive bladder cancer (Choi et al., 2012, Karni-Schmidt et al., 2011). 
Interestingly, p63 has been shown to be capable of inducing FGFR3 transcription 
(Sayan et al., 2010). Moreover, FGFR3 expression appeared to directly correlate 
with p63 expression in a set of human bladder cancer cell lines (Cheng et al., 
2013). Altogether, these observations imply a role of FGFR3 mutation in tumour 
progression and invasion.  
Recently, a study suggested subcategorising muscle-invasive bladder cancers into 
basal-, luminal-, and p53-like tumours (Choi et al., 2014). According to the 
results of a large number of tumours that were analysed, basal-like tumours are 
characterised by the expression of CK5, CK6, CK14, CD44, ZEB, Cadherin-3 
(CDH3), Vimentin (VIM), MYC and EGFR and are associated with squamous 
differentiation. Luminal-like tumours were enriched with CK20, CD24, Forkhead 
box protein A1 (FOXA1), Trans-acting T-cell-specific transcription factor 
(GATA3), X-box binding protein 1 (XBP1), E-Cadherin and FGFR3. p53-like 
tumours expressed luminal biomarkers and an additional wild type p53 gene 
expression signature. p53-like tumours were associated with chemotherapy 
resistance. The basal-like subtype-associated expression of MYC, CD44, CK5, CK6 
and CK14 has been shown to be widely controlled by the p63 isoform ΔNp63 in 
other tissues (Romano et al., 2009, Boldrup et al., 2007, Marquis et al., 2012). 
p63 expression was associated with progression of muscle-invasive tumours (Choi 
et al., 2012, Karni-Schmidt et al., 2011). TP53 mutation frequencies were similar 
in all of the muscle-invasive subtypes (Choi et al., 2014).  
Exposure to carcinogens often causes DNA damage, which can be lethal to the 
cell if not fully repaired (Roos and Kaina, 2006). Alternatively, it can lead to 
genomic instability promoting cancer formation (Lord and Ashworth, 2012). The 
induction of double-strand breaks activates the ATM/ChK2 DNA repair machinery 
leading to the phosphorylation of histone H2aX (γH2aX) (Bartkova et al., 2005). 
γH2aX has been shown to be expressed in rat bladders following OH-BBN 
treatment (Toyoda et al., 2013). γH2aX has also been shown to be expressed in 
human non-invasive low-grade urothelial carcinoma (Cheung et al., 2009). 
Epithelial tumours progressing towards invasion often express proteins indicative 
of epithelial-to-mesenchymal-transition (EMT), such as Fascin, zinc finger E-box 
binding homeobox 1 (ZEB1), β-catenin, Sex Determining Region Y-Box 9 (Sox9) 
and E-cadherin (Schmalhofer et al., 2009, Thiery, 2002). Fascin has been 
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reported to be expressed in various stages of bladder tumours (Karasavvidou et 
al., 2008, Chen et al., 2012), and is often found at high levels in tumour cells 
where it marks the invasive edge (Karasavvidou et al., 2008, Tong et al., 2005). 
ZEB1, a zinc finger transcription factor, is another marker of EMT that is 
associated with tumour cell migration and invasion by regulating cell fate 
(Schmalhofer et al., 2009). β-catenin and Sox9 expression is associated with 
stemness/progenitor properties, cancer progression and invasiveness (Wang et 
al., 2008, Fodde and Brabletz, 2007). E-Cadherin expression is associated with 
loss of cell-cell adhesion in the process of malignant progression, stabilising the 
invasive mesenchymal phenotype (Schmalhofer et al., 2009). Nuclear 
accumulation of p53 protein can be an indication of TP53 mutation, which is 
associated with greater risk of muscle-invasive disease and reduced survival 
(Esrig et al., 1994). p21 is a direct target of p53 and regulates cell cycle 
progression at the G1/S phase (el-Deiry et al., 1993). Loss of p21 (CIP1/WAF1) 
expression has been shown to be an indicator of bladder cancer progression, and 
it was strongly associated with higher recurrence and lower patient survival 
(Stein et al., 1998). 
In this chapter, we aimed to investigate the role of FGFR3 in tumour progression 
and invasion in vivo. Based on our results in Chapter 3, we hypothesised that an 
FGFR3 mutation can predispose urothelial cells to tumourigenesis. Moreover, 
based on two recent publications that FGFR3 mutation is also found in a subset 
of muscle-invasive bladder tumours, we hypothesised that the receptor mutation 
can contribute to cancer progression. Experimentally, we approached the 
question of the role of FGFR3 mutation in tumour progression by subjecting 
Fgfr3-mutant and Wild type mice to OH-BBN. Furthermore, we also analysed 
Fgfr3-Pten double mutation in OH-BBN-induced tumours.  
We have based our previous in vivo experiments on an Fgfr3 K644E mutation, 
which leads to highly activated receptor signalling (Naski et al., 1996). However, 
the frequency of the human equivalent FGFR3 K650E is less than 2% of the FGFR3 
mutations in bladder cancer (Tomlinson et al., 2007a). In contrast, FGFR3 S249C 
accounts for ~66% of all FGFR3 mutations in human non-invasive urothelial cell 
carcinoma (Tomlinson et al., 2007a, Duenas et al., 2013, Bernard-Pierrot et al., 
2006). Therefore, it is possible that the two mutations have a differential 
oncogenic effect in the urothelium. This is supported by cell culture studies 
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where different FGFR3 mutations caused different mechanisms of kinase activity 
affecting morphological transformation, cell proliferation, and anchorage-
independent growth (Tomlinson et al., 2007a, di Martino et al., 2009). In order 
to resemble the conditions of human bladder cancer more closely, it would be of 
interest to analyse the effect of an S249C mutation in FGFR3 in the urothelium. 
We therefore generated a transgenic line carrying Tg(UroII-hFGFR3IIIbS249C) 
construct to introduce a human FGFR3 S249C mutation to the murine 
urothelium. We then sought to compare two different point mutations in FGFR3, 
namely murine Fgfr3 K644E and human FGFR3 S249C, in the normal untreated 
urothelium as well their effect on tumour progression in established OH-BBN-
induced neoplasms.  
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5.2 Generation of the Tg(UroII-hFGFR3IIIbS249C) mouse 
The transgenic line Tg(UroII-hFGFR3IIIbS249C), which I will call FGFR3-S249C 
from now on, was generated by Dr T. Iwata (University of Glasgow), Prof M. 
Knowles (Leeds, UK) and Dr D. Tomlinson (Leeds, UK). The design of the vector 
and generation of the transgenic line is described in the Methods (Chapter 2.3). 
The line was rederived from frozen embryos that were thawed and implanted 
into pseudo pregnant C57Bl/6 mice. Following crosses were carried out on 
C57Bl/6 background.  
Firstly, we confirmed the presence of the S249C mutation in FGFR3 in the 
offspring (Figure 5-1). 
A PCR assay was performed on isolated genomic DNA from mouse tail tips (A). A 
PCR product of 396 bp was detected in n=5 tested animals (lanes 1-5). Due to a 
DNA quality issue the assay failed to produce a clean band in one case (lane 6). 
Sequencing of the product revealed a nucleotide exchange of cytosine to 
guanine (C -> G) (B, arrow). The sequence was compared against the NCBI whole 
human genome database using the BLAST search tool (Altschul et al., 1990), 
where a percentage of 99% identity was found in chromosome 4.  
 
Figure 5-1: Establishment of the Tg(UroII-hFGFR3IIIbS249C) model 
FGFR3 S249C point mutation detected in five animals by PCR (A) and by sequencing (B). 
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The five FGFR3-S249C mice that were positively tested for the S249C mutation 
were subsequently bred to C57Bl/6 mice in order to establish the line.  
We also generated a cohort of UroIICre Tg(UroII-hFGFR3IIIbS249C) Ptenflox/flox , 
further called FGFR3-S249C Pten, by intercrossing FGFR3-S249C with transgenic 
UroIICre (Zhang et al., 1999) and mice homozygous for floxed Pten allele, 
Ptenflox/flox (Lesche et al., 2002). For comparison we used our previous mouse 
cohort with Fgfr3 K644E mutation, UroIICre Fgfr3+/K644E, further called Fgfr3-
K644E (Table 5-1).  
FGFR3-S249C bladders were harvested at 6 months (n=3) and 12 months (n=6) of 
age. FGFR3-S249C Pten bladders were harvested at 9-12 months of age (n=10). 
Some animals were euthanised due to causes unrelated to changes in the 
bladder, including infection or pregnancy.  
 
 
Table 5-1: Summary of mouse cohorts for FGFR3-S249C transgene analysis 
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In order to examine the effect of FGFR3 S249C mutation in the bladder alone 
and in combination with Pten deletion, we analysed the appearance of the 
transgenic urothelia (Figure 5-2). 
The urothelia of Wild type (n=11) (A) and Fgfr3-K644E (n=25) (D) appeared 
similar to FGFR3-S249C (n=9) (G) at 12 months of age. FGFR3-S249C Pten 
bladders did not show any histological abnormalities (n=10) (J) in contrast to 
UroIICre Fgfr3+/K644E Ptenflox/flox (Chapter 3), where severe morphological changes 
of the urothelium had been observed. 
Proliferation was similarly low in Wild type (B), Fgfr3-K644E (E), FGFR3-S249C 
(H) and FGFR3-S249C Pten (K) in all layers of the urothelium. 
Similar levels and patterns of FGFR3 protein expression were detected in the 
urothelium of Wild type (C), Fgfr3-K644E (F) and FGFR3-S249C (I), indicating 
that FGFR3 expression was not influenced by the nature of the Fgfr3 mutation. 
FGFR3 staining of FGFR3-S249C Pten urothelia was not available at the time of 
writing.  
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Figure 5-2: Urothelial appearance of Wild type, Fgfr3-K644E, FGFR3-S249C and FGFR3-
S249C Pten at 12 months 
Representative sections of Wild type, UroIICre Fgfr3
+/K644E
, Tg(UroII-hFGFR3IIIbS249C)
 
and 
UroIICre Tg(UroII-hFGFR3IIIbS249C)
 
Pten
flox/flox
 stained by H&E (A, D, G, H), anti-Ki67 (B, E, H, K) 
and anti-FGFR3 (C, F, I). Scale bar represents 100 µm (A-K).  
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5.3 Mouse cohorts that were subjected to OH-BBN 
In order to evaluate the role of FGFR3 S249C mutation in tumour progression, we 
subjected FGFR3-S249C mice as well as Wild type to 0.05% w/v N-butyl-N-(4-
hydroxybutyl)-nitrosamine (OH-BBN) for 10 weeks followed by a period of 10 
weeks with normal drinking water (further called “10+10 weeks”) (Table 5-2). 
Furthermore, we generated cohorts of UroIICre Ptenflox/flox (Pten) and FGFR3-
S249C Ptenflox/flox (FGFR3-S249C Pten). At the time of writing, no UroIICre 
Fgfr3+/K644E (Fgfr3-K644E) mice had been subjected to OH-BBN due to insufficient 
numbers. 
 
Table 5-2: OH-BBN-treated mouse cohorts 
Mice were subjected to 0.05% w/v N-butyl-N-(4-hydroxybutyl)-nitrosamine for 10 weeks, followed 
by 10 weeks of normal drinking water. Mice were sampled over a time course as indicated 
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5.4 FGFR3 S249C mutation increases sensitivity to 
tumourigenesis after long-term OH-BBN exposure 
We compared the histological changes in the urothelium of Wild type, FGFR3-
S249C, UroIICre Ptenflox/flox (Pten), FGFR3-S249C Cre Ptenflox/flox (FGFR3-S249C 
Cre Pten) and UroIICre Fgfr3+/K644E Ptenflox/flox (Fgfr3-K644E Pten) subjected to 10 
weeks of carcinogen exposure followed by 10 weeks of normal drinking water 
(“10+10”) (Figure 5-3). As an example of histological features of OH-BBN-treated 
urothelia at high magnification, FGFR3-S249C bladders are shown (Figure 5-4). 
Based on their cell-morphological changes, tumours among all five cohorts 
seemed to be comparable in terms of grade and severity (Figure 5-3). Cell-
morphological changes among all cohorts included the absence of umbrella cells 
in the urothelium, small nests with cellular atypia (Figure 5-3 C and H, black 
arrows). 
While none of these abnormal features were seen in untreated FGFR3-S249C 
bladders (n=9) (Figure 5-4 A), we observed characteristics of advanced tumours 
in OH-BBN-treated bladders, including squamous cell transformation with 
keratinisation (Figure 5-3 C, red arrow, and (Figure 5-4 C, arrow), carcinoma in 
situ (CIS) with lobular appearance of the urothelium-stroma boundary cohorts 
(Figure 5-4 B, dotted line), and invasion through the basement membrane 
(Figure 5-3 G, black arrow and (Figure 5-4 D, arrow with dotted line).  
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Figure 5-3: OH-BBN treated urothelia after 10+10 weeks 
Two examples per genotype of Wild type, FGFR3-S249C, Pten, FGFR3-S249C Pten and Fgfr3-
K644E Pten stained by H&E. Dotted lines represent invasive edge of tumour cells with 
neighbouring stroma. Scale bar represents 100 µm (A-J).  
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Figure 5-4: Abnormal features in FGFR3-S249C at high magnification upon OH-BBN 
treatment  
Untreated FGFR3-S249C (A) and OH-BBN-treated FGFR3-S249C (B-D) sections stained by H&E 
showing CIS in the urothelium with lobulation (B), squamous cell transformation with keratinisation 
(C) and invasion through the basement membrane (D). Dotted line indicates basement membrane. 
Scale bar represents 100 µm in A, D and 50 µm in B, C. 
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Next we scored the presence of carcinoma in situ (CIS), hyperplasia, keratinised 
squamous epithelium, lobulation of the urothelium-stroma boundary, tumour 
incidence and invasion in bladders of Wild type (n=17), FGFR3-S249C (n=17), 
Pten (n=16), FGFR3-S249C Pten (n=19) and Fgfr3-K644E Pten (n=7) after 10+10 
weeks of OH-BBN exposure Table 5-3 and Figure 5-5). 
A significantly higher incidence of CIS was observed in FGFR3-S249C (71%) and 
FGFR3-S249C Pten (74%) compared to Wild type (29%) (Pearson Chi-Square, 
p=0.015 and p=0.018 respectively). The incidence of CIS in Fgfr3-K644E Pten was 
also higher (57%), but did not reach significance compared to Wild type. 
Hyperplasia was observed in the majority of samples across all genotypes. 
Keratinising squamous metaplasia was significantly more frequent in FGFR3-
S249C (53%) compared to Wild type (12%) (p=0.026). Lobulation of the 
urothelium-stroma boundary was more often seen in FGFR3-S249C (71%) 
(p=0.038), FGFR3-S249C Pten (74%) (p= 0.018) and Fgfr3-K644E Pten (71%; NS) 
compared to Wild type (29%). Tumours occurred significantly more often in 
FGFR3-S249C (53%) (p=0.026), FGFR3-S249C Pten (60%) (p=0.006) and Fgfr3-
K644E Pten (43%; NS) compared to Wild type (12%). Invasion was more often seen 
in FGFR3-S249C (47%) (p=0.024) and FGFR3-S249C Pten (47%) (p= 0.031) 
compared to Wild type (12%). In Fgfr3-K644E Pten invasion was at a similar 
frequency (14%) compared to Wild type (12%).  
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Table 5-3: Histological changes of OH-BBN-treated mouse cohorts (“10+10 weeks”) 
Mice were subjected to 0.05% w/v N-butyl-N-(4-hydroxybutyl)-nitrosamine for 10 weeks, followed 
by 10 weeks of normal drinking water. *Initially we generated n=20 UroIICre Tg(UroII-
hFGFR3IIIbS249C) Pten
flox/flox 
animals. One was found dead with a bladder tumour, which was not 
included into histological analysis with the other n=19. However, it was counted for “tumour 
incidence” with a total of 12 out of 20 animals. 
 
 
 
Figure 5-5: Frequency of histological features and tumour formation in OH-BBN-treated 
cohorts after 10+10 weeks 
Wild type (Wt, green), FGFR3-S249C (S249C, yellow), UroIICre Pten
flox/flox 
(Pten, blue), FGFR3-
S249C Pten
flox/flox 
(S249CPten, red) and Fgfr3-K644E Pten
flox/flox 
(K644EPten, pink). CIS= 
Carcinoma in situ  
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5.5 Fgfr3 K644E mutation increases sensitivity to 
tumourigenesis after long-term OH-BBN exposure 
In order to examine the effects of Fgfr3 mutation on malignant progression 
towards potential metastatic development, we subjected a small cohort of 
UroIICre Fgfr3+/K644E mice (Fgfr3-K644E, n=7) as well as Controls (n=6) to 0.05% 
w/v OH-BBN for 20 weeks continuously without a following water period (“20 
weeks”) (Table 5-4 and Figure 5-6). We also generated cohorts of UroIICre 
Ptenflox/flox (Pten, n=7) and UroIICre Fgfr3+/K644E Ptenflox/flox (Fgfr3-K644E Pten, 
n=6) that were subjected to the same OH-BBN time schedule. At the time of 
writing, no FGFR3-S249C mice had been treated for 20 weeks continuously due 
to insufficient numbers.   
It has to be noted that the mice in this experiment were 4-9 months older than 
the mice that were previously treated for 10+10 weeks, starting the treatment 
at 8-11 months of age. The term “Control” in this 20-weeks experiment as 
opposed to “Wild type” in other Chapters refers to mice of C57Bl/6 and mice 
with presence of T2/Onc3 which does not lead to any bladder phenotype by 
itself.  
CIS was most frequently observed in Wild type (100%) and Pten (100%), compared 
to Fgfr3-K644E (86%) and Fgfr3-K644E Pten (67%). Hyperplasia was observed 
most frequently in Fgfr3-K644E (100%), Pten (100%) and Fgfr3-K644E Pten 
(100%), compared to Wild type (67%). Squamous transformation was more 
frequently seen in Fgfr3-K644E (86%), Pten (57%) and Fgfr3-K644E Pten (50%), 
compared to Wild type (33%). The difference in squamous cell transformation 
between Fgfr3-K644E and Wild type was statistically significant (p=0.029, 
Pearson Chi-Square test). Lobulation of the urothelium-stroma boundary was 
more often seen in Fgfr3-K644E (100%) and Fgfr3-K644E Pten (100%) compared to 
Wild type (50%) and Pten (86%). Tumours were more frequently seen in Fgfr3-
K644E (71%) than in Wild type (33%), Pten (57%) and Fgfr3-K644E Pten (50%). 
Invasion was also more often seen in Fgfr3-K644E (71%) than in Wild type (17%), 
Pten (57%) and Fgfr3-K644E Pten (50%).  
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Apart from the incidence of squamous cell transformation, there was no 
significance in the distribution across the cohorts, which may be due to the 
small number of animals. 
Table 5-4: Histological changes of OH-BBN-treated mouse cohorts (“20 weeks”)  
Mice were subjected to 0.05% w/v N-butyl-N-(4-hydroxybutyl)-nitrosamine for 20 weeks 
continuously. 
 
 
 
Figure 5-6: Frequency of histological features and tumour formation in OH-BBN-treated 
cohorts with Fgfr3 K644E mutation after 20 weeks continuously  
Control (green), UroIICre Fgfr3
+/K644E
 (purple), UroIICre Pten
flox/flox 
(blue), UroIICre Fgfr3
+/K644E
 
Pten
flox/flox 
(pink). CIS= Carcinoma in situ  
Results – The role of FGFR3 in tumour progression and invasion  (Chapter 5)  162 
 
 
 
Next we examined proliferation, expression of cell cycle regulating genes, as 
well as expression of markers indicating epithelial-to mesenchymal transition 
(EMT) in OH-BBN-induced tumours. Fgfr3-K644E mutant bladders, with a high 
incidence of tumours, were used as an example (Figure 5-7). 
Ki67 expression was seen at low levels in the untreated Fgfr3-K644E urothelium 
(A). Increased proliferation was typically found along the basal layer of cells of 
the transformed urothelium (B) as well as in the tumour mass (D).  
p53 expression was low in untreated Fgfr3-K644E bladders(D). Following OH-
BBN-induced DNA damage, p53 protein was elevated along the basal cell layer as 
well as in some of the intermediate cells (E). p53 expression had not been lost in 
most of the invading tumour cells; in fact it seemed to have accumulated in 
some regions of the tumours (F). 
p21 expression was restricted to umbrella cells in untreated Fgfr3-K644E 
bladders (G). Following OH-BBN exposure, a fraction of p53-positive cells, in 
particular along the basal cell layer, was p21-positive (H). Invading tumour cells 
also expressed p21 (I, above black dotted line); however, the expression was less 
intense in areas with high p53 expression (I, between black and white dotted 
lines). This could indicate that the p53-antibody, particularly noticeable in (I), 
may have visualised regions with mutant p53 rather than wild type p53, which 
could explain the lack of p21 induction in those regions. 
To visualise breakthrough of the basement membrane as well as the invasive 
edge, Fascin expression levels were analysed. In the untreated Fgfr3-K644E 
urothelium, Fascin was observed in basal and some intermediate cells (J). Fascin 
expression was seen along the lobulated urothelium-stroma boundary (K) and 
marked the invasive edge (L, arrow heads).  
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Figure 5-7: Abnormal protein expression in Fgfr3-K644E at high magnification after 20 
weeks continuous OH-BBN treatment  
Immunohistochemistry showing Ki67 (A-C), p53 (D-F) p21 (G-I) and Fascin (J-L) levels of 
untreated Fgfr3-K644E (A, D, G, J) and OH-BBN-treated Fgfr3-K644E bladders (B, C, E, F, H, I, K, 
L). Scale bar represents 100 µm in A-L.  
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We further characterised the nature of the tumours by analysing the expression 
of urothelial layer-specific proteins as well as markers indicative of epithelial-
mesenchymal transition (EMT) (Figure 5-8). 
Expression of Cytokeratin 5 (CK5), which is normally expressed in basal cells 
(Castillo-Martin et al., 2010), was seen along the lobulated urothelium-stroma 
boundary as well as in invading tumour cells (a). Similarly, p63, which is 
normally expressed in basal and intermediate cells (Castillo-Martin et al., 2010), 
was seen along the basal layer and in tumour cells (b), indicating that these 
tumour cells could potentially be of basal cell origin. 
Invading cells were also positive for β-catenin (c) and Sox9 (d), indicating that 
these cells had undergone a change in their genetic program. Loss of 
membranous E-Cadherin expression was observed in invading cells (e), indicating 
loss of cell-cell adhesion in the process of malignant progression (Schmalhofer et 
al., 2009). Invading cells were also positive for ZEB1 (f), further supporting that 
EMT had occurred. 
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Figure 5-8: The effects of Fgfr3 K644E mutation in tumour progression upon OH-BBN 
treatment 
Representative sections of the bladders stained for CK5 (a), p63 (b), β-Catenin (c), Sox9 (d) E-
Cadherin (e) and ZEB1 (f). Bottom scale bar represents 100 µm in main pictures a-f. Insert scale 
bar (f) represents 50 µm for magnified inserts a-f. 
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5.6 FGFR3 S249C mutation promotes pre-neoplastic 
changes in a time course of OH-BBN exposure 
To investigate the difference in tumourigenesis between Wild type and FGFR3-
mutant bladders, we examined the histological changes in the urothelium in 
response to OH-BBN treatment in a time course over 20 weeks (Figure 5-9 and 
Figure 5-10). 
Bladders of Wild type (n=5) and FGFR3-S249C (n=5) were compared at two weeks 
after starting the OH-BBN treatment (Figure 5-9, A and B respectively). Loss of 
polarity (A, arrows), cellular atypia and pleomorphism (B, circle) and 
hyperchromatic nuclei (B, arrows), was observed in all examined samples of both 
genotypes.  
Similarly at 6 weeks of OH-BBN treatment all examined Wild type (n=5) (C) and 
FGFR3-S249C (n=5) (D) mice additionally displayed frequent mitoses (D, arrow) 
and dysplasia as indications of CIS in the urothelium.  
 
Figure 5-9: Histological changes of Wild type and FGFR3-S249C bladders after two and six 
weeks of OH-BBN exposure  
Representative H&E sections of Wild type and Tg(UroII-hFGFR3IIIbS249C). Scale bar represents 
100 µm (A-D).   
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We continued the OH-BBN treatment up to a total of 10 weeks followed by 
additional 2 weeks of normal drinking water (“10+2 weeks”, Figure 5-10). 
Additional features such as hyperplasia (A, B, arrows), squamous cell 
transformation (C, arrows), and lobulation of the urothelial-stroma boundary (A, 
B, C, dotted lines) were observed in samples of Wild type (n=5) (A), FGFR3-
S249C (n=5) (B), as well as in UroIICre Ptenflox/flox (n=5) (C). 
 
 
Figure 5-10: Histological changes of Wild type, FGFR3-S249C and UroIICre Pten
flox/flox
 
bladders after 10+2 weeks of OH-BBN exposure  
Representative H&E sections of Wild type (n=5) and Tg(UroII-hFGFR3IIIbS249C) (n=5). Scale bar 
represents 100 µm (A-C).  
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We then scored the presence of carcinoma in situ (CIS), hyperproliferation, 
keratinising squamous metaplasia, lobulation of the urothelium-stroma 
boundary, tumour incidence and invasion in bladders of Wild type (n=5), FGFR3-
S249C (n=5) and UroIICre Ptenflox/flox (Pten) (n=5) at 10+2 weeks of OH-BBN 
exposure (Figure 5-11). 
CIS was observed in all samples (n=5, 100%) of Wild type and Pten. FGFR3-S249C 
showed a decrease in CIS, with presence in only 60% of the samples. Hyperplasia 
was most frequently seen in FGFR3-S249C (n=5, 100%) compared to Wild type 
(n=2, 40%) and Pten (n=4, 80%). Squamous metaplasia was most frequently 
observed in FGFR3-S249C (n=3, 60%) compared to Wild type (n=1, 20%) and Pten 
(n=1, 20%). Lobulation of the urothelium-stroma boundary was also most 
frequently observed in FGFR3-S249C (n=3, 60%) compared to Wild type (n=2, 
40%) and Pten (n=1, 20%). No tumours or signs of invasion were detectable in 
Wild type, FGFR3-S249C or Pten at 10+2 weeks of OH-BBN exposure. 
The distribution was not statistically significant in any of the categories (Pearson 
Chi-Square test).  
 
Figure 5-11: Frequency of histological features and tumour formation after 10+2 weeks  
OH-BBN-treated Wild type (green), Tg(UroII-hFGFR3IIIbS249C)
 
(S249C, yellow) and UroIICre 
Pten
flox/flox
 (Pten, blue). CIS= Carcinoma in situ 
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5.7 Analysis of DNA damage in Wild type and FGFR3 
mutants 
We compared the DNA-damaging effect of OH-BBN on the urothelium of Wild 
type and FGFR3-S249C bladders in a time course over 20 weeks (Figure 5-12).  
In the absence of carcinogen treatment, γH2aX phosphorylation was seen in Wild 
type bladders (n=3 out of 3) (A) as well as in FGFR3-S249C bladders (n=3/3) (B) 
at low levels. In two out of three untreated Wild type samples (n=2/3), γH2aX 
positivity was observed throughout all layers of the urothelium in (A). In 
untreated FGFR3-S249C bladders (n=3/3), γH2aX phosphorylation was mainly 
observed in the umbrella cells, but not in intermediate or basal cells (B).  
At two weeks of OH-BBN treatment, strong phosphorylation of γH2aX was 
detected in Wild type (n=2/2) (C), as well as in FGFR3-S249C (n=2/3) (D), 
indicating a high incidence of double strand breaks.  
Similarly, at six weeks of OH-BBN treatment, γH2aX phosphorylation was seen at 
high levels in Wild type (n=3/3) (E), as well as in FGFR3-S249C (n=2/3) (F), 
which was overall comparable with the γH2aX phosphorylation level at two 
weeks of OH-BBN exposure (C-D).  
At ten weeks of OH-BBN exposure followed by two weeks of normal drinking 
water (10+2 weeks), a decrease in γH2aX phosphorylation was observed in Wild 
type (n=2/3) (G), as well as in FGFR3-S249C (n=2/3) (H) compared to γH2aX 
phosphorylation at two and six weeks (C-F). Cells that had undergone squamous 
transformation in FGFR3-S249C (n=1/3) were negative for γH2aX (H, black 
arrow); whereas cells along the lobulated urothelium-stroma boundary were 
positive (H, red arrow). 
At ten weeks of OH-BBN exposure followed by ten weeks of normal drinking 
water (10+10 weeks), two tumours had developed in FGFR3-S249C, which 
showed high levels of γH2aX (J, red arrows, n=2/2). No tumours had developed 
in the Wild type cohort at this point, where therefore no comparison of γH2aX 
phosphorylation levels could be made. In areas of Wild type samples that 
retained relatively normal urothelium, γH2aX phosphorylation was present 
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(n=3/3) (I), however at much lower levels compared to Wild type samples at 
two- or six-weeks of treatment (C, E). FGFR3-S249C urothelia underwent more 
dramatic changes, such as hyperplasia or CIS with varying γH2aX phosphorylation 
in each sample (n=3 total), which requires to be addressed in future experiments 
in order to generate conclusive data. 
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Figure 5-12: Double-strand breaks upon OH-BBN treatment  
Immunohistochemistry for γH2aX in bladders of Wild type (A, C, E, G, I) and Tg(UroII-
hFGFR3IIIbS249C)
 
(B, D, F, H, J). Scale bar represents 100 µm (A-J).   
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5.8 Discussion 
To address the question whether an FGFR3 mutation could predispose urothelial 
cells to tumourigenesis, and to evaluate its role in tumour progression, we 
subjected Fgfr3- and FGFR3-mutant as well as Wild type mice to a bladder-
specific carcinogen, N-butyl-N-(hydroxybutyl)-nitrosamine (OH-BBN). We 
compared two different point mutations in Fgfr3 and FGFR3, as well as the 
effect of Pten deletion and Fgfr3-Pten double mutation in OH-BBN-induced 
tumours. 
5.8.1 Tg(UroII-hFGFR3IIIbS249C) line 
The generation of FGFR3-S249C transgenic mice revealed that mice carrying the 
FGFR3-S249C transgene retained a histologically normal urothelial appearance at 
12 months (Figure 5-2), consistent with our observations with heterozygous Fgfr3 
K644E knock-in mutation in the urothelium (Ahmad et al., 2011c). In the 
presence of either of the two Fgfr3 mutations, the proliferation rate in the 
urothelium was similarly low as in Wild type. Furthermore, FGFR3 expression 
levels were comparable between both genotypes and compared with Wild type. 
These results support our previous experiments, suggesting that FGFR3 
activation by itself is not able to induce urothelial pathogenesis. 
In contrast to UroIICre Fgfr3+/K644E Ptenflox/flox bladders, where significant 
increase in urothelial thickness and severe cell-morphological changes were 
observed (Chapter 3), we did not see any urothelial abnormalities in UroIICre 
FGFR3-S249C Ptenflox/flox bladders (Figure 5-3). FGFR3-S249C Ptenflox/flox urothelia 
showed no similarities to UroIICre Fgfr3+/K644E Ptenflox/flox, which suggests that 
activated FGFR-signalling with a K644E mutation is more potent than an S249C 
mutation to induce urothelial cell changes in a Pten deficient background in a 
non-tumour context. 
In the comparison of the two FGFR3 mutations, S249C and K644E, it needs to be 
noted that Tg(UroII-hFGFR3IIIbS249C) is a transgene (see Methods, Chapter 2.3), 
which is expressed in addition to endogenous FGFR3 levels. UroIICre Fgfr3+/K644E 
on the other hand is a knock-in construct, generating a heterozygous activating 
mutation at the expense of one endogenous Fgfr3 copy (Iwata et al., 2000, 
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Ahmad et al., 2011c). Furthermore, FGFR3-S249C generates human recombinant 
FGFR3 protein in the mouse bladder, whereas UroIICre Fgfr3+/K644E produces 
FGFR3 protein of murine origin. Both S249C and K652E have been shown to be 
able to transform NIH-3T3 cells, but to have no obvious effect on normal 
urothelial cells in culture (di Martino et al., 2009).  
Although both K644E and S249C mutation lead to highly activated FGFR3 
signalling, their mechanisms may be different and could explain the different 
urothelial phenotypes seen in our in vivo studies. K644E mutation leads to a 
conformational change in the receptor that favours autophosphorylation (Naski 
et al., 1996). It has been suggested that K644E mutation may therefore 
deregulate a mechanism for controlling the kinase activity (Naski et al., 1996), 
which may possibly result in differential downstream signalling activation. S249C 
on the other hand triggers constitutive receptor dimerisation as a result of a 
higher level of disulfide bond formation (d'Avis et al., 1998, di Martino et al., 
2009). This may lead to a different shape of the FGFR3 protein and could affect 
receptor function or preference in binding to certain adapter proteins 
downstream.  
S249C may be of greater clinical relevance since it accounts for ~66% of human 
non-invasive urothelial cell carcinoma with FGFR3 mutant status (Tomlinson et 
al., 2007a, Duenas et al., 2013, Bernard-Pierrot et al., 2006). 
5.8.2 FGFR3 mutation increases sensitivity to tumourigenesis 
after OH-BBN exposure 
In response to OH-BBN treatment, and regardless of the nature of additional 
genetically introduced mutations, the urothelia underwent a number of pre-
neoplastic changes, such as loss of polarity, cellular atypia and pleomorphism, 
hyperchromatic nuclei, frequent mitoses and dysplasia as indications of 
carcinoma in situ (CIS) (Figure 5-4). Keratinising squamous metaplasia, which is 
considered rather a pre-neoplastic condition, is infrequently found in human 
bladder biopsies in the UK (Ahmad et al., 2008). However, it may pose a risk of 
malignant transformation to invasive bladder cancer (Guo et al., 2006). In fact, 
squamous cell transformation, which is a neoplastic condition, frequently co-
occurs with urothelial cell carcinoma at an advanced stage at the time of 
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diagnosis, and it is associated with enhanced expression of EGFR and p53 (Guo et 
al., 2006).  
Strikingly, after 10+10 weeks of OH-BBN treatment we found that FGFR3 S249C 
mutation can promote malignant progression in carcinogen-induced bladder 
tumours (Figure 5-3 and Figure 5-4). FGFR3 mutated mice exhibited a 2.4-fold 
higher incidence of CIS and a 4.4-fold higher incidence of squamous cell 
transformation upon administration of OH-BBN compared to Wild type controls. 
They also showed a 4.4-fold higher incidence of tumour formation and 3.9-fold 
higher incidence of invasion. The urothelium showed characteristics of advanced 
tumours including breakthrough of the basement membrane and expression of 
Fascin (Karasavvidou et al., 2008). It is therefore possible that FGFR3 mutation 
predisposes urothelial cells to tumourigenesis or acts as a tumour promoter in 
already established neoplasms. This could be of relevance to the prognosis of 
patients with a bladder tumour with FGFR3 mutation, as FGFR3 signalling may 
provide a growth advantage to the cells and may drive progression of an existing 
tumour towards muscle invasion. In human invasive bladder cancer, wild type 
FGFR3 is frequently found overexpressed (Tomlinson et al., 2007a). However, we 
have not addressed FGFR3 expression levels in our carcinogen-induced mouse 
tumour model with FGFR3 mutation. 
Surprisingly, we observed a lower incidence of tumour formation and invasion as 
well as lower incidence of CIS and squamous metaplasia in UroIICre Ptenflox/flox 
compared to FGFR3-S249C, suggesting that the presence of an FGFR3 S249C 
mutation promotes tumourigenesis upon OH-BBN exposure considerably more 
than Pten loss. In fact, the frequency of these features in UroIICre Ptenflox/flox 
was overall similar to OH-BBN-treated Wild type mice. It is possible that MAPK 
activation may be more potent than Akt activation in order to promote 
progression of an existing tumour. 
This was also supported by the fact that FGFR3 S249C in combination with Pten 
deletion (FGFR3 S249C Ptenflox/flox) had a higher incidence in tumour formation 
as well as CIS, squamous cell transformation, lobulation and invasion than 
UroIICre Ptenflox/flox alone, emphasising the potent effect of FGFR3 S249C on 
malignant progression (Figure 5-5). A similar trend was observed for Fgfr3 K644E 
in combination with Pten deletion treated for 10+10 weeks (Figure 5-5). 
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Although not significant, these mice also showed a higher incidence of CIS and 
tumour formation compared to Pten only. These results indicate that an Fgfr3 
K644E mutation may have a similar effect towards malignant progression as 
FGFR3 S249C in the presence of Pten deletion. However, at the time of writing 
there were no OH-BBN-treated UroIICre Fgfr3+/K644E mice available for a direct 
comparison between S249C and K644E mutation upon OH-BBN treatment in 
tumour progression. 
Using a treatment schedule where OH-BBN was administered for 20 weeks 
continuously, Fgfr3 K644E also showed 2-fold increase in tumourigenesis, a 2.5-
fold increase in squamous metaplasia and a 4-fold increase in invasion compared 
to Wild type (Figure 5-6). This result supports the suggestion that Fgfr3 mutation 
is likely to play a role in carcinogen-induced bladder cancer in mice, and that 
Fgfr3 mutation may be involved in promotion of squamous cell transformation as 
well as invasion. A similar trend was observed in UroIICre Ptenflox/flox urothelia as 
well as both Fgfr3 and Pten mutations in combination. It has to be noted that a 
longer OH-BBN protocol was used, the number of animals was too low for 
statistically solid conclusions, and that the mice in this experiment were older 
than the mice that were previously treated for 10+10 weeks. In a recent study, 
where Secreted Protein Acidic and Rich in Cysteine (Sparc)-deficient mice were 
treated for 25 weeks continuously with OH-BBN, mice showed decreased survival 
and accelerated urothelial pathology with metastasis to the lymph nodes and 
lungs (Said et al., 2013). It would be interesting to extend our current treatment 
protocol to a time where metastases occur in the animal model in order to 
investigate the effect of FGFR3 mutation in late stages of cancer progression. 
5.8.3 DNA damage response upon OH-BBN 
Although no obvious phenotypic difference was evident by H&E staining between 
Wild type and FGFR3 S249C mutant bladders, we examined the urothelia at the 
molecular level to see whether the sensitivity to DNA damage or the DNA repair 
machinery is altered in FGFR3-mutant cells (Figure 5-12). Due to the small 
number of samples no conclusive statement could be made. However, in two out 
of three untreated Wild type samples, γH2aX positivity was observed throughout 
all layers of the urothelium, whereas in untreated FGFR3-S249C bladders, γH2aX 
phosphorylation was mainly observed in the umbrella cells but not in 
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intermediate or basal cells in three out of three samples. Whether this indicates 
a possible difference between Wild type and FGFR3 S249C in frequency and 
location of urothelial cells carrying double strand breaks remains to be 
addressed in future experiments. It would also be interesting to include γH2aX 
levels of Fgfr3 K644E mutant bladders in future analyses.  
Upon carcinogen exposure, γH2aX phosphorylation was the highest at 2-6 weeks 
of OH-BBN treatment in both Wild type and FGFR3-S249C. When the carcinogen 
was removed after 10 weeks of OH-BBN treatment and the mice were continued 
on normal drinking water, the bladders showed a mild decrease in γH2aX 
phosphorylation in samples from 10+2 and 10+10 weeks. This may be due to 
elimination of cells with DNA damage alongside urothelial hyperproliferation, 
resulting in increased production of new cells with intact DNA. Interestingly, in 
other organs such as the intestine, cells with DNA damage are eliminated and 
renewed after 4-5 days (van der Flier and Clevers, 2009). In the bladder, 
presumably due to the slow turnover rate of the urothelium (Khandelwal et al., 
2009), these cells were still present even 10 weeks after OH-BBN-induced DNA 
damage. Due to the difference in the number of tumours that had formed in 
FGFR3 S249C but not in Wild type, no comparison could be made in terms of 
expression level and pattern of γH2aX in the tumour cells. Future experiments 
could also include Western blotting in order to examine γH2aX phosphorylation 
levels; however the separation of the urothelium from the bladder wall in mice 
is technically challenging and the amount of cells is usually low or insufficient 
for protein extraction. 
5.8.4 OH-BBN as a tool to induce invasive bladder cancer in mice 
OH-BBN provides a reliable tool to induce urothelial cell carcinoma in mice, 
since it resembles human bladder cancer not only histologically, but also at a 
molecular level (Becci et al., 1981, Yao et al., 2004). They are generally of 
highly invasive nature and often show a mixed histology with features of both 
urothelial cell carcinoma and squamous cell differentiation (Becci et al., 1981). 
Molecularly, OH-BBN tumours frequently carry mutations in genes that regulate 
major signalling pathways such as p53, RAS, EGFR and TGF-β (Yao et al., 2004). 
Despite the fact of systemic distribution by administration through gavage or 
drinking water, the carcinogen appears to induce mutations in an organ-specific 
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manner (He et al., 2012). However, a limitation of carcinogen-induced 
mutagenesis is that the DNA damage occurs in a random fashion. Therefore, OH-
BBN cannot induce specific DNA mutations, which may be desired in an 
experimental setting.  
Exposure to chemical carcinogens is one of the risk factors of developing bladder 
cancer. It is estimated that more than one third of bladder tumours are 
associated with cigarette smoking (Parkin, 2011). Smoking appears to influence 
p53 mutation status and is associated with invasive, high-grade bladder cancer 
(Wallerand et al., 2005). In contrast, FGFR3 mutations are not associated with 
smoking and may result from endogenous DNA damage (Wallerand et al., 2005). 
Our data show that FGFR3 does have an effect on progression of existing tumours 
in mice. It is possible that in humans FGFR3 mutation as an early event may 
initially help the tumour to progress, and that it is lost later at a more advanced 
stage of the tumour. 
5.8.5 Future work 
Firstly, it would be interesting to confirm in a larger cohort of carcinogen-
induced Fgfr3-mutant mice whether Fgfr3 K644E mutation has an effect similar 
to FGFR3 S249C in accelerating bladder tumour formation. 
Secondly, further studies of the FGFR3 signalling pathway are essential and will 
aid the development of therapies for both non muscle-invasive and muscle-
invasive bladder cancer with deregulation of FGF signalling. For example, it 
would be essential to test the effect of FGFR3 inhibitors on OH-BBN-induced 
FGFR3-S249C bladder tumours. This could be done in vitro and in vivo. FGF 
signalling inhibitors have been developed and applied in many cancer types 
(Brooks et al., 2012). Inhibition of FGFR has been suggested as a therapeutic 
option in urothelial cell carcinoma (Lamont et al., 2011, Tomlinson et al., 
2007b, Network, 2014). Several novel drugs against FGFRs including R3Mab (Qing 
et al., 2009), BGJ398 (Guagnano et al., 2011) and AZD4547 (Gavine et al., 2012) 
have been shown to be effective in cell lines and xenograft models. For a 
translational benefit, further studies of the FGFR3 signalling pathway and its 
inhibitors are therefore essential. However, it has to be kept in mind that 
Results – The role of FGFR3 in tumour progression and invasion  (Chapter 5)  178 
 
 
 
inhibition of the FGFR3 pathway may trigger EGFR activation (or other pathway 
activation) as an escape mechanism (Herrera-Abreu et al., 2013).  
Lastly, it would be interesting to identify FGFR3-cooperating mutations that can 
promote tumour progression alongside FGFR3. This could be elucidated by 
exome sequencing of OH-BBN-induced tumours of Fgfr3 mutant bladders, which 
would help to identify molecular events that occur together with Fgfr3 mutation 
to drive urothelial cell carcinoma or potentially further aid progression. 
5.8.6 Conclusion 
Altogether, the present results demonstrate that an FGFR3 S249C mutation alone 
does not lead to tumourigenesis in the urothelium, similar to Fgfr3 K644E 
mutation alone. Differential effects between K644E and S249C on the cellular 
architecture were only apparent in combination with another mutation such as 
Pten deletion. Moreover, our results indicate that FGFR3 can predispose 
urothelial cells to tumourigenesis or can even act as an active tumour promoter 
in already established neoplasms. This could be of relevance to the prognosis of 
patients with a high-grade bladder tumour with FGFR3 mutation, as FGFR3 
signalling may provide a growth advantage to the cells and may drive progression 
of an existing tumour towards muscle invasion.  
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6.1 Introduction  
6.1.1 AdenoCre 
Given that UroIICre recombination appeared to be missing the basal cells which 
have been a putative cell origin for urothelial cell carcinoma, we next wished to 
use a model where basal cells can be targeted. Moreover, due to UroplakinII 
expression in other tissues, some of our previous UroIICre models had developed 
tumours in the skin and lung (Ahmad et al., 2011c). This may indicate a later 
cancer onset in the bladder and therefore require more specific recombination 
in a smaller number of urothelial cells to allow the emergence of bladder 
tumours. 
Most urothelial Cre promoters, including the fatty acid-binding protein (Fabp), 
Sonic hedgehog (Shh), Cytokeratin 5 (CK5), p63 (ΔNp63) and Uroplakin-II (UroII) 
also drive the expression of the recombinase in other tissues. For example, the 
Fabp promoter drives Cre expression in all cell layers of the urothelium as well 
as in the renal calyces and pelvis, ureters, and small intestinal and colonic 
epithelium (Saam and Gordon, 1999, Tsuruta, 2006). Shh-Cre is primarily 
expressed in a subgroup of basal cells; but it is also expressed in the prostate 
(Shin et al., 2011). CK5-and ΔNp63-Cre have been used to drive the expression of 
the recombinase in the urothelium (Pignon et al., 2013, Gandhi et al., 2013). 
However, CK5 and p63 are also commonly expressed in the skin (Di Como et al., 
2002, Moll et al., 2008).  
At the time of our previous experiments (Chapters 3, 4 and 5) the UroplakinII 
promoter was the best available option to drive Cre recombination in the 
urothelium. UroIICre-driven recombination to express FGFR3 in combination with 
OH-BBN exposure, which specifically targets the bladder, resulted in invasive 
urothelial tumours (Chapter 5). However, OH-BBN acts on the entire bladder, 
which can potentially promote tumourigenesis in all exposed urothelial cells. 
The resulting tumours present with large and fast growth behaviour, which likely 
reach the pre-determined end point of the experiment before potential 
metastasis can occur. With the use of OH-BBN it is difficult to induce specific 
genetic mutations, because the carcinogen induces random DNA damage in all 
cells. Therefore, each of the resulting tumours is composed of a large set of 
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different mutations, leading to great variability of genetic profiles at the time of 
tumour examination. 
An alternative method of Cre delivery to the tissue of interest involves the use 
of a recombinant Adenovirus (Anderson et al., 2000, Anton and Graham, 1995). 
Cre-recombinant Adenovirus type 5 (AdenoCre) is a viral vector that is 
replication-deficient due to deletion of the 0-9.2 map units, which include the 
left inverted terminal repeat (ITR) region, as well as transformation-deficient 
due to lack of the original E1a sequence (Anderson et al., 2000). In replacement 
of E1a, AdenoCre harbours the Cre transgene, which is controlled by a 
Cytomegalovirus (CMV) promoter (Anton and Graham, 1995). Since Adenoviruses 
do not integrate into the host genome, the expression of Cre is transient (Brody 
and Crystal, 1994).  
Adenoviral gene transfer has successfully been used to transduce cells in culture 
(Hawley et al., 2010, Prost et al., 2001), as well as tissues in vivo such as the 
lung (Jackson, 2001), breast (Russell et al., 2003), uterus (Wang et al., 2006) 
and brain (Davidson et al., 1993). 
AdenoCre has recently also been tested in the bladder, where the virus was 
orthotopically instilled via laparotomy or catheterisation (Puzio-Kuter et al., 
2009, Yang et al., 2013). The work by Puzio-Kuter suggested that AdenoCre 
could target basal cells (Puzio-Kuter et al., 2009). The study further reported 
muscle-invasive tumours by six months with 100% penetrance in p53flox/flox 
Ptenflox/flox mice (Puzio-Kuter et al., 2009). 60% of these tumours metastasised to 
lymph nodes and distant sites between 4-6 months. No tumours were observed in 
p53 or Pten single mutants. Loss of either p53 or Pten in combination with loss 
of Retinoblastoma protein (Rb) following AdenoCre injection did not result in 
tumour formation or a visibly abnormal urothelial phenotype (Puzio-Kuter et al., 
2009). In a second study in which p53flox/flox Kras+/LSLG12D mice were orthotopically 
instilled with AdenoCre, bladders developed mild urothelial hyperplasia at six 
months but showed no evidence of tumour initiation (Yang et al., 2013).  
In this chapter we aimed to generate an invasive bladder cancer model in which 
the effect of different gene combinations can be tested in a spatially and 
temporally controlled fashion. We therefore sought to replace UroIICre-driven 
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recombination by AdenoCre delivery. AdenoCre infection not only allows 
bladder-restricted recombination (Puzio-Kuter et al., 2009, Seager et al., 2010) 
but also may enable recombination in a smaller number of cells that are 
individually surrounded by a normal tissue environment. Furthermore, we wished 
to assess whether these smaller lesions may allow models to survive longer and 
therefore tumours to have the potential to progress and eventually metastasise.  
6.1.2  In vivo imaging 
In the bladder, clinical signs of tumours such as a palpable mass or haematuria 
are generally present at late stages of the disease. Therefore, a number of non-
invasive in vivo imaging techniques have been developed to detect tumours at 
early stages and to monitor disease progression as well as drug response. These 
include ultrasound, magnetic resonance imaging, computer tomography, and 
bioluminescent or fluorescent imaging (Lyons, 2005).  
Ultrasound imaging has been used to detect tumours as small as 0.52 mm3 in an 
orthotopic bladder cancer model (Patel et al., 2010). Optimised micro-
ultrasound with targeted contrast enhancement involves detection of a probe 
that has been inserted into the bladder via a catheter (Chan et al., 2011). 
Probes such as microbubbles coated with a monoclonal antibody against a target 
molecule can be detected and quantified. A drawback of ultrasound imaging 
techniques is the variability of the images acquired from the same tumour as 
well as motion artefacts resulting from breathing (Chan et al., 2009a). 
Magnetic resonance imaging (MRI) provides the advantage of early tumour 
detection with high resolution (Kikuchi et al., 2003). However, image acquisition 
and processing is very costly and time consuming. MRI scanners are therefore not 
available at every institute. 
Computer tomography (CT) is an x-ray-based technology that allows creating a 3-
dimensional picture with high spatial resolution based on the density of the 
analysed tissue (Martiniova et al., 2010). Positron emission tomography (PET) is 
often used in combination with CT (CT-PET), where a biologically active 
molecule is introduced into the body to improve image acquisition. However, 
introduction of contrast-enhancing agents may trigger an immune response.   
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Furthermore, due to the high sensitivity of this technology, minor tissue 
abnormalities can lead to misinterpretations. 
Bioluminescent imaging (BLI) is based on luciferase, an enzyme that converts 
substrates such as luciferin into light signals emitting between 500-620nm. 
Luciferase-transfected cancer cells can therefore easily be detected in 
orthotopic models; however, it is unclear whether luciferase may trigger an 
immune response in the animal and it gives no information on tumour anatomy 
(Henriquez et al., 2007). 
Fluorescent imaging is based on genetically introduced reporters such as GFP or 
RFP (Lyons, 2005). An RFP signal can be detected between 570-620nm, whereas 
GFP is between 465-520nm. Fluorescent reporters can also be used in 
combination. However, this imaging method suffers from autofluorescence of 
abdominal hair and internal organs, and in the case of the bladder from the 
presence of urine.  
With the aim to detect and monitor tumour development and progression in 
living animals, we tested fluorescent imaging and ultrasound imaging in the 
mouse bladder. 
6.1.3 In vitro models 
In vitro cell culture provides the opportunity to analyse cancer initiation and 
progression, as well as to test the effectiveness of therapeutic drugs in a 
controlled environment. In vitro approaches to investigate urothelial cell 
carcinoma include cell culture techniques of human and mouse primary tumour 
cells, bladder cancer cell lines, as well as organotypic cultures.  
Sphere formation in a 3-dimensional (3D) environment such as in Matrigel has 
been described as an indication of self-renewal as characteristic of stem cells 
(Sato et al., 2009, Xin et al., 2007) and cancer stem cells (Nicolis, 2007). For 
example, the highly invasive human bladder cancer cell line T24 cultured on 
ultra-low attachment plates starts to form spherical colonies after 7 days as an 
indicator of stem cell behaviour (Zhang et al., 2012). Sphere formation has also 
been tested using cells from Stat3-activated bladder tumours in mice (Chen et 
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al., 2012). Furthermore, it was shown in normal mouse bladders that FACS-
sorted Shh-expressing urothelial cells are capable of forming spheres in Matrigel 
(Shin et al., 2011). In contrast to monolayer cultures, it has been shown that 3D 
tumour sphere cultures match the in vivo response to chemotherapeutics better 
(Kim and Alexander, 2013), supporting the use of 3D culture systems.  
Organotypic slice culture of the bladder has been described as a tool to analyse 
tissue development and the underlying signalling pathways in a well-defined 
environment (Batourina et al., 2012). The advantage of this culture technique is 
that the tumour can be kept in its original environment, surrounded by 
urothelium, connective tissue and striated muscle. The effect of therapeutic 
drugs on invasion in this ex vivo system has not been tested yet; however, the 
technique can potentially constitute useful assay.  
With the aim to image invasive bladder cancer in vivo, and to assess 
transformation and cell migration we set out to establish essential ex vivo 
techniques and assays.  
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6.2 Establishment of techniques to generate and detect 
invasive bladder cancer in mice 
6.2.1 Generation of mouse cohorts to test AdenoCre 
recombination efficiency 
In order to test adenoviral Cre delivery to the mouse bladder we used RFP 
reporter mice (Rosa26 tdRFP) where recombined cells can be visualised upon 
successful AdenoCre transduction (Luche et al., 2007) (Table 6-1). As an 
alternative we used Rosa26 lacZ mice, where recombination can be traced by X-
gal staining on frozen tissue. We also generated mice carrying one or two copies 
of an activating β-catenin mutation, β-catenin+/exon3 or β-cateninexon3/exon3 
respectively, where recombination can be visualised by immunohistochemistry 
against β-catenin protein. This method has also been used in previous studies, 
where upregulation of nuclear β-catenin was demonstrated in β-cateninexon3/exon3 
bladders under the control of UroIICre (Ahmad et al., 2011a, Ahmad et al., 
2011b). 
 
Table 6-1: Summary of mice injected for recombination analysis  
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene   
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6.2.2 Assessment of recombination 
In order to analyse the location and frequency of AdenoCre recombination upon 
infection, as well as to establish an imaging technique by which disease 
progression can be monitored in living animals, we tested the IVIS Spectrum in 
vivo imaging system.  
We instilled Rosa26 tdRFP (n=16) and a Wild type control (n=1) orthotopically 
with Ad5CMVCre-eGFP and imaged the mice after 12-40 days using the IVIS 
Spectrum (Figure 6-1). In the bladder, an AdenoCre dose of 1x109 pfu has been 
demonstrated to successfully generate tumours in a p53flox/flox Ptenflox/flox 
background (Puzio-Kuter et al., 2009). We used an Ad5CMVCre-eGFP dose of 
1x109 pfu in Rosa26 tdRFP (n=8), as well as 2x109 pfu in Rosa26 tdRFP (n=8) and 
Wild type (n=1). 
An RFP (mCherry) signal between 587-610nm was expected from cells that have 
undergone recombination. A strong RFP signal was observed in the guts of Wild 
type (A, circled) as well as the reporter mice (B), a background signal which 
most likely results from alfalfa, a plant that is part of the rodent diet that the 
animals are commonly provided with at the Beatson animal unit. The bladders of 
Wild type and reporter mice (A, B, yellow arrows) emitted only a weak RFP 
signal. Due to high background fluorescence in the guts, and the weak signal 
from the bladders, the occurrence of recombination in the bladder could not be 
unambiguously determined. No difference was observed between AdenoCre-
injected low-dose (1x109 pfu) and high-dose (2x109 pfu) mice based on 
fluorescent signal intensity using the IVIS spectrum (data not shown). 
The transduction of cells by AdenoCre can be visualised through an eGFP 
reporter carried by the recombinant adenovirus (Ad5CMVCre-eGFP). 
A GFP signal between 465-520nm was expected from AdenoCre-infected bladder 
cells. A strong GFP signal was observed in Wild type (C, yellow arrow) as well as 
the reporter mice (D, black arrows). However, this is likely to have resulted 
from urine that is autofluorescent. This is supported by the fact that a 
prominent spot of GFP-positive urine was seen in Wild type (C, white arrow).  
Results – Technological improvement of an invasive bladder cancer model  (Chapter 6) 187 
 
 
 
 
Figure 6-1: Cre recombination upon adenoviral transduction visualised by IVIS Spectrum  
Wild type mouse (A, C) and three Rosa26 tdRFP expressing mice (B, D) imaged for RFP (A, B) 
and GFP (C, D) at 12 days after injection of 2x10
9 
pfu Ad5CMVCre-eGFP.  
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Next we examined AdenoCre transduction and recombination in the urothelium 
at the cellular level (Figure 6-2). We first examined the expression of GFP and 
RFP to visualise the events of transduction and recombination, respectively, in 
the urothelium of Rosa26 tdRFP mice.  
GFP expression was detected in a low number of urothelial cells located in the 
umbrella and intermediate layer of Rosa26 tdRFP reporter mouse bladders (A), 
indicating successful transduction of a small number of cells by AdenoCre.  
RFP antibody staining showed broad unspecific positivity in the majority of cells 
in the urothelium (B). Some individual cells in the umbrella and intermediate 
layer occasionally showed stronger staining intensity (B, arrows), similar to the 
one observed in the GFP staining (A).  
X-gal staining was performed on frozen sections from bladders carrying a lacZ 
reporter (n=3) (C). The majority of umbrella cells showed positive blue staining, 
indicating recombination to have occurred. However, as shown in (Figure 3-2), 
X-gal generally stains umbrella cells independently of a recombination event.  
As an alternative to the RFP and lacZ reporter systems, we aimed to visualise 
AdenoCre recombination in β-cateninexon3/exon3 bladders using a β-catenin 
antibody. In our experiments, a small number of positive recombination events 
was observed in urothelial cells, along with broad recombination in a large 
number of cells in the stromal compartment (D, arrows).  
Altogether, AdenoCre recombination was most effectively detected by nuclear 
β-catenin expression in the presence of a β-cateninexon3/exon3 activating mutation. 
GFP expression was generally low in the urothelium, and at times even absent in 
a full bladder section. Furthermore, GFP positivity only reveals successful 
transduction and not recombination. Therefore, GFP staining was only used in 
combination with other reporters in future experiments. Due to the non-
specificity on the RFP antibody, no conclusions could be drawn on urothelial 
recombination, and therefore the staining was discontinued. Likewise, X-gal 
staining was discontinued in future experiments due to non-specific blue staining 
of umbrella cells. The exact percentage of successfully recombined cells could 
not be determined by immunohistochemistry.  
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Figure 6-2: Cre recombination at cellular level upon high-dose AdenoCre transduction 
Immunohistochemistry for GFP (A) and RFP (B) on bladder sections of Rosa26 tdRFP. X-gal 
staining on Rosa26 lacZ (C). Immunohistochemistry for β-catenin on β-catenin
exon3/exon3
 bladder (D).  
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6.2.3 Monitoring tumour formation and progression in vivo 
Although IVIS Spectrum has only been used to image healthy bladders of reporter 
mice, it seemed to provide an insufficient tool to monitor bladder tumours due 
to high level of background signal at two different wavelengths (Chapter 6.2.2). 
We therefore aimed to establish an alternative, the Vevo 770 Visualsonics 
ultrasound, as an imaging system for the bladder in order to monitor tumour 
progression in living animals. 
To establish the methodology, we first aimed to image transgenic animals that 
were known to develop carcinoma in the bladder. In a previous study, we had 
generated mice with β-catenin and Hras activation, UroIICre β-cateninexon3/exon3 
HrasQ61L, which reliably produced tumours by 8 months of age (Ahmad et al., 
2011b). We then generated mice without UroIICre, where AdenoCre was be used 
to induce cell transformation, namely β -cateninexon3/exon3 HrasG12V/G12V (Chapter 
6.4). In contrast to the H-Ras Q61L overexpression model (Ahmad et al., 2011b), 
our Hras G12V cohort carries a homozygous knock-in mutation that allows 
expression of endogenous levels of oncogenic Hras G12V. Bladders were 
examined using ultrasound (Figure 6-3).  
Injected Wild type bladders (n=1) and non-injected Wild type bladders (n=3) 
showed a normal bladder wall of approximately 0.3-0.4 mm in thickness (A). In 
AdenoCre-injected β-cateninexon3/exon3 HrasG12V/G12V mice (n=6), we observed 
bladder wall thickening with an irregular surface towards the bladder lumen at 
5.5 months post injection in all bladders (B).  
Upon bladder wall thickening, tumours were monitored in n=4 mice over 14 
weeks, all of which showed increasing growth. Shown as representative in 
(Figure 6-3), we observed a small exophytic tumour of 0.5 mm in diameter in the 
same animal at 8 months post injection (C, arrow). At 9 months post injection, 
the tumour had grown to a larger size, filling a considerable part of the bladder 
lumen (D). These results indicated that ultrasound imaging is likely to be 
sensitive enough to detect relatively small growths (≥0.5 mm) within the 
bladder.  
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Figure 6-3: Monitoring of tumour progression using Vevo 770 Visualsonics ultrasound  
Bladders of non-injected Wild type (A) and AdenoCre-injected β-catenin
exon3/exon3
 Hras
G12V/G12V 
(B-D) 
at different stages post AdenoCre injection. Scale bar represents 1 mm (A-D). 
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6.3 Highly aggressive tumours in AdenoCre p53 Pten 
bladders 
6.3.1 Tumours in AdenoCre p53flox/flox Ptenflox/flox bladders 
In order to develop a model that reliably produces muscle-invasive bladder 
tumours we generated mice with p53 and Pten deficiency that are known to 
develop highly aggressive tumours by 6 months post AdenoCre injection (Puzio-
Kuter et al., 2009)  
Bladders of p53flox/flox Ptenflox/flox mice at 2 months of age (n=5), were injected 
with 2x109 pfu of Ad5CMVCre (Table 6-2). 
All injected mice developed pelvic tumours by 3.5 months post-injection 
(Chapter 6.6). One animal had to be killed due to the pelvic tumour formation at 
2.8 months post injection in order to comply with the Home Office regulations. A 
second animal was killed at 2.8 months post injection due to adverse effects 
from a bladder tumour. 
 
Table 6-2: Summary of p53 and Pten deleted mice injected with AdenoCre 
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene. Asterisks 
indicate cause of death or termination due to signs of illness 
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The other three double knockout mice were examined by ultrasound after 3.5 
months (Figure 6-4). Large tumours were detected in all p53flox/flox Ptenflox/flox 
(n=3) (B, circled in white) unlike in non-injected Wild type controls (A).  
 
 
Figure 6-4: Ultrasound of AdenoCre p53
flox/flox 
Pten
flox/flox 
bladders at 3.5 months post 
injection  
Representative bladders of non-injected Wild type (A) and AdenoCre-injected p53
flox/flox 
Pten
flox/flox 
(B). Scale bar represents 1 mm (A-B).  
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Following tumour detection via ultrasound imaging, bladders were harvested at 
3.5 months post injection. 
Upon examination of the H&E-stained sections, we observed characteristics of 
highly aggressive tumours in four out of five p53flox/flox Ptenflox/flox bladders 
(Figure 6-5). Bladders presented CIS in the urothelium (A, arrow). There was also 
a surrounding tumour mass; however this had no obvious connection to the 
urothelium (A, dotted line). Tumours displayed poorly differentiated cells with 
pleomorphism and frequent mitoses (B, arrows), invasion of cells into the 
bladder muscle (C, arrows and dotted line), as well as invasion into the 
“honeycomb”-shaped adipose tissue (D, arrows). 
 
 
Figure 6-5: Histology of AdenoCre p53
flox/flox 
Pten
flox/flox
 bladders at 3.5 months post injection  
Representative bladder sections stained by H&E. Scale bar represents 100 µm in A, C, D, and 50 
µm in B). 
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In order to further characterise the tumour type, we performed 
immunohistochemistry for the urothelial markers pan-cytokeratin (pan-CK) and 
p63 to determine the cell of origin, as well as immunohistochemistry for Fascin 
and Sox9 as indicators of invasion and stemness (Figure 6-6).  
Pan-CK was strongly expressed in the urothelium of p53flox/flox Ptenflox/flox 
bladders, but not in the underlying tumour cells, indicating a non-epithelial 
origin of the tumours (A, arrows; for orientation of tissue compare with H&E 
Figure 6-5 A). Similarly, p63 was exclusively present in the urothelium and 
absent in the tumour (B, arrows), further supporting non-epithelial origin of 
these tumours. 
Fascin was expressed along the basal cells of the urothelium as shown before in 
Chapter 5 (Figure 5-7 J). Furthermore, it was widely expressed in the underlying 
tumour (C, arrows), indicating aggressive growth and potential for invasion 
(Karasavvidou et al., 2008). Sox9 was seen in a small number of cells within the 
tumour (D, arrows). This may indicate that these cells had undergone a change 
in their genetic program as Sox9 expression is associated with 
stemness/progenitor properties, cancer progression and invasiveness (Wang et 
al., 2008).  
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Figure 6-6: Immunohistochemistry of AdenoCre-induced p53
flox/flox 
Pten
flox/flox 
bladders at 3.5 
months post injection  
Immunohistochemistry for pan-CK (A), p63 (B), Fascin (C) and Sox9 (D) on representative bladder 
sections. Scale bar represents 100 µm in A-D. 
  
Results – Technological improvement of an invasive bladder cancer model  (Chapter 6) 197 
 
 
 
In order to confirm that the AdenoCre p53flox/flox Ptenflox/flox tumours originated in 
the muscle and not in the urothelium, we performed immunohistochemistry for 
smooth muscle actin (SMA) (Kirsch et al., 2007) (Figure 6-7). 
SMA was expressed in the normal bladder muscle (A, white arrow). SMA was 
strongly expressed in the tumour, supporting that the tumours originated in the 
smooth muscle of the bladder (A, black arrow, and B). 
Based on our histology and immunohistochemistry results, our AdenoCre 
p53flox/flox Ptenflox/flox tumours are different from the ones that were previously 
described in the same bladder cancer model (Puzio-Kuter et al., 2009). We 
suggest that these highly aggressive tumours in p53flox/flox Ptenflox/flox originated in 
the muscle around the site of AdenoCre injection rather than from recombined 
urothelium.   
 
 
Figure 6-7: Smooth muscle actin staining on AdenoCre-induced p53
flox/flox 
Pten
flox/flox 
bladders at 3.5 months post injection 
Immunohistochemistry for smooth muscle actin (SMA) on two representative bladder sections (A-
B). Scale bar represents 200 µm in A and 100 µm in B. 
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6.3.2 Tumours in AdenoCre p53R172H/R172H Ptenflox/flox bladders 
We also analysed the effect of the dominant-negative p53 R172H mutation in 
combination with Pten deletion in the urothelium of p53R172H/R172H Ptenflox/flox 
mice. Mutant p53 is also commonly found in human bladder cancer (Sidransky et 
al., 1991), but the effect of a dominant-negative mutation has never been 
analysed in the mouse bladder.  
Bladders of p53R172H/R172H Ptenflox/flox mice at 2-6 months of age (n=3), were 
injected with 2x109 pfu of Ad5CMVCre (Table 6-3). 
Strikingly, AdenoCre p53R172H/R172H Ptenflox/flox developed adverse effects as early 
as 1.7 months (n=2) and 2 months (n=1) post injection. This was one month 
earlier than AdenoCre p53flox/flox Ptenflox/flox (Chapter 6.3.1). Two mice developed 
a lung tumour, and one mouse developed an additional lymphoma, while the 
third mouse presented with a big and fast growing soft tissue tumour in the 
flank.  
 
Table 6-3: Summary of p53 and Pten deleted mice injected with AdenoCre 
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene. Asterisks 
indicate cause of death or termination of the experiment due to signs of illness  
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In order to see whether the bladders had developed urothelial abnormalities or 
tumours, we examined H&E-stained sections (Figure 6-8). 
Bladders presented with a hyperplastic urothelium (A). This was, however, 
without increased proliferation as indicated by Ki67 immunohistochemistry (B). 
The surrounding muscle showed a similar histological phenotype as p53flox/flox 
Ptenflox/flox, including poorly differentiated cells with pleomorphism and frequent 
mitoses (C, arrows). In contrast to the hyperplastic urothelium, these tumours 
underneath were highly proliferative as indicated by Ki67 immunohistochemistry 
(D).  
p53 was highly upregulated in these muscle tumours (E) compared to a 
representative area of the muscle that was not affected by the tumour (E, 
insert), indicating that the R172H mutant form of p53 was expressed upon 
AdenoCre recombination.  
Tumours were positive for smooth muscle actin (SMA) (F), indicating that the 
origin of these tumours was likely to be the bladder muscle. 
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Figure 6-8: Histology of AdenoCre-induced p53
R172H/R172H 
Pten
flox/flox 
bladders at 1.7 months 
post injection  
Representative bladder sections stained by H&E (A, C), Ki67 (B, D), p53 (E) and smooth muscle 
actin (SMA) (F). Non-tumourous area of the muscle stained by p53 (E, insert). Scale bar represents 
100 µm in A-F. 
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We also examined the lung lesions that had developed in 2 out of 3 AdenoCre 
p53R172H/R172H Ptenflox/flox mice (Figure 6-9). 
The lung harboured one large mass of tumour cells as well as multiple small 
lesions as visualised by H&E (A, arrows), accompanied by a large number of small 
dark-nucleated immune cells. Ki67 staining indicated high proliferative activity 
in these areas (B). 
p53 expression was absent, suggesting that both copies of mutant p53 may have 
been lost as a characteristic of advanced grade and stage of the primary tumour 
(C). 
Tumours were negative for smooth muscle actin (SMA) (D), indicating that these 
lesions were most likely lung primary, and not metastatic from the bladder 
muscle. 
 
Figure 6-9: Histology of an AdenoCre-induced p53
R172H/R172H 
Pten
flox/flox 
lung at 1.7 months 
post injection 
Representative lung sections stained by H&E (A), Ki67 (B), p53 (C) and smooth muscle actin 
(SMA) (D). Scale bar represents 100 µm in A-D.  
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We also examined the grossly normal looking livers of AdenoCre p53R172H/R172H 
Ptenflox/flox mice that had been sacrificed due to lung tumour formation (Figure 
6-10). 
As visualised by H&E, the livers harboured multiple areas of small dark cells 
surrounding the blood vessels (A, arrows). Ki67 staining indicated high 
proliferative potential of these areas (B).  
Together with the presence of primary tumours in various organs (Figure 6-9), 
these results indicate that the adenovirus may have accessed the blood stream, 
distributed throughout the body, and recombined tissue at distant sites leading 
to tumour formation outside of the bladder. 
 
 
 
Figure 6-10: Histology of an AdenoCre-induced p53
R172H/R172H 
Pten
flox/flox 
liver at 1.7 months 
post injection  
Representative liver sections stained by H&E (A) and Ki67 (B). Scale bar represents 100 µm in A-
B. 
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6.4 Exophytic tumours in AdenoCre β-cateninexon3/exon3 
HrasG12V/G12V bladders 
In a previous study we have generated mice with β-catenin and Hras activation, 
UroIICre β-cateninexon3/exon3 HrasQ61L, which reliably produced tumours by 8 
months of age (Ahmad et al., 2011b). Mice had to be sacrificed at 8 months due 
to clinical signs of illness such as haematuria or abdominal swelling. No 
metastases were found in these mice, and the tumours showed histological 
characteristics of low-grade, non-invasive urothelial carcinoma.  
We aimed to refine this model of Wnt activation in order to allow more time for 
β-catenin and Hras activated tumours to grow and adopt invasive behaviour. 
Since AdenoCre infection allows recombination in a smaller number of cells 
(Puzio-Kuter et al., 2009, Seager et al., 2010), we wished to assess whether 
these fewer lesions may allow models to survive longer and therefore the 
tumours would have the potential to progress and eventually metastasise.  
We generated a cohort without UroIICre, where AdenoCre was used to induce β-
cateninexon3/exon3 HrasG12V/G12V. We injected n=9 bladders with 2x109 pfu of 
Ad5CMVCre-eGFP of mice that were 2 months of age (Table 6-4). 
Two out of eight β-cateninexon3/exon3 HrasG12V/G12 mice had to be killed due to 
pelvic tumour formation after 2 and 3.5 months respectively (Figure 6-16). Two 
mice developed a large liver tumour after 6.5 and 9 months respectively. One 
mouse developed a pancreatic tumour after 9.3 months (Figure 6-12). 
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Table 6-4: Summary of β-catenin and Hras mutant mice injected with AdenoCre 
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene. Asterisks 
indicate cause of death or termination of the experiment due to signs of illness. u= detected by 
ultrasound 
 
 
 
The bladders of three sacrificed β-cateninexon3/exon3 HrasG12V/G12V animals were 
analysed by H&E (n=3) (Figure 6-11). Bladders had developed regional 
hyperplastic lesions (A, arrows) as well as low-grade exophytic tumours (C, 
arrows).  
To visualise cells that had been transformed, we performed β-catenin 
immunohistochemistry as it was done previously in UroIICre β-cateninexon3/exon3 
mice (Ahmad et al., 2011a).  
A marked upregulation of nuclear β-catenin was observed in β-cateninexon3/exon3 
HrasG12V/G12 bladders (n=3) (Figure 6-11). The staining revealed multiple areas 
with nuclear β-catenin expression within the hyperplastic lesion (B, arrows), as 
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well as positivity throughout the entire tumour (D, arrows), indicating that the 
tumour originated from recombined cells. Furthermore, stromal β-catenin 
activation was observed (B, circled), indicating that recombination had not only 
occurred in the urothelium but also in surrounding tissue layers such as the 
connective tissue. 
 
Figure 6-11: AdenoCre β-catenin
exon3/exon3 
Hras
G12V/G12V 
bladders at 2 months (A-B) and 3.5 
months (C-D) post injection  
Representative bladder sections stained by H&E (A, C) and immunohistochemistry for β-catenin (B, 
D). Scale bar represents 200 µm (A-D). 
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The two tumours that developed in the liver and pancreas in two animals, 
respectively, were also assessed by H&E and β-catenin immunohistochemistry 
(Figure 6-12). Both organs harboured large mass of tumour cells as visualised by 
H&E (A, B). β-catenin immunohistochemistry revealed nuclear β-catenin 
translocation in both tumours (C, D), indicating that the neoplasms in these 
distant organs were caused by AdenoCre recombination. 
 
Figure 6-12: AdenoCre β-catenin
exon3/exon3 
Hras
G12V/G12V 
tumours in liver and pancreas  
Representative sections of hepatic tumour (A, C) and pancreatic tumour (B, D) stained by H&E (A, 
B) and immunohistochemistry for β-catenin (C, D). Scale bar represents 100 µm (A-D). 
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The alive remaining n=5 and otherwise healthy animals were examined by 
ultrasound at 8 months post infection (Figure 6-13). Four out of five β-
cateninexon3/exon3 HrasG12V/G12V animals harboured small bladder tumours of 4-5 
mm in size (B, arrow), whereas no bladder thickening was observed in Wild type 
controls (A). 
 
Figure 6-13: Ultrasound of AdenoCre β-catenin
exon3/exon3 
Hras
G12V/G12V 
bladders at 8 months 
post injection  
Representative bladders of non-injected Wild type (A) and AdenoCre-injected β-catenin
exon3/exon3
 
Hras
G12V/G12V 
(B). Scale bar represents 1 mm (A-B). 
 
 
 
Bladder tumours had formed only in 7 of 9 animals (78%). Following tumour 
detection via ultrasound imaging, β-cateninexon3/exon3 HrasG12V/G12V bladders were 
harvested between 8-9 months post injection. The H&E-stained bladders 
presented regional hypertrophic lesions as well as small low-grade exophytic 
tumours that were not obviously different in size, stage or histological grade to 
the exophytic tumours observed at 3 months post injection (Figure 6-11). 
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6.5 Hypertrophy in AdenoCre Hras+/G12V Ptenflox/flox 
bladders 
We also analysed the effect of the Hras mutation in combination with Pten 
deletion in the urothelium of Hras+/G12V Ptenflox/flox mice. HRAS mutation and loss 
of PTEN are both frequently found in human bladder tumours (Hras in 15-40% 
and Pten in 30%) (Jebar et al., 2005, Aveyard et al., 1999). However, co-
occurrence of these mutations have been shown to be rare (Jebar et al., 2005) 
suggesting some redundancy between these pathways. In a mouse model of 
prostate cancer, it has been shown that Pten deletion and KRAS activation 
cooperate to promote EMT and metastatic progression (Mulholland et al., 2012). 
Also, it was shown that loss of Pten cooperates with HRAS activation to promote 
the development of melanoma and its metastasis (Kim, 2010). Furthermore, the 
combination of Pten and Kras mutation dramatically accelerated the 
development of endometrial cancer (Kim et al., 2010).  However, in the bladder 
the combined effect of Hras and Pten mutation has never been analysed.  
We generated Hras+/G12V Ptenflox/flox mice (n=9) and injected them with 2x109 pfu 
of Ad5CMVCre-eGFP at 2-3 month of age (Table 6-5). We also generated 
Ptenflox/flox mice (n=8) to see the effect of Pten deletion by itself in the 
urothelium upon AdenoCre transduction.  
None of the animals showed any adverse effect or clinical signs of bladder 
tumours at 6.5 months post infection.  
Table 6-5: Summary of Hras and Pten mutant mice injected with AdenoCre 
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene   
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In order to assess tumour development, two animals from the AdenoCre 
Hras+/G12V Ptenflox/flox cohort were examined by ultrasound imaging (Figure 6-14). 
Bladders of Hras+/G12V Ptenflox/flox presented with a normal bladder wall and no 
indication of tumours or irregularities in thickness (B) compared to non-injected 
Wild type controls (A). Since the double mutants did not show any urothelial 
abnormalities, mice with single mutation (AdenoCre Ptenflox/flox) were not 
examined by ultrasound. 
 
Figure 6-14: Ultrasound of AdenoCre Hras
+/G12V
 Pten
flox/flox 
bladders at 6.5 months post 
injection  
Bladders of non-injected Wild type (A) and AdenoCre-injected Hras
+/G12V 
Pten
flox/flox 
(B). Scale bar 
represents 1 mm (A-B).  
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Both the Ptenflox/flox and the Hras+/G12V Ptenflox/flox cohort were sacrificed at 8 
months post injection, a time point where UroIICre-driven Hras mutant bladders 
had presented hyperplasia and/or low-grade non-invasive urothelial carcinoma 
(Zhang et al., 2001, Ahmad et al., 2011b). 
Histological features were analysed by H&E (Figure 6-15). We did not detect any 
indication of bladder tumour formation or any major cellular abnormalities in 
Ptenflox/flox (A) or Hras+/G12V Ptenflox/flox bladders (B) apart from occasional mild 
hypertrophy (C, D), which may be an effect of Pten deletion as described in 
Chapter 3, Figure 3-3 c, g, and by others (Tsuruta, 2006).  
 
 
Figure 6-15: Histology of AdenoCre Pten
flox/flox 
and Hras
+/G12V
 Pten
flox/flox 
bladders at 8 months 
post injection  
Representative bladder sections stained by H&E. Scale bar represents 100 µm (A-D).  
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6.6 AdenoCre off-target effects: soft tissue tumours and 
other non-urothelial tumours  
A number of animals developed tumours in the soft tissue of the pelvic region as 
well as in organs other than the bladder upon AdenoCre incubation (Table 6-6 
and Figure 6-16). 
Two out of nine β-cateninexon3/exon3 HrasG12V/G12V mice (22%) (B, C), five out of five 
p53flox/flox Ptenflox/flox (100%) (A) and one out of three p53R172H/R172H Ptenflox/flox 
mice (33%) (not shown) produced tumours in the pelvic soft tissue close to the 
AdenoCre injection site. Pelvic soft tissue tumours were not adherent to any 
internal organs, and presented fast growth behaviour.  
One out of nine β-cateninexon3/exon3 HrasG12V/G12V mice (11%) developed a 
pancreatic tumour, and two out of nine (22%) developed a hepatic tumour 
(Figure 6-12). 
Two out of three p53R172H/R172H Ptenflox/flox mice (67%) developed a lung tumour 
(Figure 6-9) and one out of three (33%) developed a lymphoma (not shown). 
 
Table 6-6: Summary of non-urothelial tumours upon AdenoCre injection 
Mouse bladders were injected with 2x10
9 
pfu Ad5CMVCre-eGFP with 10% Polybrene   
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Figure 6-16: Pelvic tumour formation at 2.8 -3.5 post AdenoCre injection 
Male p53
flox/flox
 Pten
flox/flox
 mouse with a bladder tumour (A, red arrow) and a soft tissue tumour (A, 
white arrow). Female β-catenin
exon3/exon3
 Hras
G12V/G12V
 with soft tissue tumour (B, C, white arrows; 
bladder removed). 
 
In order to characterise the cellular morphology as well as the origin of the 
pelvic tumours from β-cateninexon3/exon3 HrasG12V/G12V mice, we performed H&E 
and immunohistochemistry. 
H&E-stained sections presented features of invasive, keratin-rich squamous cell 
carcinomas (Figure 6-17). The pelvic tumours showed glandular areas (A, circled) 
mixed with regions of squamous metaplasia and poorly differentiated of cells 
(A). Keratinisation was observed in some regions of the tumours (A, arrow).  
We observed pan-CK positivity along the borders of the glandular structures (B, 
dotted line), indicating that these tumour cells could potentially be of basal cell 
origin. 
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β-catenin was highly upregulated in the nuclei of the tumour cells but not in the 
adjacent stroma (C, arrows), indicating that AdenoCre-dependent recombination 
had occurred.  
Tumours were highly proliferative along the borders but not inside of the 
glandular structures as indicated by expression of Ki67 (D, arrows). 
In comparison to the pelvic tumours from p53flox/flox Ptenflox/flox mice, these β-
cateninexon3/exon3 HrasG12V/G12V tumours have different characteristics, such as the 
keratinisation and glandular structure which were not observed in p53flox/flox 
Ptenflox/flox. This may indicate that the different histological phenotype is due to 
different nature of mutation and altered signalling in the tissue.  
 
 
Figure 6-17: Histology of pelvic tumours at 2.8 -3.5 post AdenoCre injection 
Representative photos of pelvic tumour sections of AdenoCre β-catenin
exon3/exon3
 Hras
G12V/G12V
 
stained by H&E (A), pan-CK (B), β-catenin (C) and Ki67 (D). Scale bar represents 100 µm in A-B 
and 50 µm in C-D).  
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6.7 The use of LentiCre as an alternative to AdenoCre 
In order to explore an alternative for AdenoCre-mediated recombination, we 
tested Cre delivery via lentivirus (LentiCre) (Kumar et al., 2008). Lentiviruses 
are routinely used as vectors to transduce cells and tissues (Heldt and Ressler, 
2009). In contrast to adenoviruses, lentiviruses integrate into the host genome 
resulting in stable transgenic Cre expression (Naldini et al., 1996). Lentiviruses 
also detain host immune response after infection, a defence mechanism which 
aims to eliminate transiently infected cells from the microenvironment (Brody 
and Crystal, 1994).  
In order to test the effectiveness of lentivirus in mediating recombination via 
Cre recombinase, we injected n=3 β-cateninexon3/exon3 HrasG12V/G12V mice with 
4x106 pfu LentiCre to analyse the recombination efficiency. At the time of 
writing at six months post injection, the LentiCre-injected mice are healthy and 
show no clinical signs of illness. 
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6.8 Establishment of techniques to assess growth and 
invasion in vitro 
6.8.1 Development of an organotypic collagen-I invasion assay 
It is yet unclear whether invasion can be detected using ultrasound. In order to 
develop a platform from which tumour invasion can be addressed at the cellular 
level, we adapted an organotypic collagen-I assay to murine primary bladder 
cancer cells in collaboration with Dr Paul Timpson (Garvan Institute, Sydney, 
Australia). This fibroblast-containing collagen-I assay had previously been used 
to assess invasion of pancreatic ductal adenocarcinoma and melanoma cells 
(Timpson et al., 2011). In the assay, cells with invasive behaviour migrate out 
into the matrix along a nutrient gradient, which is created by placing the 
matrices on a grid that is in contact with DMEM media only from the bottom. 
We sought for a suitable cell type to model tumour invasion in collagen-I. β-
cateninexon3/exon3 HrasG12V/G12V is not a model of muscle-invasive bladder cancer 
per se. In our previous study, β-catenin and Hras activation (UroIICre β-
cateninexon3/exon3 HrasQ61L), resulted in non-invasive papillary carcinomas with no 
signs of invasion (Ahmad et al., 2011b). Also, unpublished data from our group of 
mice with β-catenin and Hras activation using UroIICre (UroIICre β-
cateninexon3/exon3 HrasG12V/G12V), did not obviously exhibit an invasive cancer 
phenotype.  
Instead, the highly invasive human bladder cancer cell line EJ138 was chosen to 
test the system (Figure 6-18). EJ138 is in fact T24 (or sometimes referred to as 
MGH-U1), which has been shown by isoenzyme analysis and HLA profiles (O'Toole 
et al., 1983).  
Invasion of EJ138 (4x104 seeded cells) into the collagen-I matrix containing 
human telomerase-immortalised fibroblasts (TIFFs) was clearly detectable after 
14 days by H&E staining (A). Ki67 staining showed strong proliferation of invading 
cells (B). The direction of cell migration is indicated by the black arrows (A-C). 
To visualise migrating cells in the matrix, Fascin expression levels were 
analysed. Fascin has been reported to be expressed in various stages of bladder 
tumours and is associated with cell dedifferentiation (Karasavvidou et al., 2008). 
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Invading cells close to the matrix surface expressed Fascin (C, black arrow); 
however, the expression was reduced in cells that migrated deeper into the 
collagen-I matrix (C, red arrow).  
 
Figure 6-18: EJ138 human cell line migrating into organotypic collagen-I matrix  
Representative section of EJ138 cells after 14 days of migration into collagen-I matrix stained by 
H&E (A) Ki67 (B) and Fascin (C). Scale bar represents 100 µm (A-C). 
 
This organotypic assay was subsequently used to assess migration of cancer cells 
derived from murine OH-BBN driven bladder tumours, where invasion had been 
demonstrated by H&E and immunohistochemistry (Chapter 5).  
Migration of OH-BBN-driven Wild type, Tg(UroII-hFGFR3IIIbS249C) and UroIICre 
Ptenflox/flox tumours was examined  in matrices containing normal human 
fibroblasts (NHF) or human telomerase-immortalised fibroblasts (TIFFs). Because 
the culture was contaminated it was not possible to assess invasion in these 
assays. 
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6.8.2 Development of an ex vivo assay to test the effects of 
therapeutic drugs 
6.8.2.1 Sphere culture 
In order to examine the potential of urothelial cells to form 3D spheres in 
Matrigel, we used three bladder cell cultures with different growth 
characteristics. We examined the growth of normal murine Wild type urothelial 
cells, cells from a murine non-invasive tumour, and cells of a human invasive 
bladder carcinoma cell line. Murine cells from normal bladders and bladder 
tumours were scraped off the urothelium and pooled. Based on established 
sphere culture protocols of intestinal crypts and adenoma (Sansom laboratory, 
BICR), urothelial spheres were grown in Matrigel with ADF media without growth 
factors (Figure 6-19). 
The urothelium of n=9 Wild type mouse bladders was scraped off and pooled, 
processed into single cells, and resuspended in Matrigel and distributed into 10 
wells. These Wild type cells did not form spheres after 9 days in culture (A) and 
died after the first passaging.  
Pieces of bladder tumours from UroIICre β-cateninexon3/exon3 HrasG12V/G12V (n=3) 
were processed into single cells, resuspended in Matrigel and distributed into 10 
wells. Tumour cells formed spheres of a variety of different shapes, including 
perfectly round (B, white arrow), polarised (not shown), or blobbing and 
sprouting (B, yellow arrow) as early as after 3 days in culture. We were able to 
passage UroIICre β-cateninexon3/exon3 HrasG12V/G12V formed spheres up to 7 times, 
freeze and recover for another 4 passages until all cells had died. 
The highly invasive human bladder cancer cell line EJ138 (passage 34 upon 
arrival) was processed into single cells, resuspended in Matrigel and distributed 
into 10 wells. EJ138 formed sphere-like structures with outgrowths of stretched 
differentiated cells (C, arrows). Cells were viable after passaging, freezing and 
recovering without impairment of secondary sphere formation. 
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Figure 6-19: Matrigel culture of wild type urothelium, non-invasive tumour, and invasive 
tumour  
Representative bright field photos of Wild type urothelium (A), UroIICre β-catenin
exon3/exon3 
Hras
G12V/G12V 
bladder tumour (B) and EJ138 cell line (C) after 3 days in Matrigel culture. Scale bar 
represents 10 µm (A-C). 
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6.8.2.2 Optimisation of sphere culture 
Upon successful culture of UroIICre β-cateninexon3/exon3 HrasG12V/G12V tumour 
spheres, where a variety of different shapes had formed after 3 days in culture 
(Chapter 6.8.2.1), we sought to define the optimal growth conditions by testing 
different growth factors using this cell type (Figure 6-20). 
A piece of UroIICre β-cateninexon3/exon3 HrasG12V/G12V bladder tumour (n=1) was 
processed into single cells, resuspended in Matrigel. In a triplicate experiment 
the addition of 50 ng/ml recombinant human EGF (hEGF) in ADF media resulted 
in a mild increase in the number of tumour spheres of UroIICre β-
cateninexon3/exon3 HrasG12V/G12V (B) compared to wells where no growth factors had 
been added (None) (A). 
 
 
Figure 6-20: Effect of EGF on UroIICre β-catenin
exon3/exon3 
Hras
G12V/G12V 
tumour sphere culture  
Representative bright field photos of UroIICre β-catenin
exon3/exon3 
Hras
G12V/G12V 
sphere culture with 
no addition of growth factors (A) and supplemented with hEGF (B) after 3 days in Matrigel. Scale 
bar represents 10 µm (A-B). 
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Next, we tested the effect of a number of other growth factors on sphere 
formation, including mouse Sonic hedgehog (mShh), human tumour growth 
factor alpha (hTGF-α), human fibroblast growth factor 16 (hFGF16), human 
keratinocyte growth factor (hKGF, also known as FGF7), as well as a TNF-α 
inducing salt compound, lithium chloride (LiCl) (Figure 6-21). We examined the 
growth of a hyperproliferative urothelium where no tumours are expected of 
mice with a heterozygous Hras mutation; UroIICre Hras+/G12V (compare H&E of 
UroIICre Hras+/G12V in Chapter 4, Figure 4-7 A). 
Pooled urothelium of n=9 UroIICre Hras+/G12V bladders was processed into single 
cells, resuspended in Matrigel and distributed into 12 wells. Growth factor 
addition was carried out in duplicate wells.  
The addition of 10mM LiCl to ADF media resulted in a mild decrease in the 
number of spheres (Figure 6-21 B) compared to wells where no growth factors 
had been added (None) (A).  
The addition of 25ng/ml of recombinant hTGF-α, or 20ng/ml of hFGF16 had no 
obvious effect on the number or size of UroIICre Hras+/G12V spheres (D and E 
respectively). 
The addition of 50ng/ml recombinant mShh, or 20 ng/ml hKGF, also known as 
FGF7, resulted in an increase in the number and size of spheres (C and F 
respectively). 
In summary, this result shows that the addition of 50ng/ml mShh and 20ng/ml 
KGF/FGF7 to the media may enhance sphere number and size, and is therefore 
likely to improve growth conditions for spheres from non-tumourous urothelial 
tissue. 
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Figure 6-21: Effect of different growth factors on UroIICre Hras
+/G12V
 sphere culture  
Representative bright field photos of UroIICr 
 
Hras
+/G12V
 sphere culture with no addition of growth 
factors (A) and supplemented with 10mM LiCl (B), 50ng/ml mShh (C), 25ng/ml hTGF-α (D), 
20ng/ml hFGF16 (E), 20ng/ml hKGF/FGF7 (F) after 11 days in Matrigel. Scale bar represents 10 
µm (A-F). 
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6.8.2.3 Sphere culture of OH-BBN-induced bladder tumours 
Next, we sought to examine the growth of cells derived from invasive mouse 
bladder tumours in Matrigel. Invasive tumours had been established in Wild type 
and Tg(UroII-hFGFR3IIIbS249C) mutant mice by OH-BBN treatment for 10+10 
weeks (Chapter 5; compare H&E in Figure 5-6) 
Cells from macroscopically thickened bladders of Wild type and Tg(UroII-
hFGFR3IIIbS249C) were processed into single cells, resuspended in Matrigel and 
distributed into 8 wells per genotype. Matrigel with ADF media was 
supplemented with 50ng/ml mShh and 20ng/ml KGF/FGF7 (Figure 6-22). 
Cultures form OH-BBN-treated Wild type bladders (n=3) showed little sphere 
formation after 3 days (A) and died by 14 days (C). After 3 days, spheres were as 
few as 1 sphere in 8 wells, which were generated from one half of a bladder. 
OH-BBN Tg(UroII-hFGFR3IIIbS249C) cultures (n=8) showed a larger number of 
spheres after 3 days (B) compared to OH-BBN Wild type (A). OH-BBN Tg(UroII-
hFGFR3IIIbS249C) spheres grew up to 3-times of the initial diameter size in 11 
days (day 14 in culture) (D). 
OH-BBN cultures of Ptenflox/flox (n=1) and Tg(UroII-hFGFR3IIIbS249C) Ptenflox/flox 
(n=1) under the same conditions failed to form spheres after 3 days and died by 
22 days in culture (data not shown).  
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Figure 6-22: Sphere culture of OH-BBN-treated Wild type and Tg(UroII-hFGFR3IIIbS249C) 
after 3 and 14 days  
Representative bright field photos of OH-BBN-treated Wild type (A, C) and Tg(UroII-
hFGFR3IIIbS249C) (B, D) sphere culture supplemented with mShh and hKGF/FGF7 after 3 days 
(A, B) and 14 days (C, D) in Matrigel. Scale bar represents 10 µm (A-D). 
 
In summary, cells derived from the OH-BBN-induced invasive mouse bladder 
tumours of Wild type, FGFR3 mutant, Pten deletion, or a combination thereof, 
formed only very few spheres in Matrigel.  
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6.8.2.4 Organotypic slice culture  
A major disadvantage of the Matrigel culture is the fact that urothelial cells are 
disconnected from their natural environment of the surrounding stroma and the 
bladder muscle. We therefore sought to develop a technique where the 
urothelium or the tumour cells can be cultured with a minimum of distortion of 
the natural signalling from surrounding tissue.  
We aimed to establish an organotypic bladder slice culture to grow bladder 
tumour explants ex vivo in order to examine the effect of inhibitor treatment in 
real time. These experiments were performed in collaboration with Prof Cathy 
Mendelsohn’s lab at Columbia University, New York, USA.  
In a pilot experiment we cultured bladder slices of normal bladders on 
membrane culture inserts soaked in basal conditional media supplemented with 
recombinant rat glial cell line-derived neurotrophic factor (rGDNF), human 
hepatocyte growth factor (hHGF), and human keratinocyte growth factor (hKGF, 
also known as FGF7) as previously described (Batourina et al., 2012). 
Bladders of established reporter lines were used, including UroIIIa-GFP-Cre-ERT2 
mCherry (UroIIIa-GCE; mCherry), K5-CreERT mTomato/mGFP (K5-CreERT 
mT/mG), and Shh-Cre YFP. UroIIIa-GCE; mCherry expresses an eGFP-Cre-ERT2 
fusion protein under the Uroplakin IIIa (UroIIIa) promoter. mCherry is expressed 
upon tamoxifen induction in this model (Gandhi et al., 2013). K5-CreERT 
mTomato/mGFP expresses a Cre-ERT2 fusion protein under the Cytokeratin-5 
(K5) promoter. mTomato is expressed before tamoxifen induction, mGFP is 
expressed afterwards(Gandhi et al., 2013). Shh-Cre YFP expresses Cre and YFP 
under the Sonic hedgehog (Shh) promoter (Gandhi et al., 2013). 
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Bladder explants were analysed under a fluorescent microscope, and 
immunohistochemistry was subsequently performed on paraffin-embedded 
sections of the explants (Figure 6-23). 
Tamoxifen-induced UroIIIa-GCE; mCherry bladders (A, B) showed overall healthy 
appearance until termination of the experiment at day 14 in culture. 
UroplakinIIIa-expressing cells were detected by mCherry-positivity (B, arrows). 
In order to see whether the cultured organotypic slices maintain the bladder 
morphology, immunohistochemistry was performed on paraffin-embedded 
sections of Wild type bladder explants after 8 days in culture (C). We observed 
p63-positivity in basal and intermediate cells (C, red), as well as UroII-positivity 
in umbrella cells of the explant (C, green). This was similar to Wild type 
bladders that are processed directly from the animal (Chapter 3, compare Figure 
3-7). 
Tamoxifen-induced K5-CreERT mT/mG bladders (D, E, F) showed overall healthy 
appearance until termination of the experiment at day 12 in culture. Keratin5-
expressing cells were detected by GFP-positivity (E, arrows, magnified in F, 
arrows). 
Bladder explants of Shh-Cre YFP mice were viable for 21 days in culture until 
termination of the experiment (data now shown). 
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Figure 6-23: Organotypic slice culture of fluorescent reporter bladders 
Representative photos of slice culture of a tamoxifen-induced UroIIIa-GFP-Cre-ERT2 mCherry 
under bright field (A) and red channel (B). Immunohistochemistry for UroplakinII (green) and p63 
(red) on section of paraffin-embedded organotypic bladder slice from Wild type (C). Representative 
photos of slice culture of a tamoxifen-induced K5-CreERT mTomato/mGFP under bright field (D) 
and green channel (E). GFP expression of same animal at higher magnification (white insert in E) 
(F). Scale bar represents 200 µm in A-B and D-E, 100 µm in F, and 50 µm in C. 
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6.8.2.5 Organotypic slice culture of OH-BBN-induced bladder tumours 
In order to test whether the effect of therapeutic drugs can be assessed by the 
organotypic slice assay, we set out to culture explants of OH-BBN-induced 
tumours that we treated with the FGFR3 inhibitor R3Mab. 
R3Mab is a monoclonal antibody against wild type and mutant forms of FGFR3, 
which has been shown to exhibit anti-tumour activity against bladder carcinoma 
and multiple myeloma xenografts in mice (Qing et al., 2009). The control 
antibody is a non-functional version of the R3Mab molecule that is dissolved in 
the same buffer. 
We used OH-BBN-induced Tg(UroII-hFGFR3IIIbS249C) bladder tumours (n=2) and 
OH-BBN-induced Wild type control bladders (n=6) to be subjected to 10nM 
R3Mab or 10nM of a control antibody mixed into basal conditional media for 4 
days starting from the first day of culture. Explants were paraffin-embedded and 
stained by H&E to analyse a potential inhibitory effect of R3Mab on invasion. 
We encountered difficulties in the interpretation of the H&E results on the 
effect of R3Mab, since both OH-BBN-induced Wild type and Tg(UroII-
hFGFR3IIIbS249C) tumour slices showed signs of urothelial cell disintegration and 
tumour cell disintegration in the H&E stained sections (Figure 6-24). 
Regarding the orientation of the tissues, a minimal layer of coherent cells (A, 
arrow) was visible and defined as the urothelium. Dotted lines represent the 
invasive edge down to which urothelial cells have migrated. In panel (B), the 
urothelium is most likely located above the fine dotted line with invading 
tumour cells between the two dotted lines, and striated muscle below the thick 
dotted line. A clear cut of striated muscle can be identified in (C, arrow). The 
formation of blood vessels was visible in (D, arrow). 
In OH-BBN-induced Wild type and Tg(UroII-hFGFR3IIIbS249C) bladder slices, 
tumour cells were visible far beyond the urothelial lining in deep layers of the 
bladder (dotted lines in A, C and B, D, respectively). No obvious difference in 
the overall depth of invasion was observed comparing the two genotypes. 
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Comparing OH-BBN-induced Wild type tumour slices that had been treated with 
Control- or R3Mab antibody, no obvious difference in the overall depth of 
invasion was observed (A, C). 
Similarly, in OH-BBN-induced Tg(UroII-hFGFR3IIIbS249C) tumour slices that had 
been treated with Control- or R3Mab antibody, no obvious difference in the 
overall depth of invasion was observed (B, D). 
R3Mab treatment for 14 days resulted in further disintegration of the urothelium 
within the tumour slice and greater difficulties in interpreting H&E results in 
terms of an inhibitory effect on invasion (data not shown). 
 
 
Figure 6-24: Organotypic slice culture of Wild type and Tg(UroII-hFGFR3IIIbS249C) tumours 
treated with FGFR3 inhibitor (R3Mab)  
Representative H&E sections of paraffin-embedded organotypic bladder slices from OH-BBN-
induced Wild type (A, C) and Tg(UroII-hFGFR3IIIbS249C) (B, D) tumours that were treated with 
control antibody (A, B) or R3Mab antibody (C, D). Scale bar represents 200 µm (A-D). 
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6.9 Discussion 
In this chapter we examined the effectiveness of AdenoCre to generate 
urothelial tumours with different combinations of genetic mutations. We 
replaced UroIICre-driven recombination by AdenoCre delivery. Furthermore, we 
tested fluorescent imaging and ultrasound imaging in the mouse bladder in order 
to detect and monitor tumour development and progression in living animals. 
Moreover, we tested in vitro systems such as an organotypic collagen-I assay, 3D 
sphere culture, and an organotypic slice culture to assess cell migration and the 
effect of therapeutic drugs ex vivo.  
6.9.1 Recombination  
In order to assess the recombination efficiency at a cellular level, we performed 
lacZ staining as well as immunohistochemistry for GFP, RFP and β-catenin 
(Figure 6-2). We showed that GFP immunohistochemistry can be used to detect 
infected cells; however the staining is not sufficient to specify recombination. 
RFP and lacZ detection was discontinued due to unspecific staining. In this 
study, AdenoCre recombination was most effectively detected by β-catenin 
staining in the presence of a β-cateninexon3/exon3 activating mutation. The exact 
percentage of successfully recombined cells could not be determined in our 
experiments. It has been shown that viral transduction efficiency can be 
influenced by the pH, as well as by addition of calcium phosphate (Jackson, 
2001), which poses a chance to optimise recombination rates for future 
experiments.  
Some studies have shown that urothelial stem cells, or at least a subgroup 
thereof, may reside in the basal cell compartment (Kurzrock et al., 2008, Gaisa 
et al., 2011, Shin et al., 2011, Chan et al., 2009b, Gandhi et al., 2013). From 
this study it appears that the incidence of stem cell recombination upon 
adenovirus infection may be very low. However, it unknown at this point 
whether more than one type of urothelial progenitors exists, and whether 
urothelial stem cells are the cancer initiating cells in the bladder. 
AdenoCre penetration has previously been assessed in human ureters (Chester et 
al., 2003). In the study, intact normal human ureters were transduced ex vivo 
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with Adv-cmv-β-gal viral solution and stained for β-galactosidase activity. 
Immersion with Adv-cmv-β-gal resulted in transduction of the most superficial 
layers of the urothelium only, with no obvious time dependence of viral 
exposure. Taken into account that those experiments were performed on human 
ureters, the results could indicate that deeper layers may not be transduced 
using adenoviral Cre infection in mice. However, in contrast to the human 
urothelium which consists of seven layers on average, the mouse urothelium is 
composed of only three layers, which could help the virus to penetrate deeper 
layers. In the first publication using AdenoCre in the mouse bladder, it was 
described that the entire urothelium can be targeted with 10% recombination 
efficiency using a titre of 1x109 pfu (Puzio-Kuter et al., 2009). Our results did 
not recapitulate these data. In our hands, AdenoCre recombination was mainly 
observed in umbrella and intermediate cells, consistent with previous 
suggestions in human ureters (Chester et al., 2003). 
Comparing the recombination efficiency of AdenoCre and UroIICre, it is evident 
that UroIICre promotes recombination in the majority of cells in the urothelium 
(Figure 3-2) whereas AdenoCre mediates recombination only in a small number 
of cells (Figure 6-2). UroIICre recombination was predominantly observed in 
umbrella and intermediate cells, whereas basal cells showed fewer cells with 
GFP-positivity (Figure 3-2). AdenoCre recombination was mainly observed in 
umbrella and intermediate cells (Figure 6-2). Therefore, the basal cell 
compartment may not have been effectively targeted yet in our models. It would 
be interesting to utilise a Cre promoter that drives the expression of the 
recombinase in the basal cell layer given that the cancer cell of origin may 
reside therein. A study on urothelial regeneration has utilised a tamoxifen-
inducible Sonic hedgehog-Cre (ShhCreER), where recombination in the basal cell 
compartment of the urothelium was reported (Shin et al., 2011). ShhCreER has 
not yet been tested in controlling the expression of bladder-specific mutations. 
Furthermore to the comparison of AdenoCre and UroIICre recombination, both 
systems promoted the growth of exophytic papillary tumours in β-catenin and 
Hras mutated bladders (Chapter 6.4 and (Ahmad et al., 2011b). However, 
AdenoCre-driven tumours seemed to be smaller in size compared to UroIICre β-
cateninexon3/exon3 HrasQ61L bladders upon dissection at 8 months. This may indicate 
that the fewer number of recombined cells by AdenoCre results in fewer 
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tumours or a smaller tumour mass combined. By defining a suitable and potent 
combination of genetic mutations, this may pose an opportunity to potentially 
study metastatic progression before the urothelial tumour reaches a lethal size.  
6.9.2 In vivo imaging 
In order to monitor tumour progression in living animals, we tested fluorescent 
imaging and ultrasound imaging in the mouse bladder (Table 6-7). 
 
Table 6-7: Summary of in vivo imaging techniques tested in the study  
 
 
Monitoring of AdenoCre –induced tumours in vivo was assessed by IVIS Spectrum 
(Figure 6-1). We were confronted with high background signal from the guts and 
urine, which made assessment difficult at both RFP and GFP wavelengths. It may 
be possible to reduce the background signal from the guts by feeding an alfalfa-
free diet, which may help to obtain a clearer RFP signal from the bladder (Inoue 
et al., 2008). Furthermore, it is possible that collective RFP emission from a 
tumour cell mass may result in a stronger signal. However, bladder tumours with 
an RFP reporter construct were not available at the time of experiments. 
Moreover, it is possible that the expression level of the RFP reporter is 
particularly low in the bladder and that changing to a different reporter system 
such as an mTomato or mCherry line could be an alternative to potentially 
enhance the signal from the bladder (Muzumdar et al., 2007), 
(http://www.gudmap.org). 
Using ultrasound imaging we were able to monitor tumour progression in vivo 
(Figure 6-3). Bladder wall thickening, as well as tumours as small as 0.5 mm in 
diameter, can be detected and the growth can be monitored. This is consistent 
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with a previous study where tumours as small as 0.53 mm3 were detected using 
this method (Patel et al., 2010). However, it is as yet unclear whether invasion 
can be addressed by this method. Ultrasound imaging could further be improved 
by targeted contrast enhancement (Chan et al., 2011). 
6.9.3 AdenoCre 
We have confirmed that orthotopic AdenoCre injection mediates recombination 
in the bladder, leading to tumours with different combinations of genetic 
mutations. The combination of β-catenin and Hras mutation caused exophytic 
papillary tumours in the urothelium as early as 3.5 months post injection in β-
cateninexon3/exon3 HrasG12V/G12V. AdenoCre-driven tumours seemed to be smaller in 
size, compared to UroIICre β-cateninexon3/exon3 HrasQ61L bladders, upon dissection 
at 8 months (Ahmad et al., 2011b). This may reflect the smaller number of cells 
that was likely to be recombined by AdenoCre compared to broad recombination 
in umbrella and intermediate cells using UroIICre. Bladder tumours had formed 
only in 7 of 9 animals (78%). Whether these tumours will develop muscle-invasive 
potential or metastatic disease has to be tested in future experiments. 
Hras activation in combination with Pten deletion did not produce tumours or 
any cellular abnormalities by 8 months in HrasG12V/G12V Ptenflox/flox, indicating that 
AdenoCre-induced Pten deletion on its own or in combination with Hras is 
insufficient to induce urothelial tumourigenesis. This is in accordance with the 
findings in Chapter 3, where a mouse model of co-activated MAPK/AKT signalling 
through FGFR3 in combination with Pten deletion (UroIICre Fgfr3+/K644E 
Ptenflox/flox) presented a hypertrophic urothelium but did not result in carcinoma 
development (Chapter 3). As speculated before, this may be due to redundant 
pathway activation (Jebar et al., 2005). Mutual exclusivity of Pten and Ras 
pathways has also been demonstrated in skin papilloma formation (Mao et al., 
2004). Alternatively, it is possible that the AdenoCre induction was incomplete. 
p53 and Pten deletion in combination, p53flox/flox Ptenflox/flox, caused tumours in 
the bladder as reported before (Puzio-Kuter et al., 2009). However, in the study 
by Puzio-Kuter it was not fully clarified whether these tumours were of 
epithelial- or muscle origin. Based on our immunohistochemistry and histological 
observations, we and other groups (Yang et al., 2013) define these tumours as of 
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non-urothelial origin. Due to AdenoCre recombination in the muscle upon needle 
insertion, these tumours seem to have originated in the striated muscle or other 
soft tissue surrounding the injection site. Our tumours were negative for 
urothelial markers such as CK5 and p63, which is in accordance with the work 
done by Yang, where pan-cytokeratin was used to demonstrate non-urothelial 
origin. Furthermore, our tumours resemble the appearance of the sarcomas in 
the p53flox/flox Kras+/LSLG12D mouse model generated by Kirsch that were also 
positive for smooth muscle actin (SMA) (Kirsch et al., 2007). In contrast to Puzio-
Kuter, we did not observe metastasis in the p53flox/flox Ptenflox/flox model. 
p53 dominant-negative mutation and Pten deletion in combination, p53R172H/R172H 
Ptenflox/flox , caused tumours in the bladder muscle that were similar to the ones 
observed in p53 and Pten deficient mice; however the tumour onset was 1 
month earlier, indicating that a homozygous dominant-negative p53 mutation 
may promote faster tumour growth than homozygous p53 deletion. 
An issue of AdenoCre infection was the frequent observation of non-urothelial 
tumours. Depending on the type of mutations that were introduced, we observed 
sarcoma formation in the bladder muscle, tumours in other areas of the pelvic 
region, as well as tumours in distant organs. For example, AdenoCre-injected 
p53R172H/R172H Ptenflox/flox mice developed lymphoma, lung tumours, and soft 
tissue tumours in the pelvis. In our hands all p53flox/flox Ptenflox/flox mice (n=5) 
developed soft tissue sarcomas in the bladder muscle, which was not reported in 
the original study where the AdenoCre-mediated p53 Pten mouse model was first 
described (Puzio-Kuter et al., 2009). However, pelvic soft tissue tumours with 
similar histology have been observed in p53flox/flox Kras+/LSLG12D bladders after 
8.46x108 pfu AdenoCre treatment using catheterisation and urethral suture (Yang 
et al., 2013). Similar to our sarcomas in p53flox/flox Ptenflox/flox, Yang also 
observed invasion of these tumours into adipose tissue and striated muscle 
layers at 4-8 weeks post AdenoCre exposure. Our β-cateninexon3/exon3 HrasG12V/G12V 
mice developed tumours in the liver and pancreas, as well as keratin-rich 
squamous cell carcinomas in the pelvic region. Based on histological observations 
and immunohistochemistry these distant growths were primary tumours (Figure 
6-9). Furthermore, transformed cells were particularly present nearby blood 
vessels (Figure 6-10), suggesting presence of the adenovirus in the blood stream, 
which has led to recombination in distant sites outside of the bladder.  
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Mouse sarcomas induced by AdenoCre were originally described in p53flox/flox 
Kras+/LSLG12D mice (Kirsch et al., 2007). Soft tissue sarcomas in our cohorts 
generally developed in the pelvic region around the area of injection. We 
speculate that the exposed muscle tissue around the entry site of the needle is 
infected by AdenoCre and undergoes recombination. The issue with sarcoma 
formation is that these growths occur before the development of urothelial 
tumours, which may be due to the different proliferation rates of the two 
tissues. To overcome soft tissue sarcoma development, the technique of virus 
delivery needs to be improved. However, both methods, orthotopic instillation 
(this study, (Puzio-Kuter et al., 2009)) and catheterisation (Yang et al., 2013), 
have led to the formation of sarcomas. It would be possible to surgically remove 
pelvic sarcomas in order to allow more time for urothelial pathogenesis to occur. 
However, non-urothelial tumours such as in the liver, lung or pancreas were not 
easy to detect at an early stage and most likely difficult to remove without 
risking the wellbeing of the animal. Another possible modification of the 
technique could be the use Matrigel to solidify the virus solution in order to 
reduce virus influx into the blood stream. It could also be considered to pre-
treat the urothelium with chemical agents in order to increase the transduction 
efficiency.  
The virus titre is a parameter that needs to be chosen carefully in order to allow 
sufficient but specific recombination in the urothelium. The bladder lining is 
equipped with an effective defence barrier, the urothelial plaques made of a 
thick polyglucan layer and crystallised Uroplakin particles, which reduce the 
absorption of toxic substances that are present in the urine. We speculated that 
this natural barrier may also hamper the viral infection process, and that a high 
virus titre would be beneficial to maximise transduction. Furthermore, in case of 
a not completely voided bladder, the dilution of urine may pose a second hurdle 
to the amount of virus needed. Therefore, it needs to be ensured that the 
bladder has been sufficiently voided of urine before virus injection. The virus 
titre can also be adjusted according to the nature of the targeted mutations. For 
example, if a model of metastasis is desired, it may be beneficial to select 
“strong” tumourigenesis-inducing mutations in combination with a low virus 
titre. This would ensure recombination in only a small number of cells and 
therefore allow more time for metastasis to occur.  
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When AdenoCre was introduced for the first time as a driver of recombination in 
p53flox/flox Ptenflox/flox mice, a titre of 1x109 pfu was used (Puzio-Kuter et al., 
2009). This resulted in a recombination efficiency of 10% of successfully 
transduced urothelial cells (Puzio-Kuter et al., 2009). In a different study with 
p53flox/flox Kras+/LSLG12D mutant mice, a titre of 8.5x108 pfu was administered by 
catheterisation (Yang et al., 2013). This method resulted in higher 
recombination efficiency, however, the procedure is more time consuming and 
only female mice could be used for catheter instillation. Furthermore, this 
method has been shown to also result in soft tissue sarcomas (Yang et al., 2013) 
and would therefore not pose an advantage to our current surgical method of 
AdenoCre delivery. In our study, we used twice the amount of virus (2x109 pfu) 
as Puzio-Kuter to induce tumourigenesis in the same p53flox/flox Ptenflox/flox mouse 
model (Figure 6-5). Our p53flox/flox Ptenflox/flox mice developed tumours by 3 
months post injection, while Puzio-Kuter reported tumours by 6 months post 
injection. However, our p53flox/flox Ptenflox/flox tumours arose in the muscle where 
recombination had taken place. It is possible that a lower AdenoCre titre may 
result in a higher rate of urothelial tumours rather than sarcomas as reported by 
Puzio-Kuter (Puzio-Kuter et al., 2009).  
As an alternative to AdenoCre-mediated recombination we tested LentiCre-
mediated Cre delivery in a still ongoing experiment. As a consequence of virus 
integration into the genome, the possibility of insertional mutagenesis cannot be 
excluded. LentiCre is currently not commercially available at the same high titre 
as AdenoCre.  
Overall, AdenoCre has the advantage of recombining a small number of cells that 
are surrounded by a normal tissue environment, which would allow examination 
of signalling interaction between tumour and host tissue. In this matter, 
AdenoCre represents an interesting tool for modelling bladder cancer. The 
technique could also allow lineage tracing of cancer stem cells in a developing 
bladder tumour. However, at this point AdenoCre also comes with the 
disadvantage of frequent non-urothelial tumour formation in adjacent soft tissue 
or distant organs which precede the emergence of urothelial tumours and 
remains to be addressed in future experiments.   
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6.9.4 In vitro models 
In order to assess transformation and cell migration as well as to test 
therapeutic drugs, we tested ex vivo techniques and assays including a CollagenI 
invasion assay, 3D sphere culture and an organotypic slice culture (Table 6-8). 
Table 6-8: Summary of in vitro techniques tested in the study 
 
 
 
Invasion at the cellular level was assessed using an organotypic collagen-I assay 
(Figure 6-18). We were able to detect migration of a human bladder cancer cell 
line into the matrix; however the system needs to be optimised for murine 
tissues. An issue with optimising the assay conditions is the current lack of a 
positive control of an invading mouse tumour. At the time of writing this assay is 
being repeated with a new set of OH-BBN-induced bladder tumours. 
A 3D tumour sphere culture assay was developed in order to test the effects of 
therapeutic drugs by assessing the sphere formation and renewal capacity in 
Matrigel (Figure 6-19 to Figure 6-22). Murine Wnt-activated tumours as well as 
invasive human cell lines were capable of growing and renewing in Matrigel 
conditions with ADF media (Figure 6-20). In contrast, tumours of other 
genotypes, including OH-BBN-induced Wild type Tg(UroII-hFGFR3IIIbS249C) and 
UroIICre Ptenflox/flox showed reduced sphere formation and renewal Figure 6-22). 
Wild type urothelial cells completely failed to form spheres (Figure 6-19 ). It is 
Results – Technological improvement of an invasive bladder cancer model  (Chapter 6) 237 
 
 
 
possible that adult Wild type urothelial cells do not have sufficient renewal 
capacity to form spheres. On the other hand, these cells may need special media 
conditions and a particular supply of growth factors, which was not further 
tested. In future experiments the diameters of spheres could be considered to 
be measured by ImageJ software. However, the number of urothelial cells from 
normal bladders was generally low, and therefore cells from multiple bladders 
had to be pooled in order to reach sufficient material to be plated. Therapeutic 
drugs were not tested in this assay due to the low rate of tumour sphere 
formation. Although the 3D sphere culture assay has successfully been used for 
drug screening in tumour spheres derived from other tissues such as the breast 
(Kim and Alexander, 2013), it may not be suitable for application in the bladder.  
Organotypic slice culture was developed in order to test the effects of 
therapeutic drugs on invasion under natural conditions of a generally intact 
organ environment (Figure 6-23). In this slice culture system, normal bladder 
explants were viable for up to 21 days. However, slices of tumours quickly 
showed signs of urothelial cell and tumour cell disintegration, which made the 
interpretation of the results on the effect of R3Mab difficult (Figure 6-24). The 
orientation of the tumour slice in paraffin and properly cut sections are of great 
importance in order to analyse the depth of tumour cell invasion or impairment 
thereof. At the time of writing, this FGFR3 inhibition assay is being repeated in a 
new set of OH-BBN-induced Fgfr3-mutant bladder tumours.  
6.9.5 Future work 
For in vivo imaging it would be interesting to assess tumour growth or drug 
response in a three dimensional (3D) space. Therefore, it would be essential to 
work out volume measurements in the ultrasound software. 
Regarding viral Cre injections, we are awaiting the results of the LentiCre 
experiment (Chapter 6.7), which will shed light on the effectiveness of LentiCre 
as an alternative to AdenoCre. Recombination efficiency and tumour 
development can be assessed in direct comparison with the AdenoCre-injected 
β-cateninexon3/exon3 HrasG12V/G12V mice. Furthermore, AdenoCre could also be a 
useful tool for lineage tracing of cancer stem cells in a developing bladder 
tumour and potentially during metastatic spread. 
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For the in vitro assays, it would be essential to optimise the collagen-I assay 
using a positive control of invasive mouse tumour cells, as well as to optimise 
the organotypic slice culture conditions to impede the disintegration of the 
tissue in the culture in order to test therapeutic drugs. 
6.9.6 Conclusion 
We have validated the effectiveness of AdenoCre to generate urothelial tumours 
in mice with β-cateninexon3/exon3 HrasG12V/G12V mutation and used ultrasound to 
monitor the growing tumours in vivo. Furthermore, we tested in vitro systems 
such as an organotypic collagen-I assay, 3D sphere culture, and an organotypic 
slice culture, which may become useful applications to assess cell migration and 
the effect of therapeutic drugs ex vivo.  
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7.1  Summary of the findings 
The overall aim of this study was to examine the role of FGFR3 mutation in 
bladder cancer initiation and progression by using mice as a model organism.  
Firstly, we demonstrated that Fgfr3 and Pten mutations cooperatively promote 
morphological changes of the urothelium, but not when mutated individually 
(Chapter 3). Our results provided functional evidence that supports the 
hypothesis that upregulation of FGFR3 signalling plays a causative role in 
urothelial pathogenesis of non-invasive bladder cancer together with 
upregulated PI3K-AKT signalling. However, mice still did not develop urothelial 
cell carcinoma. 
Therefore, we searched for cooperating mutations of urothelial tumourigenesis 
in mice with FGFR3, PTEN or RAS mutation using Sleeping Beauty (SB) insertional 
mutagenesis (Chapter 4). The SB system failed to produce bladder tumours in 
Fgfr3 as well as in Hras mutant mice and may therefore constitute an inefficient 
tool in the bladder to induce urothelial tumourigenesis. Furthermore, it is 
possible that other more realistic mutations are required to drive cancer in the 
bladder. In mice with Pten deletion, one tumour was generated and general 
hypertrophy with cellular abnormalities was observed in all samples. No direct 
association between Fgfr3 and Pten mutations was found; however, SB 
mutagenesis supported that Fgfr3 and Pten cooperation may merge at the 
signalling downstream.  
Thirdly, we compared two point mutations, S249C and K644E, in FGFR3 and 
Fgfr3 respectively in the otherwise normal urothelium in vivo, and demonstrated 
that an FGFR3 S249C mutation alone does not lead to tumourigenesis, similar to 
Fgfr3 K644E mutation alone (Chapter 5). Differential effects between K644E and 
S249C on the cellular architecture were only apparent in combination with 
another mutation such as Pten deletion. Furthermore, we compared S249C and 
K644E, as well as the effect of Pten deletion and Fgfr3-Pten double mutation in 
OH-BBN-induced tumours (Chapter 5). Our results indicated that Fgfr3 mutation 
may have an effect on tumour progression of established neoplasms.  
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Lastly, we validated the effectiveness of AdenoCre to generate urothelial 
tumours in mice with β-cateninexon3/exon3 HrasG12V/G12V mutation and used 
ultrasound imaging to detect and monitor tumour development and progression 
in vivo (Chapter 6). Moreover, we tested in vitro systems such as an organotypic 
collagen-I assay, 3D sphere culture, and an organotypic slice culture, which may 
become useful applications to assess cell migration and the effect of therapeutic 
drugs ex vivo. 
Taken together, our data supported previous evidence of functional involvement 
of FGFR3 in the development and progression of urothelial cell carcinoma. 
Furthermore, technological improvement of our in vivo and in vitro models may 
create useful tools to generate and assess invasive bladder cancer, and to 
perform preclinical drug testing.  
7.2 Contribution of FGFR3 to tumour initiation, 
progression and invasion 
Regarding tumour initiation, FGFR3 seems unlikely to be the sole driver of 
bladder tumourigenesis. This is in accordance with the current understanding of 
cancer biology where multiple ‘hits’ to DNA are required for a tumour to arise. 
Interestingly, in vitro, a single FGFR3 mutation is able to induce morphological 
transformation, cell proliferation, and anchorage independent growth (di 
Martino et al., 2009). However, in mice we showed that a single mutation in the 
kinase domain of the receptor, K644E, was insufficient to promote cancer 
formation (Ahmad et al., 2011c). Similarly, a mutation in the linker region of the 
Ig-like domains in FGFR3, S249C, on its own did not lead to tumour initiation in 
the mouse bladder (Chapter 5). These results strongly suggest that FGFR3 needs 
a cooperating mutation to induce urothelial tumourigenesis.  
It has been suggested that FGFR3 mutation is an early event during bladder 
cancer development (Knowles, 2007, Zieger et al., 2005, Bakkar et al., 2003) 
due to the fact that FGFR3 is found mutated in 60-80% of non-invasive bladder 
cancers including papilloma, PUNLMP, and low- and high-grade papillary 
carcinoma (Billerey et al., 2001, Cappellen et al., 1999, Tomlinson et al., 2007a, 
van Rhijn et al., 2012, van Rhijn et al., 2002). The urothelia of our mouse 
models with Fgfr3 mutation and activated PI3K/AKT signalling showed 
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histological features comparable with hyperplasia and dysplasia, which are 
regarded as early stages bladder cancer pathogenesis in humans (Chapter 3). The 
model supports that these early-stage lesions with FGFR3 mutation are unlikely 
to progress, as they did not produce tumours in the life time of the animal 
models up to 18 months (Chapter 3).  
In terms of tumour progression of established neoplasms, we showed in vivo that 
FGFR3 S249C mutation can have an effect on cancer progression and invasion 
upon carcinogen-induced tumourigenesis (Chapter 5). Similar observations were 
made with a kinase domain mutation, Fgfr3 K644E, supporting the tumour-
promoting properties of activated FGFR3 signalling (Chapter 5). Previous studies 
have linked FGFR3 mutation to the development of early papillary lesions; 
however, the progression of advanced bladder cancer seemed to be unaffected 
by the presence of FGFR3 mutations (Zieger et al., 2005). It would therefore be 
interesting to sequence our OH-BBN-induced tumours with FGFR3- or Fgfr3-
mutant status in order to obtain information on potential cancer initiating 
mutations or cooperating mutations. 
Mechanistically, the role of FGFR3 in bladder cancer is still being debated. It was 
proposed that FGFR3 can promote cellular proliferation and provide a growth 
advantage while apoptotic mechanisms and genomic stability are still 
maintained (Bakkar et al., 2003). This was supported in cell culture studies, 
where increased FGFR signalling provided a proliferation and survival advantage 
to urothelial cells (di Martino et al., 2009). FGFR3 may also bypass the cell cycle 
checkpoint at G1, which could promote the development of benign precursor 
lesions that may be able to progress due to accumulated replicative stress 
(Bartkova et al., 2005, Zieger et al., 2005). Our results potentially support the 
concept of FGFR3 in promoting cellular proliferation and/or providing a growth 
advantage to urothelial cells, since FGFR3-mutant bladders were linked to a 
significantly higher incidence of tumours compared to Wild type upon carcinogen 
treatment (Chapter 5). To further elucidate the mechanism behind FGFR3-
dependent progression in OH-BBN-induced tumours, it would be essential to 
analyse alterations in the pathways downstream of FGFR3 S249C mutant 
signalling. It would also be interesting to investigate further to our experiments 
on γH2aX phosphorylation in FGFR3-S249C and Wild type bladders (Chapter 5), 
whether the presence of an FGFR3 mutation can alter the sensitivity to DNA 
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damage or the DNA repair machinery in FGFR3-mutant cells in a larger number 
of samples.  
7.3 Tumour progression across pathogenesis pathways 
The current model of two independent pathogenesis pathways of urothelial cell 
carcinoma has been suggested based on histological and genomic analysis of non-
invasive and invasive tumours (Knowles, 2008, Lindgren et al., 2012). A question 
of immense clinical relevance remains: that is whether these pathways can 
overlap, or whether tumours can stage progress across these pathways to adopt 
a more aggressive phenotype and growth behaviour. 
Indication of potential overlap of the tumourigenesis pathways comes from a 
study in mice where SV40T was overexpressed under the UroII promoter (Cheng 
et al., 2003). Cheng reported that the majority of mice developed CIS that 
evolved into high-grade, superficial papillary tumours before a small fraction of 
them advanced to invasive and metastatic cancer. This suggests that a fraction 
of CIS may constitute precursors of high-grade, papillary tumours with increased 
risk of progressing to invasive and metastatic disease. This could also fit with the 
study by Choi, where muscle-invasive bladder cancer was suggested to be 
subcategorised into basal-, luminal-, and p53-like tumours based on their 
immunohistochemical expression pattern (Choi et al., 2014). In this model, 
luminal-like tumours were enriched with FGFR3 mutations amongst others, and 
could therefore potentially represent a subset of muscle-invasive tumours that 
have derived from non-invasive papillary tumours where FGFR3 mutations are 
frequent (van Rhijn et al., 2012, Billerey et al., 2001, Hernandez et al., 2006). 
FGFR3 has been associated with non-invasive low grade/stage pTa tumours. 
However, in muscle-invasive bladder tumours, FGFR3 is mutated in only 10-15% 
of the cases (Billerey et al., 2001). This could indicate that non-invasive lesions 
with FGFR3 mutation never progress to invasive tumours, and that invasive 
lesions arise predominantly from wild type FGFR3 cells (Tomlinson et al., 
2007a). It is possible that a subset of FGFR3-mutated invasive lesions may 
acquire FGFR3 mutation later during stage progression (Choi et al., 2014, Sjodahl 
et al., 2012). However, it is also possible that the mutant FGFR3 allele is lost 
during potential stage progression from non-invasive to invasive tumours.  
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Studies showed that non-invasive papillary carcinomas can indeed progress to a 
higher grade (Zieger et al., 2000, Herr, 2000, Cheng et al., 1999, Leblanc et al., 
1999). It was also demonstrated that human FGFR3-mutant tumours can progress 
and acquire a CIS gene signature following the muscle-invasive pathway (Zieger 
et al., 2005). However, the presence of FGFR3 mutation did not seem to be 
directly involved in the cancer progression (Zieger et al., 2005). This observation 
could potentially be explained under the hypothesis that the tumours were part 
of the 10-15% muscle-invasive tumour subset that carries FGFR3 mutation 
(Billerey et al., 2001). 
Our data indicates that FGFR3 mutation can be functionally involved in 
urothelial changes that may represent early changes in human urothelial 
papilloma (Chapter 3) as well as in cancer progression of OH-BBN-induced 
tumours (Chapter 5). Whether superficial papillary tumours with FGFR3 mutation 
can progress towards the muscle-invasive pathogenesis pathway where the 
receptor mutation then promotes tumour progression and invasion requires 
further experiments. 
7.4 Cooperating mutations 
Mutations that cooperate with activated FGFR3 in the formation and progression 
of urothelial cell carcinoma have not fully been discovered.  
Our previous data suggested that one of the potential candidates of FGFR3-
cooperating mutations could be a component of the PI3K/AKT pathway (Ahmad 
et al., 2011c). Moreover, we have shown in mice that AKT pathway activation 
though Pten deletion together with FGFR3 activation induced global hypertrophy 
with several cellular characteristics indicative of abnormal differentiation, 
which was overall similar to the early histopathological changes seen in human 
urothelial papilloma (Chapter 3 and 4). The morphological changes were likely to 
be caused cooperatively by Fgfr3 and Pten. Potential cooperation of the 
PI3K/AKT and the FGFR signalling pathways is supported by the fact that FGFR3 
and PIK3CA mutations often co-occur in human bladder tumours across all stages 
and grades (Lopez-Knowles et al., 2006, Kompier et al., 2010, Duenas et al., 
2013). However, the PI3K/AKT pathway may not be the only signalling pathway 
that is potentially able to cooperate with FGFR3 activation. 
Final Discussion  (Chapter 7)   245 
 
 
 
FGFR3-cooperating mutations within the RAS/MAPK pathway were not identified 
in our models. Mice that carried heterozygous Fgfr3 and Hras mutation in 
combination showed no urothelial abnormalities at 12 months apart from 
occasionally mild hyperplasia (Chapter 4). Although RAS/MAPK signalling cannot 
be fully excluded as a potential functional cooperator, co-occurrence of FGFR3 
and RAS mutations in human bladder tumours have been shown to be rare 
events, possibly due to redundancy of pathway activation (Kompier et al., 2010, 
Jebar et al., 2005, Juanpere et al., 2012, Ahmad et al., 2011c).  
7.5 Current models of bladder cancer  
Mice have been shown to resemble human urothelial cell carcinoma better than 
any other available laboratory animal by sharing many histological features with 
human bladder cancer, and by recapitulating tumour development in well-
defined stages (Chan et al., 2009a). Recently, we presented for the first time a 
mouse model with Fgfr3 mutation in the bladder (Ahmad et al., 2011c). Here we 
present a mouse model where the bladder of Fgfr3 Pten double mutant mice 
showed histological features that may be comparable with those of early 
urothelial papilloma in humans (Chapter 3). Furthermore, our results suggested 
that FGFR3 activation can have an effect on progression in an invasive model of 
carcinogen-induced bladder cancer (Chapter 5), in which the effect of signalling 
inhibitors could be tested in vivo in future experiments. The use of a recently 
published AdenoCre technique to allow tissue-specific recombination in a small 
number of cells in order to generate tumours of the bladder has been evaluated 
in this study. The technique requires technological improvement but could 
potentially help to refine existing mouse models of bladder cancer, and could 
also allow lineage tracing of cancer stem cells in a developing urothelial tumour. 
Our results emphasise the importance of in vivo tumour models in cancer 
research to investigate the mechanisms of cancer development and progression. 
However, the bladder also poses a challenge as a target organ of cancer research 
in mice, since it is slowly proliferative (Stewart et al., 1980), which makes it a 
slow system to model tumour development. Therefore, it may be crucial to 
introduce mutations that promote proliferation in order to drive bladder 
tumourigenesis. Depending on the promoter that is used, this may promote 
earlier tumour formation in other organs that proliferate more quickly than the 
bladder as we have shown before (Ahmad et al., 2011c). Furthermore, stem cells 
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of the bladder have not been clearly identified, which may create ambiguity of 
which promoters are the most suitable ones to induce mutations in the putative 
stem cells of the mouse urothelium. 
With the objective to assess tumour behaviour such as proliferation, renewal, 
invasion, as well as to test the effect of therapeutic drugs on cancer cells, the 
necessity of in vitro assays becomes evident. Our in vitro assays, including 
sphere formation, Collagen-I invasion, and organotypic slice culture are 
currently under development (Chapter 6). The assays can potentially be valuable 
in order to test therapeutic drugs as well as to study the characteristics of 
cancer cells ex vivo. Similar organotypic cell culture systems that serve as 
experimental intermediates towards living organisms have been tested with 
tumour cells derived from other organs, such as from pancreas, skin, intestine 
and breast (Kim and Alexander, 2013, Timpson et al., 2011, Sato et al., 2009). 
Cultures of cells derived from the normal urothelium or from bladder tumours 
have also been described previously (Chen et al., 2012, Shin et al., 2011, 
Batourina et al., 2012). However, these culturing systems appear to be more 
difficult compared to cultures of other organs, since they require FACS-based 
cell sorting of the urothelium, complex growth conditions specific to the nature 
of cell type, as well as a large number of urothelial cells with sufficient 
proliferative potential. 
7.6 FGFR3 as a biomarker in bladder cancer 
Biomarkers in cancer research are defined by the National Cancer Research 
Institute (NCI) as “A biological molecule found in blood, other body fluids, or 
tissues that is a sign of a normal or abnormal process, or of a condition or 
disease. A biomarker may be used to see how well the body responds to a 
treatment for a disease or condition." (NCI Dictionary of Cancer Terms, National 
Cancer Institute, 2014).  
Biomarkers can be categorised as (1) diagnostic, (2) prognostic or (3) predictive. 
Diagnostic biomarkers help to identify the current condition, such as early- or 
late-stage disease. Prognostic biomarkers help to forecast whether the cancer is 
likely to progress or whether it is stable in the absence of treatment. Predictive 
biomarkers help to predict how well a patient will respond to treatment. 
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Since recurrence is a major issue of bladder cancer management, there is great 
interest in developing urine-based tests to reduce the necessity of expensive 
cystoscopic surveillance. FGFR3 has been examined as a diagnostic biomarker in 
urine (van Rhijn et al., 2003); however, due to lack of sensitivity and/or 
specificity, the tests are still not standard use in the clinic. 
To date there are no validated prognostic molecular biomarkers available in 
bladder cancer (di Martino et al., 2012). However, several studies have 
examined the prognostic value of FGFR3 in terms of recurrence, progression and 
survival of bladder cancer patients. FGFR3 mutation is generally associated with 
favourable disease characteristics as it is linked to low grade/stage pTa tumours 
(van Rhijn et al., 2012, Billerey et al., 2001, Hernandez et al., 2006), whereas 
p53 expression is generally associated with higher stage and grade and worse 
clinical outcome (Schmitz-Drager et al., 2000, Malats et al., 2005).  
We have demonstrated that FGFR3 mutation alone is unlikely to drive 
tumourigenesis in the bladder (Ahmad et al., 2011, and Chapter 5 in this study). 
However, we showed that FGFR3 activation can play a causative role in 
urothelial pathogenesis of non-invasive bladder cancer in cooperation with 
upregulated PI3K-AKT signalling in mice (Chapter 3). Since the animal model did 
not produce tumours in the life time up to 18 months, we concluded that these 
early-stage lesions with FGFR3 mutation are unlikely to progress. This is in 
accordance with a rather good prognosis that is generally associated with the 
presence of FGFR3 mutation in urothelial tumours (van Rhijn et al., 2012). In 
contrast, our model of invasive bladder cancer induced by carcinogen treatment 
suggests that presence of FGFR3 mutation may constitute a rather bad prognosis, 
since FGFR3-mutant mice showed a 4.4-fold higher incidence of invasive bladder 
tumours than carcinogen-treated Wild type mice (Chapter 5). These results 
suggest context-dependence in terms of FGFR3 mutation as a biomarker of 
progression. In order to clinically translate these observations to predict patient 
prognosis, further experiments would be essential to clearly define the effects 
of activated FGFR3 signalling in bladder cancer.  
The prognostic value of FGFR3 as a biomarker of recurrence, which is generally 
associated with non-invasive low-grade Ta tumours, is still a matter of debate 
(Knowles, 2008). Some studies reported association of FGFR3 mutation in non-
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invasive tumours with low risk of recurrence (van Rhijn et al., 2001). Other 
groups have confirmed association of FGFR3 mutation with non-invasive papillary 
tumours of low grade, however, with a higher risk of recurrence (Hernandez et 
al., 2006). Conversely, non-invasive papillary tumours of high grade were not 
associated with recurrence or progression in patients (Hernandez et al., 2006, 
Hernandez et al., 2005). Other studies have found no association between FGFR3 
mutational status and recurrence, progression or muscle invasion (Ploussard et 
al., 2011).  
In conclusion, further research is required in order validate FGFR3 mutation as a 
prognostic biomarker in urothelial cell carcinoma. Since the effect of activated 
FGFR3 signalling may be context-dependent, the prognosis of patients with 
FGFR3-mutated tumours should be assessed with caution. 
7.7 FGFR3-targeted therapy 
The wide availability of inhibitors specific to FGF signalling may provide an 
opportunity for FGFR3-targeted translation using our in vivo models with FGFR3 
mutation for preclinical experiments. We have shown that FGFR3 mutation can 
play a functional role in bladder cancer, which suggests the possibility of FGFR3 
inhibition as a therapeutic strategy.  
FGFR3-inhibiting drugs have been suggested as a therapeutic option in urothelial 
cell carcinoma (Lamont et al., 2011, Tomlinson et al., 2007b, Network, 2014). 
Several novel drugs against FGFRs including R3Mab, NVP-BGJ398, and AZD4547 
have been shown to be effective in cell lines and xenograft models (Qing et al., 
2009, Guagnano et al., 2011, Gavine et al., 2012). All of the named drugs are 
currently being used in clinical trials (Brooks et al., 2012, Liang et al., 2013).  
Our UroIICre Fgfr3+/K644E Ptenflox/flox mouse model indicated potential cooperation 
of the PI3K/AKT and the FGFR signalling pathways. Analysis of human bladder 
tumours supports that mutations in FGFR3 and PI3K/AKT pathway genes are co-
associated (Lopez-Knowles et al., 2006, Kompier et al., 2010, Duenas et al., 
2013), which represents a therapeutic opportunity for combinatorial inhibitors. 
Combinatorial targeting is a valid approach for cancers with multiple activated 
signalling pathways, and has been shown to be successful in models of breast 
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cancer, where FGFR and PI3K/mTOR signalling were targeted in combination 
(Issa et al., 2013). In order to generate an in vivo model for combinatorial drug 
testing, our FGFR3-mutant mice can be crossed to any available mouse model 
carrying candidate mutations that cooperate with FGFR3 in tumourigenesis. 
Interestingly, two studies have reported tumour suppressive properties of 
FGFR3. In one, FGFR3 protein expression was downregulated in colorectal cancer 
(Sonvilla et al., 2010). In a second study, FGFR3 overexpression had tumour 
suppressive effects on pancreatic cancer (PDAC) cell lines (Lafitte et al., 2013). 
Although yet unclear, it is possible that FGFR3 can either promote or suppress 
tumour development or progression in a context-dependent manner. Therefore 
FGFR3-targeted therapy needs to be considered individually with caution. 
Altogether, for a translational benefit, further studies of the FGFR3 signalling 
pathway and its inhibitors are essential and will aid the development of 
therapies for both non muscle-invasive and muscle-invasive bladder cancer with 
deregulation of FGF signalling. 
7.8 Future direction 
Resistance to therapy is a major challenge of cancer treatment (Bambury and 
Rosenberg, 2013). Often patients first respond to a given drug and subsequently 
relapse. This is mostly due to the emergence of cellular mechanisms in the 
tumour to escape the effects of the drug, such as the generation of efflux 
pumps, alteration of the DNA repair machinery and modulation of apoptosis and 
survival pathways (Drayton and Catto, 2012, Herrera-Abreu et al., 2013, Chell et 
al., 2013). It would therefore be essential to elucidate resistance mechanisms in 
detail, and to test drug combinations that collectively target pathways that are 
used as escape routes. To this matter, it would also be vitally important to 
identify cooperating mutations in bladder cancer, to understand which pathways 
are co-activated and to identify drug targets within these pathways. 
Comprehensive knowledge of the molecular mechanisms underlying bladder 
cancer development and progression would also facilitate the identification of 
patients who are most likely to respond to treatment.  
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FGFR3 mutation or overexpression in the context of dissemination and 
metastasis formation is largely unknown. However, FGF signalling has been 
implicated in the regulation of EMT (Cheng et al., 2013, Tomlinson et al., 2012), 
a process that is strongly associated with invasion and formation of distant 
metastasis (Thiery, 2002). Our data suggests that FGFR3 can have an effect on 
tumour progression of existing neoplasms. It would therefore be interesting to 
investigate further whether FGFR3 can also play a role in the metastatic process 
in late-stage disease. Two recent publications reported upregulated FGFR3 
expression in bladder cancer metastases (Guancial et al., 2014b, Turo et al., 
2014). 
The tumour microenvironment has been implicated to play a role in cancer 
progression, metastasis and drug resistance (Sung et al., 2007). The stroma, as 
part of the microenvironment, secretes a variety of cytokines such as FGF 
ligands and interleukins that stimulate proliferation (Tlsty and Coussens, 2006, 
Cheng et al., 2013). Furthermore, it can host inflammatory processes that may 
influence tumour proliferation (Tlsty and Coussens, 2006). It would therefore be 
important to examine the role of the stroma in urothelial cell carcinoma and its 
potential contribution to the development or progression of bladder tumours. 
7.9 Significance 
Bladder cancer is a major health issue worldwide that causes considerable 
morbidity and mortality due to ineffective or insufficient therapeutic strategies. 
This study focused on the role of FGFR3 signalling in cancer initiation, invasion 
and progression with the objective to generate models that can answer 
questions of basic science as well as to aid preclinical drug testing.  
From the basic science question our data supported previous evidence of a 
functional role of FGFR3 in initiating changes towards superficial urothelial 
carcinoma. Our data also suggested a potential role of FGFR3 in progression of 
established neoplasms in mice. We showed that FGFR3 activation plays a 
causative role in urothelial pathogenesis of non-invasive bladder cancer in 
cooperation with Pten loss in vivo. Furthermore, we present indication of 
functional involvement of FGFR3 S249C mutation in progression and invasion of 
carcinogen-induced tumours. 
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Our findings may also be of clinical relevance. It has previously been believed 
that the presence of an FGFR3 mutation is a favourable prognostic factor since it 
is associated with superficial papillary tumours with low potential to progress. 
However, our data suggested that FGFR3 mutation in an established tumour can 
act as a tumour promoter with worse prognosis than FGFR3 wild type.  
FGFR3 may therefore constitute a promising drug target. Given the wide 
availability of inhibitors specific to FGF signalling, our FGFR3 mouse models 
together with technological improvement of our in vitro assays may provide a 
platform for FGFR3-targeted translation in urothelial disease.  
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